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Magnetic resonance (MR) is a robust platform for non-invasive, high-resolution anatomical imaging.
However, MR imaging lacks the requisite sensitivity and contrast for imaging at the cellular level. This
represents a clinical impediment to greater diagnostic accuracy. Recent advances have allowed for the in vivo
visualization of populations and even of individual cells using superparamagnetic iron oxide (SPIO) MR
contrast agents. These nanoparticles, commonly manifested as a core of a single iron oxide crystal or cluster of
crystals coated in a biocompatible shell, function to shorten proton relaxation times. In MR imaging these
constructs locally dephase protons, resulting in a decrease in signal (hypointensity) localized to the region of
accumulation of SPIO. In the context of immune cell imaging, SPIO can provide insight into the cellular
migration patterns, trafficking, temporal dynamics and progression of diseases and their related pathological
states. Furthermore, by visualizing the presence and activity of immune cells, SPIO-enabled cellular imaging
can help evaluate the efficacy of therapy in immune disorders.
This thesis examines the production, modification and application of SPIO in a range of in vitro and in vivo
immune-response-relevant cellular systems. The role of different nanoparticle characteristics including
diameter, surface charge and concentration are investigated in the labeling of T cells in culture. Following
optimization of SPIO loading conditions for lymphocytes, the effect these particles have on the activation of
primary B cells are elucidated. B cells are tracked using a variety of modalities, with and without the
application of B cell depleting therapy. This is to evaluate the efficacy of SPIO as in vivo marker for B cell
distribution.
Unmodified SPIO were applied to monitor macrophage infiltration in a transient nerve root compression
model, with implications for neck pain diagnosis and treatment. Nanoparticle accumulation and MR
hypointensity was correlated to the presence of activated macrophage at the site of injury. Taken together, the
application of SPIO to study nanoparticle uptake in vitro and visualization of immune cells in vivo provide a
basis for advanced study and diagnosis of diverse pathologies.
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ABSTRACT  
MONITORING OF IMMUNE CELL RESPONSE TO B CELL DEPLETION THERAPY AND NERVE 
ROOT INJURY USING SPIO ENHANCED MRI 
 
Daniel L.J. Thorek 
 
Andrew Tsourkas, Thesis Advisor 
 
 Magnetic resonance (MR) is a robust platform for non-invasive, high-resolution 
anatomical imaging. However, MR imaging lacks the requisite sensitivity and contrast 
for imaging at the cellular level. This represents a clinical impediment to greater 
diagnostic accuracy. Recent advances have allowed for the in vivo visualization of 
populations and even of individual cells using superparamagnetic iron oxide (SPIO) MR 
contrast agents. These nanoparticles, commonly manifested as a core of a single iron 
oxide crystal or cluster of crystals coated in a biocompatible shell, function to shorten 
proton relaxation times. In MR imaging these constructs locally dephase protons, 
resulting in a decrease in signal (hypointensity) localized to the region of accumulation of 
SPIO. In the context of immune cell imaging, SPIO can provide insight into the cellular 
vii 
 
migration patterns, trafficking, temporal dynamics and progression of diseases and their 
related pathological states. Furthermore, by visualizing the presence and activity of 
immune cells, SPIO-enabled cellular imaging can help evaluate the efficacy of therapy in 
immune disorders. 
 This thesis examines the production, modification and application of SPIO in a 
range of in vitro and in vivo immune-response-relevant cellular systems. The role of 
different nanoparticle characteristics including diameter, surface charge and 
concentration are investigated in the labeling of T cells in culture. Following optimization 
of SPIO loading conditions for lymphocytes, the effect these particles have on the 
activation of primary B cells are elucidated. B cells are tracked using a variety of 
modalities, with and without the application of B cell depleting therapy. This is to 
evaluate the efficacy of SPIO as in vivo marker for B cell distribution. 
 Unmodified SPIO were applied to monitor macrophage infiltration in a transient 
nerve root compression model, with implications for neck pain diagnosis and treatment. 
Nanoparticle accumulation and MR hypointensity was correlated to the presence of 
activated macrophage at the site of injury. Taken together, the application of SPIO to 
study nanoparticle uptake in vitro and visualization of immune cells in vivo provide a 
basis for advanced study and diagnosis of diverse pathologies. 
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CHAPTER 1. Magnetic Resonance Imaging, SPIO, and Cell Tracking 
1.1 - Overview 
Magnetic resonance (MR) imaging is a powerful diagnostic platform in 
widespread clinical use. MR demonstrates visualization of healthy and disease relevant 
features in both time and space through the display of high-resolution anatomical 
information. Image formation is dependent on the intrinsic contrast of adjacent tissues. 
This distinction in signal is provided by the different rates of realignment of hydrogen 
nuclei within an external magnetic field, following a radio frequency pulse sequence. 
However, the modality is often restricted as a result of low sensitivity to changes between 
tissues and tissue states. 
 The use of MR for molecular and cellular imaging (MCI) is an emerging subfield 
with significant potential to impact clinical and research applications. MCI has been 
defined as the non-invasive, quantitative and repetitive imaging of biomolecules and 
biological processes in living organisms (1). Unfortunately, the applicability and 
translation of MCI approaches, such as more accurate, earlier detection of disease or the 
study of biological phenomena, is hindered by MR imaging's inherently low signal-to-
noise ratio. This deficiency is mitigated through the use of contrast agents (CA). Unlike 
direct signal detection or interference as caused by CA in x-ray imaging applications, MR 
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CA function by altering characteristics of surrounding water protons through their 
magnetic properties.  
 This chapter will provide a brief overview on the fundamentals of MR and recent 
advancements in the disciplines relevant to cellular magnetic resonance imaging. First, an 
overview of the quantum mechanical principles underlying nuclear spin relaxation will be 
discussed. Image generation for biological samples will be described. This will be 
followed by an examination of issues of tissue contrast and a description of T2* contrast 
agents. A detailed overview of the physical and biological properties of 
superparamagnetic iron oxide nanoparticle agents will be given. Finally, the imaging 
approach used in the tracking and identifying of immune cells for biomedical purposes 
will be discussed. A special emphasis will be placed on the application of SPIO 
particulates for immune and inflammatory cell relevant imaging.  
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1.2 - Nuclear Magnetic Resonance and Spin Relaxation Processes 
 Magnetic resonance (MR) is a versatile instrument for non-invasive imaging of 
living specimens in the clinic and in research. In the United States alone, there were over 
26 million MR procedures at approximately 7000 hospital and non-hospital MR imaging 
sites in 2007 (2). This imaging modality is based on the same principles as its forbearer in 
research, nuclear magnetic resonance spectroscopy (NMR). As the vast majority of 
clinical research on MR and all of the work detailed in this thesis relate exclusively to the 
hydrogen nucleus, the description of MR imaging relates only to proton (1H) MR. 
However, the fundamentals discussed below can be extended to MR studies of other 
nuclei with quantum spin numbers of 1/2.  
 All quantum particles have the property of spin, a fundamental property of nature 
like electrical charge or mass. The proton, with its unmatched positive charge, can be 
thought of a spinning charged particle with a spin of 1/2. Spinning charged particles, 
similar to rotating electrically charged bodies, have a magnetic dipole (north and south) 
and MR imaging is predicated on the manipulation of this dipole through the use of radio 
waves in a static magnetic field. 
 The nuclear spin angular momentum, or spin, of 1H can be described as (S), a 
vector that can be quantified in Equation 1.1. Here, h is Planck's constant and s is the 
nuclear spin quantum number. For the proton s is equivalent to 1/2. 
! 
| S |= h2" s(s+1)     Equation 1.1   
When placed in an external magnetic field of strength (B0) the spin vector (S) of the 
proton aligns in the direction of the applied field. This 'atomic magnet' is now said to be 
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in a low energy state, as it is aligned with the applied field. The proton can undergo a 
transition to a high-energy state (anti-parallel to the applied field) through the absorption 
of a photon of specific energy. In quantum mechanics the energy transferred has a 
discrete value, ie. it is quantized. 
 The energy of this photon is equivalent to the energy difference between the two 
states; parallel (or aligned) and anti-parallel. Protons can absorb photons that have a 
frequency, !, as defined in Equation 1.2. The gyromagnetic ratio of the particle, ", for 1H 
is equal to 42.58 MHz/T. 
   
! 
" = # $ B      Equation 1.2  
This frequency, ! , is known as the Larmor or resonant frequency of the nuclei. The 
frequency of the photon can be converted to energy through the wave-particle duality as 
described in Equation 1.3.  
   
! 
E = h"      Equation 1.3  
This allows for the calculation of the energy necessary (through absorption) to switch a 
proton from the high to low energy state. This is shown in Equation 1.4. 
   
! 
E = h " # " B     Equation 1.4  
The field strength of an MR must be high in order to align the weak magnetic dipole 
moment of 1H. As field strength increases, the spectral resolution and sensitivity increase, 
resulting in improved signal to noise as the energy difference between states increases. At 
high field, photon frequencies for excitation to alter nuclear spin states are in the 
radiofrequency (RF) range (MHz).  
 Moving from a single proton or a single magnetic dipole moment to a collection 
of spins, first randomly aligned as seen in Figure 1.1A and then aligned with an external 
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field B0 along the z-axis, we see the emergence of a net magnetization vector (Mz) in 
Figure 1.1B.  
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Figure 1.1 - Magnetic Dipole Moment Alignment.  
 
(A) The spinning and precessing nuclei generate a magnetic dipole moment (red). These 
moments are randomly aligned in the absence of an external magnetic field. (B) With the 
application of that field (B0) the net magnetization the dipole moments generates an 
equilibrium net magnetization vector (M0). At equilibrium, this is equal to the z-axis 
component of the magnetization vector (Mz, blue). 
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 With an applied magnetic field along the z-axis a net magnetization vector 
develops, aligned with the applied field. This net vector (Mz) increases when placed in 
the field as the 1H become preferentially aligned in the low energy state until reaching an 
equilibrium distribution between the states. It is then equal to the equilibrium 
magnetization vector (M0). Further, there is no net magnetization of protons' magnetic 
dipoles in either the x- or y-directions. With the application of a RF pulse equal to the 
Larmor frequency of the precessing, aligned nuclei, the z-component of the net 
magnetization vector can be reduced to zero. As the system relaxes back to a lower 
energy state (globally) after the removal of the radiofrequency source, Mz = 0 returns 
back to the equilibrium condition Mz = M0. The recovery of the longitudinal 
magnetization is described in Figure 1.2.  
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Figure 1.2 - Longitudinal Magnetization and T1.  
(A) Following the application of a radiofrequency pulse at the Larmor frequency, the net 
magnetization is saturated and no longer possesses a longitudinal bias.  Immediately 
following the removal of the radio energy, the system returns to its lower energy state, 
with a majority of 1H aligned with the field. (B) The growth of the z-component 
magnetization vector (Mz) back to a fraction (1-1/e or 63%) of the equilibrium state is 
described by the time constant T1. The time (t) refers to time after removal of 
radiofrequency. 
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 Equation 1.5 describes the T1 or spin lattice relaxation time, a value used to 
describe the exponential recovery of Mz. T1 is a constant that is equal to the time 
required for the recovery of 63% of the longitudinal magnetization. 
   
! 
Mz = M0 1" e
"t T1# 
$ 
% & 
' 
(     Equation 1.5  
 The net magnetic moment can be placed, or flipped, into the orthogonal xy-plane 
through the application of specific radiofrequency pulses that result in phase coherence of 
the magnetic dipoles of the 1H nuclei. This means that an xy-component of the net 
moment (Mxy) is generated and this will rotate about the axis of the applied field. The 
frequency of this rotation will be equal to the Larmor frequency (3).  
 This state does not last following the removal of the pulse, as perturbations in the 
local magnetic field by other nuclei as well as imperfections in the applied field lead to 
reduction and finally absence of coherence. As the transverse magnetization vector 
rotates about the applied field, the Mxy will decrease as illustrated in Figure 1.3. The 
decrease in transverse magnetization can be described by T2 or the spin-spin relaxation 
time. This is the time needed for Mxy to be reduced by 63%. Mathematically, this is 
expressed in Equation 1.6. It must be stressed that the T1 and T2 relaxation are 
independent processes. They are related through the bulk direction of net magnetic dipole 
moment and occur simultaneously but describe separate physical events.  
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Figure 1.3 - Transverse Magnetization and T2. 
The net magnetization vector can be flipped into the transverse plane whereupon it is 
denoted Mxy, green. In (A), following the removal of the radiofrequency pulse the vector 
continues to rotate around the direction of the applied field, indicated by the arrow head 
on the perimeter path of the transverse vector. The rapid loss of phase coherence leads to 
the decay of Mxy. In (B), the time constant of decay of magnetization, spin-spin 
relaxation or T2 is shown. Please note the change in frame of reference. 
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! 
Mxy = Mxy 0 e
" tT 2# 
$ 
% & 
' 
( 
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 In an ideal system, all dephasing of spins would begin with all nuclei precessing 
at the same phase. However, in application the field is never fully homogeneous, and in 
all biological samples of interest there are chemical differences that disturb the phases of 
1H. This leads to enhanced non-random relaxation effects that are termed T2* decay. The 
inverse of T2* is equal to the summation of the inverse of the T2 decay and the dephasing 
produced by inhomogeneities.  
 To summarize, magnetic resonance is based on the electromagnetic properties of 
hydrogen nuclei. Their nuclear spin, coupled with their charge, creates a magnetic dipole 
moment. In bulk, the aggregate magnetic moment or net magnetization is zero in the 
absence of a magnetic field. With the application of a field, a majority of protons align 
with the field, generating a net magnetization vector aligned with the applied field. This 
net magnetization can be manipulated by switching protons from a low energy (aligned) 
to a higher energy (anti-parallel) state with the application of electromagnetic radiation of 
a specific energy. For the purposes of MR imaging this is in the RF range. Following the 
removal of the radio source, the net magnetization returns to equilibrium through two 
forms of relaxation, T1 and T2. The former sees nuclei return energy to the surrounding 
lattice or medium as the nuclei re-align preferentially with the applied field. In the latter 
process, transverse magnetization decreases as nuclei lose phase coherence (as spins must 
be in phase in the transverse direction to be detected) and through nuclei exchanging 
energy with their neighbors. 
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1.3 - Magnetic Resonance Image Formation 
 For clinical and research applications, the samples of interest are heterogeneous 
and large. MR information that is relevant for diagnostic purposes requires that spatial 
information be encoded into the signal in three directions; x, y and z. The discussion here 
will focus on the generation of 2-dimensional MR images, as acquired for analysis in this 
dissertation. 
 Spatial encoding is accomplished by time-varying the strength of the magnetic 
fields. In the simplest case, a one-dimensional linear gradient (a variation of the magnetic 
field with respect to position) along the direction of the applied field is created, termed 
the Gz or z-gradient, as shown in Figure 1.4. Now each hydrogen nuclei at a distance zi 
along the gradient precesses at a unique frequency. This frequency can be determined for 
each local field strength along the gradient, as previously shown in Equation 1.2. This 
will be termed the slice selection gradient, as we are interested in imaging a plane 
perpendicular to the applied gradient.  
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Figure 1.4 - Slice Selection. 
(A) A magnetic gradient (dashed line) is applied along the z-direction. This results in 
each plane perpendicular to the z-axis experiencing a different magnetic field. Thus, at 
each zi, protons precess at different angular frequencies. These frequencies, !i vary 
proportionately with their distance along the gradient, as the applied gradient is linear. 
(B) This can be exploited for slice selection purposes by exciting a plane selectively with 
a radiofrequency pulse of a power and bandwidth required to flip the 1H spins in the 
desired plane. The number of arrows in the cartoon body, which differ along the gradient, 
symbolize the field strength experienced at different anatomical locations. 
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 The next step in the imaging process is to spatially encode within the selected 
slice using gradients applied perpendicular to the slice selection gradient. There are two 
remaining directions, the x and the y, in which MR signal needs to be localized. First, 
phase encoding is performed. This is accomplished with the brief application of a 
gradient, Gy, in order to align the phases of the spinning nuclei within the slice, 
according to their position relative to the gradient. This brief dephasing results in a slice 
whose nuclei all spin at the same frequency, but at different phases relative to their 
location within the slice. In conventional, supine, MR this gradient is applied 
anterioposterially. As shown in Figure 1.5A this results in phase encoded nuclei that spin 
in a phase proportional to their position in the gradient in the transverse plane. In other 
words, the Larmor frequency for proton spin along the gradient is different at each 
position along that gradient. 
 The third and final spatial encoding element is obtained through application of a 
frequency encoding gradient. This results in 1H that precess at a rate that is equal for all 
nuclei at a given distance along the applied frequency encoding gradient direction, as 
shown in Figure 1.5B. This gradient is applied laterally, or in Gx for the employed 
coordinate system, and is switched on during the acquisition of data. For this reason the 
Gx gradient is also referred to as the readout gradient. The gradient is on during the 
acquisition, resulting in a spectrum of frequencies (at each distance along the x direction) 
being read, rather than a single frequency. 
 This signal is received by radiofrequency coils that surround the subject. The 
magnetization direction and magnitude of spins at locations within a subject are relayed 
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by these antennae as these magnetic fields will generate current. In order to determine the 
x-position, the radiofrequency spectrum must first be analyzed using a Fourier transform. 
This operation decomposes the spectrum into component frequencies for each position 
along the applied gradient. The y-position is determined by analyzing the phase 
distribution within each frequency. This requires that a second transform be employed as 
the acquired data is the sum of all spins with the same frequency but different phases 
(schematically within the double-lines in Figure 1.5B). The phases and thus the y-
location of the spins can be determined after all rows in a given slice are analyzed.  
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Figure 1.5 - Phase Encoding. 
(A) A phase encoding gradient, Gy, is applied and aligns the frequency of spins 
perpendicular to the axis of the gradient (i.e. in rows at equal distances along the 
gradient). The gradient is symbolized to be increasing with opacity of the Gy arrow. (B) 
The frequency encoding gradient, Gx, is applied during the readout of the resonance 
information. This gradient encodes the frequency, or rate of precession, in the selected 
slice plane for all protons experiencing the same frequency encoding magnetic field 
strength (for example within the double-lines). The gradient is symbolized to be 
increasing with opacity of the Gx arrow. For clarity - decreased, nominal and increased 
frequency of precession is noted at the top. 
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1.4 - MR Imaging Contrast 
 MR as a modality for diagnostic imaging is dependent on its ability to resolve 
distinct tissues and physiological features deep within opaque organisms. The ability to 
discern between tissues and tissue states for imaging purposes is defined by the contrast 
to noise ratio (CNR; Equation 1.7).  
   
! 
CNR = SI1 " SI2( )noise     
 Equation 1.7  
 Here, SI is the signal intensity of adjacent regions in an image and these values 
rely on the earlier discussion of relaxation properties. To recapitulate - T1 is a description 
of recovery of longitudinal magnetization (recovery of 63% of the equilibrium net 
magnetization) while T2 is a measure of the decay of the transverse magnetization (loss of 
63% of Mxy0).  
In non-ideal systems, additional effects enhance the rate of decay of transverse 
magnetization, termed T2* decay. Following removal of the RF energy, the relaxation 
and decay processes initiate immediately. In biological imaging systems there always 
exist some magnetic inhomogeneities, a result of both the field consistency and its 
interaction with the sample. These magnetic inhomogeneities serve to enhance the rate of 
decay of transverse magnetization. T2* decay is thus the combination of T2 decay added 
to the dephasing due to these inhomogeneities. The time for T1 is always longer than T2, 
which is always longer than T2*.  
 The differences in T1, T2 and proton density within a sample determine the 
intensity of signal (SI) in a given region of a 2D image and therefore its discernment. 
Using different radiofrequency (RF) and magnetic gradient pulse algorithms, hereafter 
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called sequences, the tissues' contrast can be enhanced towards one of the three inherent 
contrast parameters. This is possible because the T1, T2 and proton densities of tissues 
(and noise) differ, as summarized in the relaxation time values in Table 1.1 and can be 
exploited for the purposes of contrast throughout the body. 
 
Tissue T1 (msec) T2 (msec) 
Liver 576 ± 30 46 ± 6 
Skeletal muscle 1008 ± 20 44 ± 6 
Heart 1030 ± 34 40 ± 6 
Kidney 690 ± 30 55 ± 3 
Blood 1441 ± 120 327 ± 4 
Spinal cord 745 ± 37 74 ± 6 
White matter 884 ± 50 72 ± 4 
Grey matter 1124 ± 50 95 ± 8 
 
Table 1.1 - T1 and T2 Values for Human Tissues at 1.5 T 
Accepted values for the T1 and T2 of commonly MR investigated tissues. This table was 
adapted by Thorek, from (4). 
 
 It is useful to examine the resonance response of a single tissue. The longitudinal 
magnetization recovery of a tissue after a 90˚ pulse (or flip into the transverse plane) is 
shown in Figure 1.6A. Here we see the saturation of the signal with the 90˚ flip to zero 
and then its exponential recovery dependent on its T1 value. In (B) we see that different 
tissues or different tissue regions have variable T1 values and thus can be distinguished 
by selecting appropriate TR, repetition time, and TE, echo time, to sample the signal. The 
TR is a time value that describes the time from the application of one RF pulse to the 
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application of the next RF pulse. It is measured in milliseconds (msec). The TE is the 
time from the application of the RF pulse, to the peak of the signal induced in a receiver 
coil and is also measured in msec. Nearly all imaging protocols sample the signal at this 
echo time (peak signal). The TE determines how much decay of transverse magnetization 
is allowed to occur before the signal is read.  
 Visualization of tissue contrast based on T2, or T2-weighting (T2-w), can be 
accomplished by exploiting the equivalent T2 differences between tissues as shown for 
T1-w imaging above. This imaging mode is described in Figure 1.7. Care must be taken 
to note the superimposition of the Mxy decay curve onto that of the Mz recovery curve, 
in Figure 1.7. 
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Figure 1.6 - T1-w Tissue Contrast. 
(A) The recovery of longitudinal magnetization in a tissue, following a 90˚ RF pulse that 
has flipped the net magnetization into the orthogonal plane, is shown. The recovery is 
described by T1, mathematically shown in Equation 1.5. The T1-weighted contrast 
between different tissues; namely, white (solid) and grey (dashed) matter is shown in (B). 
Each tissue has a different T1 and by selecting a repetition time (TR) to sample the signal 
when these values have not recovered to their equilibrium values one is able to weight 
contrast between them. This contrast is symbolized by the double-edged arrow.  
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Figure 1.7 - T2-w Tissue Contrast. 
(A) The decay of transverse magnetization (Mxy) is shown. Here, the T2 of the tissue 
examined is a measure of the time needed for the exponential reduction of that signal in 
the transverse plane, as described in Equation 1.6. The hash marks on the abscissa are 
meant to indicate that the TR time is often an order of magnitude greater than the TE 
time. (B) Demonstrates the principle by which contrast between tissues can be generated 
based on their T2 properties. The echo time chosen and the contrast effected are indicated 
by the double arrow between the present tissues. 
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 Finally, proton density weighted images can be generated by long TR and short 
TE sequences. Essentially, the T1-w and T2-w are both removed. This can be observed 
looking back at Figure 1.6 at long times. The SI for each tissue is said to be proportional 
to the proton density of that tissue which can be measured following a 90˚ RF pulse and 
giving enough time for full longitudinal relaxation.  
 An image depicting tissue contrast from a human brain under various weighting 
strategies is shown in Figure 1.8. Structures of the brain can be discerned under each, 
corresponding to cerebrospinal fluid (in the ventricles), white and grey matter as well as 
to the presence of lesions in the blood brain barrier.  
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Figure 1.8 - Tissue Contrast in the Brain. 
This image shows an axial section of the brain of a subject patient under (A) T1-, (B) T2-, 
and (C) proton density (PD) weighting.  Contrast of tissues is evident under each pulse 
regime, however each possesses structurally distinct information. Here, we see the 
contrast between tissues under different weighting for a patient. (A) We are able to 
identify regions of fat as bright. Contrast enhancement of a lesion is evident (arrow). (B) 
The bright regions are areas composed of a higher proportion of water, which highlights 
the presence of CSF, while in (C) the PD-weighted image shows no abnormalities. The 
main clinical utility of PD-weighting is to identify abnormalities in neuronal function (5).  
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The images presented in Fig. 13.1 also illustrate the general applicability of the
different parameter weightings discussed. T1-weighted scans (Fig. 13.1A) find applica-
tion for depiction of detailed anatomy and detection of contrast enhancement, the latter
using a gadolinium chelate (the most commonly employed intravenous MR contrast
agent). Fat is high signal intensity, cerebrospinal fluid (CSF) low signal intensity, and
white matter is higher signal intensity than is gray matter. Depicted well in Fig. 13.1A,
due to enhancement on this postcontrast image, is a metastatic lesion (arrow) from lung
carcinoma. Heavily T2-weighted images, such as that illustrated in Fig. 13.1B, find appli-
cation for visualization of fluid (such as CSF) and to a lesser extent edema. Anatomic
detail may also be high, depending upon the specific technique used. CSF is high signal
intensity and the gray matter-white matter signal intensity ratio is reversed compared
to that of T1-weighted images. Proton density–weighted images, illustrated in Fig. 13.1C,
have few applications, due to generally poor contrast between tissues. FLAIR, illustrated
in Fig. 13.1D, being specifically a T2-weighted scan with CSF suppression, depicts
extremely well edema within the brain (with high signal intensity; arrow).
Fig. 13.1
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1.5 - MR Contrast Agents 
1.5.1 - Overview 
 Confident radiological determination of the presence and extent of disease by MR 
requires that the biological differences present in tissues be detected and distinguished 
through changes in nuclear spin. Inherent contrast between tissues can be low, as can be 
seen in several of the T1 and T2 values found for tissues above, in Table 1.1. This is 
especially true in the case of particular tissues under normal (healthy) and pathological 
conditions. The sensitivity of MR to detect these differences is also an issue as noise and 
other artifacts can contribute to loss of signal and may require prohibitively long 
acquisition times for imaging. These difficulties render accurate diagnosis based on 
contrast from MR scans problematic (6).  
 To remedy the problem of low contrast between tissues and tissue states contrast 
agents (CA) are often employed. These CA are used to selectively enhance the image 
contrast in regions of interest by locally affecting the magnetic environment of protons. 
So-called magnetopharmaceuticals differ from the CA conventionally used in X-ray and 
X-ray computed tomography (CT), such as iodine, which are directly imaged because of 
their interference or absorption of electromagnetic energy (7). MR CA function indirectly 
through their affects on the surrounding 1H found in tissues, most often in water (8).  
 This section will provide an overview of the field of MR CA beginning from their 
description and categorization. While the focus of the present dissertation is squarely on 
iron oxide nanoparticulates for MR contrast enhancement, such materials are novel and 
do not make up the majority of MR CA currently used in the clinic or for research 
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purposes. As such, a discussion of the most commonly used CA for MR, gadolinium(III) 
chelates, will also be provided, in Appendix A, which includes a description of the 
chemical compounds in clinical and academic use. The present chapter is engaged in a 
general description of the categorization of MR CA, their mechanism of action and issues 
associated with their use. The remainder of this section will then be occupied by a 
synopsis of the field of T2 and T2* CA founded on superparamagnetic particles. 
 
1.5.2 - Classification and Measurement of Relaxivity 
 Contrast agents fall under the broad categories of T1-weighted (-w) or T2-w. This 
is despite the fact that each agent will generally reduce both T1 and T2, as their relaxitive 
effects interact with both transverse and longitudinal processes. Agents are thus classified 
by the relaxation mechanism that they shorten the most, despite the fact that many agents, 
such as metal oxides, shorten both significantly (9).  
 Contrast agents are measured by their efficiency in enhancing proton relaxation. 
This can be described as the relaxivity of the contrast agent and is defined in Equation 
1.8. Here, Ri is the T1 or T2 relaxivity corresponding to Ti and C is the concentration of 
the agent.  
  
! 
Ri = "C "Ti      Equation 1.8  
Thus, relaxivity can be described as the concentration dependent effect of a contrast agent 
(CA) on proton relaxation. 
 Relaxivity is most often written in the form of (mM!sec)-1 or (mmol/L!sec)-1. 
These values are determined by a plot of the inverse of T1 or T2 time with respect to 
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concentration of the agent. As from Equation 1.8, the slope of the linear portion of the 
curve is the relaxivity. Quantitative measurement of relaxivity allows for the comparison 
of agents and their usefulness under different conditions for diagnostic, in vitro and in 
vivo systems. 
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1.6 - T2 and T2* Contrast Agents and Superparamagnetic Iron Oxide 
1.6.1 - Introduction 
 The vast majority of contrast aided clinical scans use gadolinium based agents 
(10). This type of magnetopharmaceutical is effective at reducing the T1 recovery time 
and thus results in brightening in T1-weighted imaging. While the focus of the work is on 
T2* contrast agents, gadolinium based agents are currently the most widely used contrast 
agents in the clinic. Thus, additional information on the background of and recent 
advances in the use of gadolinium(III) chelates has been included in Appendix A.  
 The second class of contrast agents in widespread clinical and research use are T2 
and T2* agents. There is a wide assortment of different manifestations of these agents 
utilizing different material and biological strategies to produce localized contrast in vivo. 
The most common T2-CA material consists of iron oxide particles on the order of 
microns down to several nanometers. As these iron oxide materials, particularly 
nanoparticles (NPs), are the focal point of the research described herein, the discussion of 
other T2 and T2* CA (such as cobalt (11) or 17Oxygen based CA (12)) will be proscribed.  
 Using iron oxide in particulate form is common because of several advantageous 
features of these materials. Iron oxide is a substance found through out the body and is 
inherently biocompatible, even at very high concentrations. They provide high change in 
signal per unit metal and as they are composed of many thousands if not millions of 
atoms, they overcome the low sensitivity of MR. Further; they can be easily manipulated 
during and after synthesis resulting in highly derivitized structures possessing 
application-specific chemical, magnetic and biological properties. 
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 This section will review important features of superparamagnetic iron oxides 
(SPIO). This discussion will include an overview of the different configurations of 
particulate iron oxides developed for imaging, the mechanism of action of 
superparamagnetism-affected transverse relaxation, the NPs' physical and chemical 
properties and a discussion of their synthesis. An appraisal of the literature relating the 
biodistribution and biomedical application of these particles, in their many different 
forms, will also be given. The final section will focus on their utility for immune cell 
tracking. 
 
1.6.2 - Terminology 
 There are many forms of SPIO MR CA in academic and medical use, to the extent 
that classification of the different manifestations of these agents has become necessary. 
Categorization of SPIO as defined by their overall hydrated diameter is the most efficient 
means to that end. However, it should be noted that the literature lacks consistency 
beyond the groupings below and the nomenclature system often refers to the same 
particle configurations several different ways. The most egregious are the multiple names 
for ultrasmall-SPIO (USPIO), as detailed below.  
 The largest particles, Oral-SPIO have an overall diameter between 300 nm and 
3.5 !m and are also referred to as micron-sized iron oxide (MPIO). The more commonly 
used SPIO formulations are on the nanometer scale. These nanoparticles are defined as 
particles with one dimension below 100 nm in length. SPIO in this classification include 
Standard-SPIO (SSPIO) at 60-150 nm, Ultrasmall-SPIO (USPIO) of approximately 5-40 
nm and monocrystalline iron oxide nanoparticles (MION - a subset of USPIO) range 
Chapter 1  29 
 
from 10-30 nm. A prevalent derivatization of MION, consisting of a chemically cross-
linked polysaccharide shell, is referred to as CLIO (Cross-Linked Iron Oxide). Molecular 
imaging of disease generally requires the use of the smaller agents in the category of 
USPIO. In the literature USPIO is the most common name; however MION, VSOP (very 
small iron oxide particles) and MNPs (magnetic nanoparticles) are used, among others. 
SPIO will be used herein to refer to MPIO, SSPIO, MION, CLIO, and USPIO, unless 
otherwise noted. 
 Trade names given to SPIO are also often confusing, primarily because the same 
formulation is often given different pharmaceutical names depending on the specific 
regional market. Ferumoxsil or AMI-121, an approximately 400 nm Oral-SPIO, is also 
known as GastroMARK (USA) and Lumirem (EU and Brazil). This agent is approved for 
use in Europe to distinguish between abdominal tissues and the bowels. Larger Oral-
SPIO such as OMP (also known as Abdoscan) has a larger hydrated diameter at 3.5 µm. 
Ferumoxide or AMI-25 is also known as Feridex IV (USA) and Endorem (EU). This 
agent is an FDA approved SSPIO, 80-150 nm in diameter, for use in detection and 
diagnosis of liver metastases. Ferumoxtran or AMI-227 (also known as Sinerem (EU) 
and Combidex (USA)) is a dextran coated USPIO (of a diameter between 20 and 30 nm) 
(13) currently in late-phase clinical trials for detection of lymph-node metastases (14, 15). 
Ferucarbotran, Ferrixan, SHU 555, or Resovist (EU and Japan) is a carboxydextran 
coated SPIO of approximately 60 nm hydrodynamic diameter approved for use in Europe 
(16, 17). Table 1.2 contains a concise listing of SPIO, their alternate names, approval 
status, application and size. 
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1.6.3 - Alternative SPIO 
 Overall, the use of the term SPIO in the literature refers to nano- and 
microparticles as defined above. These magnetopharmaceuticals of superparamagnetic 
iron oxide are not the only forms of the contrast agents that exist. Ferritin is a well 
conserved protein complex produced by all eukaryotes for intracellular iron-storage (18). 
The core of iron surrounded by the protein subunits can be substituted with a 
superparamagnetic crystal, however the rapid clearance (to the liver and spleen) of these 
protein-based-SPIO have presented major restraints to their in vivo use (19-21).  
 In another biologically inspired strategy, iron oxide nanocrystals produced by 
magnetotactic bacteria have also been exploited for imaging purposes, as an in vivo 
transgene reporter (22). Here, an adenoviral vector was used to place the nanocrystal 
manufacturing gene into cells of interest, whereupon subsequent production of SPIO 
could be visualized using gradient echo sequences. This approach, while certainly novel, 
has not seen widespread adoption to introduce SPIO biologically.  
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Class Agent Trade name(s) FDA Status Application Diameter 
AMI-121 
(Ferumoxsil) 
Lumirem, 
Gastromark 
Approved GI Lumen > 300 nm Oral-
SPIO 
OMP Abdoscan Approved GI Lumen 3.5 !m 
AMI-25 
(Ferumoxide) 
Endorem 
Feridex 
Approved Liver 80-150 nm  
 
SSPIO SHU555A 
(Ferucarbotran 
or Ferrixan) 
Resovist Approved Liver 
Blood pool 
62 nm 
AMI-227 
(Ferumoxtran) 
Sinerem, 
Combidex 
Phase III 
complete 
Lymph 
Blood pool 
20-40 nm 
NC100150 Clariscan Discontinued Blood pool 20 nm 
 
USPIO 
 
CODE 7228 
(Ferumoxytol) 
Advanced 
Magnetics 
Phase II 
complete 
Blood pool 
Kidney 
18-20 nm 
 
Table 1.2 - Commercially Available SPIO CA. 
A list of SPIO commercially available or in development for clinical use. Updated by 
Thorek, from (23).  
 
1.6.4 - Iron Oxide Core and Magnetism 
 Despite the different manifestations of SPIO noted in the preceding section, they 
typically share two common features. These are a core of iron oxide crystal(s) and an 
exterior coating material, as depicted in Figure 1.9A. The cores of the particles are 
composed of inverse spinel iron oxide crystals of magnetite (Fe3O4) and/or maghemite (!-
Fe2O3). The crystal structures are shown in Figure 1.9B. The cores of many SPIO are 
composed of multiple crystals or of imperfect crystals, generally dependent on the 
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synthesis method and conditions. The two magnetic oxides, magnetite and maghemite, 
have similar crystal structures (lattice parameters of 8.396 and 8.346 Å, respectively) and 
magnetic properties (24). In bulk, maghemite does have a lower saturation magnetization 
(saturation refers to a plateau in the magnetic flux density following increasing 
magnetization force).  
This is not a major factor in nanoparticle magnetic properties for two reasons. 
Firstly, at the magnetic fields that are utilized in MR imaging both forms of bulk 
materials are invariably saturated. The second and perhaps a more important factor is that 
at the nanoparticle length scale, the emergence of quantum magnetic effects predominate. 
This renders the bulk lattice state less crucial in determining particle relaxivity and these 
features are the real impetus behind the recent interest in nanoparticle and nanoscale 
technologies. A description of this nanoscale magnetic phenomena (superparamagnetism) 
follows after a description of the different categorizations of classical magnetic materials. 
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Figure 1.9 - Schematic of SPIO and Crystal Structure. 
(A) Representation of a superparamagnetic iron oxide nanoparticle. The iron oxide core 
is surrounded by a polymer or polysaccharide coating, either formed during the synthesis 
of the crystal or after. The surface coating can be chemically modified with functional 
sites for bioconjugation to biological and chemical items of interest. (B) Crystal 
structures of a single unit cell for the two predominant SPIO components, magnetite and 
maghemite, using a ball and stick model. The large orbs are oxygen, denoted as O, the 
smaller are iron (Fe) in the octahedral and tetrahedral sites. Information for the two 
crystals were retrieved from the American Mineralogist Crystal Structure Database and 
images were generated using CrystalMaker®.  
Iron oxide core
Chemical or biological 
modification
Polymer or polysaccharide shell
Maghemite (!-Fe2O3) Magnetite (Fe3O4)
A
B
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 Empirically, magnetic materials are characterized by their response to being 
placed in a magnetic field. The resulting magnetization of the material can take one of 
several forms and the material is described as being diamagnetic, paramagnetic or 
ferromagnetic. In the first instance, the orbital electrons in the material are moved to a 
magnetic dipole moment in the opposite direction of the applied field. In other words, the 
magnetic susceptibility (magnetization of a material in an applied field) is less than 0. In 
bulk materials this manifests in repulsion of the material away from the magnetic field. 
This phenomenon often occurs strongly within materials whose valence electrons are all 
paired, however all ‘non-magnetic’ materials exhibit some level of diamagnetism. 
Paramagnetic materials, like the gadolinium(III) ion, have a positive magnetic 
susceptibility. Thus, the induced magnetization of the material is in alignment with the 
applied field. However, in the absence of a field, the magnetic dipoles are randomly 
aligned; in other words they have no remnant magnetization. This is often found in 
elements with non-zero angular momentum (unpaired valence orbitals) and is found in 
some metals. A schematic of a paramagnetic material’s magnetic dipole configuration is 
found in Figure 1.10A. 
 Ferromagnetism is a phenomenon wherein some materials exhibit spontaneous 
magnetization in the absence of a magnetic field. The magnetic properties of 
ferromagnetic materials arise from the alignment of unpaired spins of electrons (magnetic 
dipoles) in a cooperative fashion. This is observed in some transition metals and their 
oxides. In a typical bulk ferromagnetic material, magnetic domains are aligned at short 
range and separated by a transition region called a Bloch wall.  
Chapter 1  35 
 
 
Figure 1.10 – Magnetic Dipole Characterization of Materials. 
(A) The random alignment of magnetic dipoles of a paramagnetic material. When 
exposed to a magnetic field, these spins align and enhance the field. Also shown are the 
aligned magnetic dipoles of ferromagnetic materials. (B) In a ferromagnetic material of 
sufficient size to contain crystal sub-domains parallel and antiparallel alignment, a Bloch 
wall exists to minimize inter-domain surface energy. (C) For a superparamagnetic 
material, there exists a single magnetic dipole orientation as the crystal size discourages 
the formation of Bloch walls. This creates a net magnetic dipole for the particle. Edited 
by Thorek, from (25). 
 
domain A domain BBloch wall
single domain
A
B
C
paramagnetic ferromagnetic
ferromagnetic
superparamagnetic
particle
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 At the nanometer scale, approximately 14 nm and below, the formation of the 
Bloch walls (magnetic domain boundaries) become thermodynamically unfavorable. The 
result is single magnetic domain crystals. Magnetite crystals at this scale exhibit very 
strong paramagnetic behavior, lending them the name superparamagnetic (26, 27). 
Superparamagnetic materials, like paramagnetic materials, retain no magnetization when 
removed from the applied field. As such, they are described as having no remnant 
magnetization. Any cooperative alignment of dipole moments at this nanoscale is 
overcome by thermal energy at room temperature (28). 
 The phenomenon of superparamagnetism, first observed in 1938 (29), is now an 
area of intense research for both magnetopharmaceuticals and data storage (30). The 
nanoparticles employed for MR image contrast have very high magnetic susceptibilities 
(much greater than 0). In essence they are saturated in any applied MR field. They 
function so effectively as T2 and T2* CA because of two nanoscale processes: the (1) 
Néel and (2) Brownian relaxation mechanisms.  
 The iron oxide crystal is again a single domain particle, but the lattice is 
anisotropic and thus the NPs magnetization aligns in only so called easy directions. Any 
non-cubic crystal has a degree of anisotropy energy, determined by Equation 1.9, where 
Ea is the anisotropy energy of the crystal, Ka is the anisotropy constant and V is the 
volume of the crystal. Nanoparticulates have high surface-to-volume ratios and so the 
crystal or particle-core has a high anisotropy constant, but a small volume (31). 
   
! 
Ea = KaV      Equation 1.9  
This anisotropy energy determines the Néel relaxation time, !N, described as the time 
required for the crystal's magnetization to return to equilibrium after a perturbation. This 
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relationship is described in Equation 1.10, following the Arrhenius law, where !0(Ea) is 
the pre-exponential factor, k is the Boltzmann and T is the absolute temperature. 
  
! 
"N = " 0(Ea )e
Ea
kT     Equation 1.10 
 At ambient conditions, Ea<<kT (32, 33) and thus the exponential reduces to 1. 
The Néel time thus depends on the anisotropy energy; again, this value is high for single 
crystal NPs. As the volume of the crystal decreases, the Néel time decreases and therefore 
nanometer-sized crystals have very short magnetization angle relaxation times. This 
results in a magnetization vector that fluctuates randomly in environments of sufficient 
thermal energy (33, 34). 
 The impingement of surrounding water molecules upon the nanoscopic entity is 
also able (at room and physiological temperatures), through transfer of momentum, to 
randomly translocate and reorient the particle. This latter mechanism is known as 
Brownian relaxation. This relaxation process is described in Equation 1.11 where !B is 
the Brownian relaxation time and " is the damping constant.  
  
! 
"B =
3V#
kT      Equation 1.11 
 The two relaxation mechanisms contribute to a sum relaxation rate, Equation 1.12 
(35).  
 
! 
1
"
=
1
"N
+
1
"B
     Equation 1.12 
Under conditions of very fast relaxation, where 
! 
" B predominates, the system is always at 
thermodynamic equilibrium. This behavior is named superparamagnetic (27). An 
illustration of the two processes found to contribute to the short relaxation times of the 
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magnetization vector is provided in Figure 1.11A. The NPs are able to recover their 
equilibrium magnetization faster than any applied impingement upon their magnetic 
state. The SPIO essentially behave as local magnetic field inhomogeneities leading to 
rapid dephasing of coherent protons that lie within the SPIO's induced field, as illustrated 
in Figure 1.11B. 
 It should be mentioned that nano- and micron sized particles in cells of 5-20 !m 
can be routinely detected in MR applications using imaging resolutions of 50-100 !m 
(36, 37). This is a result of the size of hypointensity susceptibility generation by 
superparamagnetic agents in T2*-w imaging. Here, the offset phase dispersal in the slice-
selection direction produces a triple-band shaped “blooming effect” (38). In phantoms 
and clinical imaging, the effect produced is much larger than the site of accumulation, 
producing darkening across a detectable voxel volume (39-41). 
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Figure 1.11 - Relaxation Mechanisms of Superparamagnetic Crystals. 
(A) The two relaxation mechanisms, Néel and Brownian, are schematically described in 
an applied field in the top and bottom row of single domain crystals, respectively in top 
and bottom rows. In the Néel phenomenon, the movement of the magnetization vector to 
some other easy axis and then back to the equilibrium magnetization is described by N. In 
the Brownian contribution, the rotation of the magnetization results from random 
movement in water above absolute zero. In (B), we see the local effect of SPIO 
nanocrystals on surrounding water protons ( ). The effect decreases with an r6 
dependence and thus is highly localized. 
 
!N
!B
B0
A B
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 SPIO possess both high longitudinal and transverse relaxivities. The majority of 
uses for iron oxide NPs in the literature are for T2*-w imaging applications, but they have 
been used in a variety of applications as T1-w imaging agents. For example, the high R1 
properties are exploited in MR angiography protocols where long circulating SPIO 
configurations are utilized as blood pool agents (42-44). 
 
1.6.5 - SPIO Synthesis 
 SPIO can be manufactured with distinct sizes and distribution profiles, magnetic 
character, physicochemical properties and coatings. The most commonly applied 
methods for producing the NPs are chemical: the co-precipitation and microemulsion 
techniques. Lesser-utilized routes include ultrasound irradiation (or sonochemcial 
synthesis) (45), thermal decomposition (46), layer-by-layer deposition (47, 48) and spray 
and laser pyrolysis (49). These latter methods can provide finer distributions and sizes of 
NPs, as well as more complex core/shell structures, however they often require advanced 
equipment and expertise. 
 In the most widely adopted procedure, that of co-precipitation, ferric and ferrous 
salts in solution are precipitated by bringing the mixture to high pH, usually through the 
addition of concentrated base. Equation 1.13 below details the chemical reaction of Fe3O4 
in the aqueous medium.  
 
! 
Fe2+ + 2Fe3+ + 8OH" # Fe3O4 + 4H2O   Equation 1.13 
The base addition precipitation of Fe3O4 begins at pH 8, at a stoichiometric ratio of 2:1 
(Fe3+/Fe2+). Absence of an oxidizing environment is required for limitation of side-
products as magnetite lacks stability, therefore this chemical route is often run under N2 
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or Ar (50, 51). The partial oxidation of magnetite to maghemite (!-Fe2O3) occurs 
spontaneously, Equation 1.14. This is driven in the presence of oxygen, but may also 
occur under aqueous conditions through ion transfer particularly at the surface of the as-
formed magnetite nuclei (52, 53). 
 
! 
Fe3O4 + 2H + "#Fe2O3 + Fe2+ + H2O   Equation 1.14 
 NPs manufactured using the co-precipitation technique offers great flexibility and 
control over the properties of the final product through relatively straightforward 
chemical means (54). The advantages of co-precipitation synthesis, in particular large 
batch volumes, scalability and ease of manufacture, are somewhat offset by wide SPIO 
size distributions. This is a result of the two steps involved in the technique: (1) 
nucleation (under inert gas, usually on ice), and (2) growth of the nuclei. The separation 
of these two steps drives the formation of many small particles followed by the controlled 
growth of these in the second. Strict size selection, usually by filtration and 
centrifugation, are subsequently required. 
 The second most common synthesis method is the microemulsion technique. This 
route generally achieves greater control of size and shape of the nanoparticles (55). 
Customarily a water-in-oil approach is pursued that sees ‘nanodroplets’ of aqueous iron 
salts dispersed and coated in a surfactant-organic solution. The size control over the 
system is greater for the resulting SPIO as they are precipitated in these pre-sized reverse 
micelles (again, often through the addition of an alkaline solution) (56, 57). These 
methods are able to produce populations of particles with very tight distributions. 
However, a significant tradeoff is that iron precipitates below 5 nm have been found to 
possess amorphous (non-crystalline) iron oxides (58, 59) and therefore often lack uniform 
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magnetic properties throughout a population of probes. The yields from this method are 
also generally smaller in practice than those of the co-precipitation technique.   
 
1.6.6 - SPIO Coating 
 The use of (typically hydrophilic) surface complexing agents is often required to 
achieve stability and enhance solubility of iron oxide colloids in physiological conditions, 
a requirement for use of SPIO in biomedical applications. Repulsive forces between the 
particles must exist to maintain their stability in solution, as there is some trend towards 
aggregation from magnetic and surface energy attraction. Bare magnetite particles have a 
weak interaction with water, leaving the iron oxide surface hydroxyl functionalized. 
These groups have an isoelectric point at approximately neutral pH (60), meaning that 
particles will flocculate and precipitate out of biologically relevant solutions unless 
otherwise coated. 
 The formation of iron oxides by the co-precipitation technique can either be 
conducted in water or in the presence of a surface coating materials such as polyethylene 
glycol (PEG), dextran or polyvinyl alcohol (PVA) (13, 61-63). More recently, chistosan 
(64, 65) and alginate (66, 67) have been explored as coating polymers because of these 
polymers' interesting electrostatic and degradation properties. Bare SPIO, which are often 
produced in a citrate ion solution, can be subsequently coated in small molecules (68-71), 
silica (72, 73) or polymers (74). Microemulsion produced nanoparticles are often not 
directly soluble in aqueous solvents, making chemical surface alterations necessary.  This 
can be achieved using surfactants (added either during or after the synthesis).  
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 Beyond magnetically induced aggregation, another benefit of surface complexing 
agents is to avoid quick opsonization (75). The introduction of bare iron oxide particulate 
species in vivo is accompanied by rapid opsonization by plasma proteins, resulting in 
rapid clearance by the reticular endothelial system. This greatly limits the ability of the 
CA to circulate to bind targets, function as blood pool agents, or distribute effectively 
into tissues (76). The effect of particular coatings on SPIO pharmacokinetics and 
biodistribution is a fundamental reason for the wide variety of different materials that 
have been tested as SPIO exteriors (77, 78). From a size perspective, carbohydrate or 
polymer-coated SPIO typically vary from ~20 to above 100 nm in hydrodynamic 
diameter (controlled by synthesis parameters such as the iron-to-polymer ratio) with iron 
oxide core sizes ranging from ~2 and 15 nm (13).   
 Surface coatings are also an efficient platform for further modification of the MR 
CA in that they can be derivatized with different surface chemical groups (79), 
transfection agents (80),  or targeting agents (81). The surfaces can also be used to 
conjugate the MR probes to other imaging media, for example nuclear and optical 
moieties to create multi-modal agents (82, 83).  
 A recent development in SPIO technology has been the investigation of the 
surface coating effects on the relaxivity of the particles, rather than their biocompatible or 
biodistribution consequences, as discussed below. The enhanced dephasing of water 
surrounding the iron oxide core is dependent on that water being within the altered field 
of the SPIO. With greater thickness coatings it can be realized that there would be less 
water in the inhomogeneous magnetic region. While the diffusion of water through most 
surface complexing materials (polymers and polysaccharides) makes computational 
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modeling more difficult, both simulations and experimental evidence have shown that the 
thickness of coating affects relaxation properties of the particles (84). Using a fixed iron 
oxide core size it was found that increasing the thickness of a PEG micellar coating 
resulted in a dramatic decrease in R2. Interestingly the drop-off in R1 was much less 
severe, likely due to the rate-limiting step of longer longitudinal water relaxation times. 
 
1.6.7 - Biocompatibility and Biodistribution 
 The broad biocompatibility of SPIO has been a significant reason for its clinical 
acceptance and basis as a research nanoparticle platform. The metabolism and toxicity of 
SPIO have been widely investigated since its introduction into the field of medicine (77).  
Given that iron is an essential element for human beings, and is critical for the delivery of 
oxygen and the proliferation/survival of all cells, it is no surprise that SPIO can enter the 
body’s normal iron metabolism cycle following uptake by the reticuloendothelial system 
(RES) (85).  In fact, SPIO were originally developed as a ferritin substitute to treat 
anemia (86-88).   
 One concern, however, has been that iron contained in SPIO could enter cells 
independent of the transferrin pathway (used to closely regulate intracellular iron levels), 
leading to high levels of non-chelated iron. This is potentially troubling as concentrated 
iron may produce radical oxygen species. Studies have shown however, that the 
breakdown of magnetite in cells leads to ferric (rather than ferrous) iron release (89).  
This iron ion is efficiently chelated by citrate and rendered non-toxic (90). 
 Extensive research (in vivo and in vitro) has been carried out on the impact of 
SPIO on cell viability and function. Recent in vitro studies have shown that SPIO are able 
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to enter the cell (for example, in macrophage (91) and mesenchymal stem cells (92)) 
through endocytosis and can then either be released back into the extracellular space or 
shuttled into low pH environments in lysosomes (92). It is in these compartments where 
they breakdown over the course of several days (80, 93).  Immortalized fibroblasts, when 
incubated with PEG-coated SPIO, showed no discernable changes in cell adhesion 
behavior or morphology (87) and the same was reported for T cells labeled with SPIO 
(94). Transfection agents such as the HIV-Tat peptide, polyarginine and protamine, as 
well as many small molecules, have been conjugated or complexed with SPIO in order to 
achieve greater cellular uptake (95). The use of these agents alongside SPIO has also 
been found to have minimal cellular toxicity revealing no significant effects on cell 
viability (80), clonogenic efficiency (82), biodistribution or immunophenotypic changes, 
for example - macrophages are not activated upon uptake (96). Many of these studies also 
expose the cells to nanoparticles for long periods of time, up to 3 days, showing little 
detriment to cell viability or division kinetics for embryonic (97) and neural stem cells 
(98).  
 While many studies generally assert the indifferent response of cells to the 
presence of the probes, further work is required to validate their use in specific 
applications and the limitations therein. For example, Feridex IV (Bayer Healthcare 
Pharmaceuticals) incubation in culture with human bone marrow-derived mesenchymal 
stem cells had no discernible affect on viability, proliferation, adipogenesis or 
osteogenesis. However chondrogenesis was found to be inhibited in a dose dependent 
manner (99). Working with the same cell line under identical loading conditions, a 
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polyvinyl pyrrolidone (PVP)-coated iron oxide nanoparticle SPIO formulation was found 
to possess no phenotype inhibiting effects (100).  
 Upon intravenous administration of SPIO, anaphylactic-like reactions and 
hypotension have been noted. Adverse events from SPIO are however usually mild and 
short in duration (101). The most common complaints included headache, back pain, 
vasodilation, and hives. Once introduced, the pharmacokinetics of each embodiment of 
SPIO is dependent primarily on the size and surface characteristics of the agent.  The 
spleen and liver are able to screen SPIO that are approximately 200 nm or above, mainly 
through mechanical filtration. SPIO below approximately 10 nm are removed through 
extravasation and renal clearance (102). Agents with a diameter of 30-50 nm have 
demonstrated longer plasma half-life, particularly when coated in amphiphilic polymers 
including dextran, PEG and polyvinyl alcohol (PVA) (103). The so-called stealth effect 
of coatings that inhibit recognition by the RES are thought to act through either 
avoidance of immune responses that stimulate opsonating proteins or conversely through 
the absorption of serum proteins that the body recognizes as benign (76). 
 In the case of targeted SPIO agents, longer circulation times can be equated with 
an enhanced probability of the probe binding its ligand (104, 105). Longer residency in 
the blood is also of benefit for non-targeted applications that seek to avert quick clearance 
by the liver and spleen (106). It should also be noted that large particle size may prevent 
effective extravasation and reduce diffusion of the agent through the interstitium, 
important considerations for many SPIO imaging objectives such as lymph node imaging. 
This is not so much an issue for the imaging of the vascular endothelium (81, 107) or 
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tumor sites possessing leaky vasculature. Here particles have routine access and tend to 
accumulate through the 'enhanced permeability and retention' effect (108, 109).  
Exploitation of this mechanism of passive (non-targeted) accumulation is used to 
generate contrast in two ways. The first is through SPIO accumulation at the pathological 
site, thereby darkening it. This has been applied for the detection of cancer and 
inflammation in many models, including blood-brain-barrier degradation following 
stroke (110, 111) and neoplasm (112, 113), bone metastases detection (114, 115) and 
occult lymph node detection (14, 15). 
The second passive accumulation strategy is essentially an inverse of that 
described above. The SPIO may be excluded from accruing in tissue or cells of interest, 
thus darkening the surrounding region where SPIO access is possible. This effectively 
results in brightening of the site of interest. This inverse contrast approach is the principal 
application of SPIO, for the delineation of hepatic metastases. Administered SPIO are 
found to accumulate in the healthy liver within Kupffer cells, whose primary function is 
to recycle and accumulate iron from the blood. The absence of Kupffer cells in 
malignancies allows for SPIO, under T2 and T2*-weighted imaging, to specifically darken 
the surrounding healthy liver (116-118). This represents a significant improvement over 
conventional non-contrast enhanced imaging of hepatic tumors It has been reported that 
non-contrast-agent enhanced imaging is limited to detection of lesions greater than 3 cm 
(119), however MR imaging of 1 cm growths is possible with SPIO enhanced approaches 
(120). 
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1.7 - Immune Cell Imaging  
1.7.1 - Relevance 
 Directed migration of specific cell types to target organs or tissues is a critical 
feature of fundamental biological processes. From development through to the 
maintenance of any complex organism, this trafficking feature is of great scientific 
interest. With its direct impact on maintaining healthy physical conditions and protecting 
the body from disease, an area of particularly concentrated research focus has been on the 
distribution of key cellular players in the immune system.  
 The immune system is composed of two interacting components; the innate and 
adaptive. The adaptive immune system is responsible for specific responses to (usually 
foreign) pathogens, and relies upon T and B cells through processes such as the 
production of antibodies. This contrasts with the non-specific, but immediate and wide 
ranging, response mounted by innate immune cells, such as macrophage and mast cells, 
against a wide range of foreign pathogens. The ability to monitor the selective 
recruitment, activation, arrival and departure of specific immune cells in homeostatic and 
disease conditions is a compulsory requirement towards greater knowledge of immune 
response and function.  
 Complicating deeper understanding of immune cell responses to pathogenesis and 
treatment is the fact that imaging of these migratory pathways is inherently difficult. This 
section will provide a review of the approaches employed to overcome the limitation 
posed to cellular tracking in the deep tissue of opaque organisms. The alternative 
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modalities and significant work in cell tracking will be presented. The particular case of 
utilizing SPIO for MR-based immune cell imaging will then be discussed. 
 
1.7.2 - Tracking Strategies 
 In order to track specific cell types of interest in vivo it is necessary to deliver 
contrast media, regardless of modality, directly to that population. There are two general 
strategies that accomplish this task: 1) ex vivo loading of cells with CA and 2) the in vivo 
targeting of the population. Each method has unique strengths and weaknesses.  
 In the first approach, control over the loading of NPs, dyes or genetic constructs 
into the cells is greater, as in vitro conditions can be optimized for specific cell types. The 
amount of the CA loading that can be obtained is also much higher as delivery of the 
agents is direct. This strategy is often also simpler (although exogenous transfection 
agents may be required) as uptake in unwanted compartments within an organism is not a 
concern. This means that the addition of supplementary modification such as the addition 
of a stealth coating (for long circulation) may not be required. The benefit of greater 
sensitivity upon subsequent implantation (through high levels of accumulated agent) and 
simpler probe design is balanced by the obligation to first acquire the cells of interest 
from a biological sample. This may have detrimental effects upon the in vivo function 
and distribution of these cells. Further, the duration of imaging is limited to the lifetime 
of the cells (or the residency time of the SPIO within the cells).  
 The second strategy sees the in vivo application of contrast with some form 
targetability, usually in the form of peptides or proteins, directed at the cells of interest. 
These constructs can be repeatedly administered to target the same (or even different) cell 
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populations of interest. Derivation of the particle with specific ligands is also not always 
needed, as in specialized applications, for example the investigation of liver metastases 
using SPIO (121). However, in most applications the non-specific uptake, deposition or 
accumulation of agent is detrimental to the imaging process. It reduces signal-to-
background levels between the population of interest and all non-specifically targeted 
tissues. This is further complicated by the fact that it is rarely possible to achieve the 
same loading levels of CA as compared to an ex vivo situation. To overcome this 
problem of lower signal, interesting tactics are sometimes employed. One example for 
use in targeting radionuclides has been the two-step system, also called pre-targeting, 
wherein an antibody-avidin is administered first. Time is given for this first agent to clear 
before introduction of a biotinylated radiotracer, which has a very high affinity for 
binding specifically with avidin (122, 123). 
 
1.7.3 - Optical Imaging 
 Diverse technologies have been used to reveal the spatiotemporal distribution of 
immune cells in vivo. These include but are not limited to fluorescent and bioluminescent 
proteins, fluorescent molecules, intravital microscopy, radionuclide-based single-photon 
and positron emission tomography (SPECT and PET), MR contrast agents and even 
ultrasound particulate contrast (124). The most commonly used of these options are the 
optical technologies because of their relative ease of use, and reduced equipment cost. 
 The major limitation of using light to probe cell distribution within an organism is 
its limited depth of tissue penetration.  It has long been understood that the absorption 
and autofluorescent properties of tissue is wavelength dependent. This is seen in the 
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absorption versus wavelength chart in Figure 1.12. Early spectroscopic studies of protein 
within in intact tissues revealed presence of a near-infrared (NIR) window. This window 
refers to the much greater NIR transparency of tissue, particularly skin, to light of 
wavelength in the range 700 - 1300 nm (125). Thus, for effective in vivo studies of cells 
and cell populations either long wavelength fluorescent molecules or proteins can be 
effective. Shorter wavelength proteins and dyes can be used, but applications usually 
involve intravital microscopy. Such techniques are inherently invasive and usually 
involve surgical exposure of the tissue(s) of interest (126). 
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Figure 1.12 - Wavelength Dependence of Tissue Absorbance.  
The use of longer wavelength dyes for the in vivo imaging of immune cells is explained 
by the fact that the tissue penetration of such NIR light is much greater than that of higher 
energy, shorter wavelength light. This feature of greater penetration occurs in the so-
called NIR window. The spectral domains of common in vivo imaging molecules and 
proteins are noted. Figure adapted from (127). 
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Detecting early cancers. A variety of reporter probes have been
used for enhanced detection of early cancers, including somato-
statin receptor–targeted probes32–34, folate receptor–targeted
agents35, tumor cell–targeted agents36–39, agents that incorporate
into areas of calcification, bone formation or both40, and agents
being activated by tumor-associated proteases41–43. Many of these
agents accumulate in (and thus enhance) tumors to a certain de-
gree; however, FRET-based agents can yield particularly high
tumor/background signal ratios because of their nondetectabil-
ity in the native state. For example, recent work has shown that
highly dysplastic tumoral precursors are readily detectable by
targeting cathepsin B (ref. 23), a protease capable of activating a
model reporter (Table 2). In this particular study, the sensitivity
and specificity of optical detection of intestinal polyps were each
>95%. Similar approaches may be particularly useful for early en-
doscopic detection and characterization of polypoid lesions as
well as laparoscopic detection of residual or recurrent tumors
such as ovarian cancer. These probes have also been used to de-
tect host response, inflammation and invasion (Fig. 3).
Assessment of molecular therapy.
One particularly interesting applica-
tion of enzyme-activatable imaging
agents has been to use them as tools
for objective target assessment of
new therapeutic agents. In one
study, the efficacy of a matrix met-
alloproteinase-2 (MMP-2) inhibitor
at varying dosing and timing was
assessed with an MMP-2-targeted
imaging probe44. Small molecule–
induced target inhibition could be
externally imaged as shortly as 8 h
after therapeutic drug administra-
tion. It is clear that other classes of
imaging agents will be developed to
image the growing array of different
drug targets.
Clinical imaging. Indocyanine
green (ICG), an NIR fluorochrome,
is approved for clinical retinal an-
giography and liver function test-
ing45. It is a safe imaging agent,
having been used in tens of thou-
sands of patients with a reported
side effect rate of <0.15%, an extremely favorable index as
compared with other reporter agents46. In addition, it has been
used in at least one clinical study as an absorber (not a fluo-
rochrome) for enhanced tumor detection31. Near-infrared fluo-
rochromes with improved biophysical properties (solubility,
quantum yield, stability, synthetic yield, conjugatability) have
recently been developed47–49 and open new avenues for high-
efficiency labeling of affinity molecules. Before they can enter
routine clinical use, however, these fluorochromes will need to
und rgo testing and receive approval from the US Food and
Drug Administration.
Table 1  Optical in vivo imaging systemsa
Technique Contrastb Depth Commonly used Clinical 
wavelength potential
Microscopic resolution
Epi A, Fl 20 µm Visible Experimental
Confocal Fl 500 µm Visible Experimental
Two-photon Fl 800 µm Visible Yes
Mesoscopic resolution
Optical projection tomography A, Fl 15 mmc Visible No
Optical coherence tomography S 2 mm Visible, NIR Yes
Laser speckle imaging S 1 mm Visible, NIR Yes
Macroscopic resolution, intrinsic contrast
Hyperspectral imaging A, S, Fl <5 mm Visible Yes
Endoscopy A, S, Fl <5 mm Visible Yes
Polarization imaging A, S <1.5 cm Visible, NIR Yes
Fluorescence reflectance imaging (FRI) A, Fl <7 mm NIR Yes
Diffuse optical tomography (DOT) A, Fl <20 cm NIR Yes
Macroscopic resolution, molecular contrast
Fluorescence resonance imaging (FRI) A, Fl <7 mm NIR Yes
Fluorescence molecular tomography Fl <20 cm NIR Yes
(FMT)
Bioluminescence imaging (BLI) E <3 cm 500–600 nm No
aNote that the combination of reporter probes (Table 2) and imaging system often imparts molecular specificity. bA,
Absorption; E, emission; S, scattering; Fl, fluorescence. cIn cleared specimen.
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Fig. 1 Interaction of light with tissue. The absorption coefficient of light
in tissue is dependent on wavelength and results from absorbers such as
hemoglobins, lipids and water. The graph is calculated assuming nor-
mally oxygenated tissue (saturation of 70%), a hemoglobin concentra-
tion of 50 mM, and a composition of 50% water and 15% lipids. The
graph also lists the emission range of several common fluorochromes and
luciferases used for imaging. The insert shows autofluorescence spectra
obtained in vivo at different excitation wavelengths (obtained from ref.
84). The excitation range, denoted as !x, is from 337 to 610 nm, and the
emission range (!m) is from 360 to 750 nm. Note the much lower tissue
autofluorescence at longer wavelengths. The mouse images at the bot-
tom show experimentally measured photon counts through the body of a
nude mouse at 532 nm (left) and 670 nm (right). The excitation source
was a point illumination placed on the posterior chest wall. Signal in the
NIR range is "4 orders of magnitude stronger for illumination in the NIR
compared with illumination with green light under otherwise identical
conditions, illustrating the advantages for imaging with NIR photons. 
©
2
0
0
3
 N
a
tu
re
 P
u
b
li
s
h
in
g
 G
ro
u
p
  
h
tt
p
:/
/w
w
w
.n
a
tu
re
.c
o
m
/n
a
tu
re
m
e
d
ic
in
e
Chapter 1  53 
 
 Long wavelength fluorescent sources have been employed in vivo to identify and 
track immune cell populations. The targeting approach for detection of a cell population 
centers primarily on organic dye conjugated antibodies. These have been used with some 
success in visualizing cancers and specific cell types (128, 129). Nanoparticulate forms of 
optical contrast also exist. Quantum dots (QD) are composed of semiconductor materials 
with a diameter of several nanometers and are of widespread research focus. They are 
also found to be phagocytized by activated macrophage when administered intravenously 
(130). Specific targeting of these NP has not been shown with immune cells. 
 Ex vivo loading of optical agents for the subsequent in vivo visualization of cells 
is a common approach for fluorescent imaging. No longer dependent upon applying cell-
type specific antibodies (which may be difficult to obtain for the sub-population of 
interest), lipophilic dyes that bind indiscriminately to the cell membrane have been 
investigated. In one study, multiple NIR dyes were used in conjunction with specialized 
laser scanning equipment to concomitantly visualize the whole mouse distribution of 
activated and naïve primary T cells labeled ex vivo (131). The cells were tracked to the 
lymph nodes and spleen as well as to tumors implanted in the mouse brain. Labeling of 
cells with such NIR dyes have been shown to have no effect on T cell proliferation, 
viability or function (132). Non-targeted QD have also been loaded in cells ex vivo for 
the in vivo visualization of macrophage and lymphocytes (133).  
 A concern with the use of any dye is that over long study times, dilution of the 
dye occurs through cell division. A recent advance in this field has been the development 
of red (584 nm excitation) and NIR fluorescent protein (684 nm excitation) that can be 
used to image sites in deep tissue (134, 135). For example transgenic mice, engineered to 
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express red fluorescent protein in lymphatic tissues have been generated to study T cell 
migration (136). 
 Luciferases, luminescent proteins, are also useful for in vivo imaging of cells. 
Although the light produced is of a short wavelength, the fact that no external excitation 
source is required means that luciferases can be detected with extremely high sensitivity 
using specialized imaging systems (137). Only the desired cell types need to be 
engineered to stably and constitutively express luciferase and the assays are relatively 
inexpensive. Several transgenic models have used this approach to study human biology 
and disease (138, 139) detecting as few as 1000 cells in the peritoneal cavity (140).  
 The majority of in vivo bioluminescent imaging has focused on tumor cells 
transformed ex vivo to express luciferase and then subsequently implanted. However, 
immune cells have also been tracked in longitudinal in vivo imaging studies using this 
strategy. These studies can be divided generally into those that have utilized 
bioluminescence either to image cells in cancer immunotherapy or to visualize 
lymphocyte trafficking in basic immune and autoimmune disease models. With respect to 
the former, the ability of biospecific antibodies to direct cytokine induced killer (CIK) 
cells towards tumor targets in vivo was rapidly assessed in real time using luciferase 
(141). The distribution of CIK cells was determined immediately following injection and 
tracked as they homed to sites of interest 72 hours later (142). Direct imaging of the 
spread of lymphoma has also been achieved using luciferase. In this work, lymphoma 
cells were transduced with a fluorescent and bioluminescent construct and implanted into 
SCID mice. Tumor growth and response to treatment was directly measured (143). 
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 In order to better understand the complex workings of the immune system, 
visualization of lymphocyte trafficking has been achieved in several transgenic models. 
In one example, mice have been engineered to only express a luciferase transgene in T 
cells, enabling highly sensitivity imaging of the migration dynamics of primary 
lymphocytes (144). This was an effective means to study the antigen initiated clonal 
expansion and response of CD4+ T cells. Several approaches have also sought to use 
bioluminescence as a means to better understand the etiology and therapeutic response in 
autoimmune disorders. In a joint inflammation model of arthritis in a transgenic mouse, T 
cell hybridomas that bind to collagen peptides were found to target joints (145). 
Trafficking of this cell population following administration revealed that lymphocytes 
migrate nonspecifically to sites of inflammation, but are able to linger once exposed to 
those sites. In an additional study devoted to the early preclinical detection of 
autoimmunity, a luciferase reporter transgene has been paired to nuclear factor (NF)-!B. 
Activation by inflammatory responses of NF-!B in a systemic lupus erythemotosus-like 
disease model generated bioluminescent signal in organs prior to the gross manifestation 
of disease or the presence of amplified antibody production (146). 
 The application of optical methodologies for the detection, tracking and function 
of immune cells has taken many forms. While several of these techniques and studies 
have expanded our understanding of cellular function and response in healthy and 
diseased states, a major limitation to their expanded use is that these agents cannot be 
used clinically. In order for translational imaging studies to be performed on the 
distribution of immune cells beyond small animal or in vitro models, the applied cellular 
and molecular imaging technique must have a clinical counterpart. Current radiological 
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techniques for cellular and molecular imaging in pre- and clinical study include 
radionuclide and magnetic resonance modalities. 
 
1.7.4 - PET and SPECT Imaging 
 Radionuclide imaging technologies have been widely employed for visualization 
of immune cells in healthy and diseased animals. The primary advantage of !+- and "-ray 
detection systems is that their sensitivity potentially allows for the detection of single 
cells. Positron emission tomography (PET) has a detection sensitivity in the pM (10-12 M) 
concentration range; single photon emission computed tomography (SPECT) is slightly 
less sensitive at 10-10 M (1). Both imaging modalities rely on the decay of short-lived (t1/2 
on the order of minutes to hours) or unstable metals. PET isotope materials are produced 
in expensive, and somewhat rare, cyclotron equipment and decay through positron 
production that leads to release of two high-energy "-rays. These agents have been used 
for detection by attachment and incorporation in small molecules, conjugated directly to 
antibodies or mediated through the pre-targeting approach, as described in section 1.7.2. 
 The most frequently used nuclear imaging agent is the PET radiotracer isotope of 
Fluorine, 18F. 18Fluorodeoxyglucose (18FDG), a glucose analogue, is used for clinical 
detection of cancer cells with upregulated metabolism (147). The agent is extensively 
used in the clinic for detection and evaluation of neoplasms before and after treatment 
(148). Uptake at sites of inflammation has long been noted as a source of false positive 
detection. 18FDG based PET tests for the detection of atherosclerotic plaque inflammation 
and ischemic stroke have been completed in both pre- and clinical work (149). The pre-
labeling of immune cells (for example white blood cells (150)) with 18FDG for tracking 
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to sites of inflammation, rather than localized uptake of small radiopharmaceuticals, has 
also been successful.  
 Single-photon imaging using radionuclides such as 99mTechnicium or 111Indium 
have been applied clinically for the detection of otherwise occult inflammation (151, 
152). The lower sensitivity of SPECT tracers is offset by their imaging system’s 
increased resolution (versus PET), generally longer half-lives and greater availability to 
clinicians (chemically rather than cyclotron derived tracers, excepting 99mTc). SPECT has 
been used for immune cell tracking as well, with particular effect in lymphocyte tracking 
in inflammatory models of bowel disease such as colitis (153, 154). 
 Radionuclide imaging approaches, while translatable and extremely sensitive for 
detection and tracking of immune cells, place restrictions on study type and duration. 
This is primarily due to the shortened window during which signal can be detected as the 
probes decompose. Further, the resolution afforded by PET and SPECT approaches is 
limited by quantum effects and detector design. This is made an even greater challenge 
by the closer proximity of organs at the small animal scale (1, 155). The functional 
information provided by PET and SPECT can be augmented by pairing these systems 
with X-ray computed tomographic (CT) systems. While this represents a major advance 
in both clinical and academic imaging, evidence has been presented that these systems 
incidentally deliver therapeutic doses of radiation (156, 157). This raises serious health 
concerns for both subjects and scientists and renders results much more ambiguous (158). 
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1.7.5 - SPIO and Immune Cell Imaging 
 MR enables whole body, non-invasive imaging over long time spans, but its low 
sensitivity requires contrast agents to be present for the imaging of single or groups of 
cells. Optical and nuclear medical approaches offer their own distinct advantages, 
however the limited depth penetration (<1 cm for bioluminescence and <10cm for NIR 
probes) of the former and the ionizing radiation and lack of anatomical detail in the latter 
impede their translational potential. Cell monitoring studies are difficult with the most 
common MR CA, gadolinium-ion chelates, which require very high metal concentration 
to make individual or groups of cells visible. However, it is worth noting that conjugates 
such as HIV-Tat-DOTA, transferrin-polylysine-DTPA and folate-dendrimer-DTPA have 
been shown to accumulate in cells and thus could be used to monitor cell migration (159-
162). Nevertheless, the intracellular accumulation of toxic gadolinium remains a serious 
concern.  
 Biocompatible SPIO particulates offer obvious advantages. SPIO have been used 
in clinical and academic studies to investigate a variety of biomedical disorders. While 
the contrast agents have been used in a range of applications (from targeted (105, 163-
165) and passive cancer detection (14, 118, 120), diagnostics (166-168), direct (169, 170) 
and drug therapy (171, 172)), the tracking of cells is a a task to which SPIO are 
particularly adept. First, investigating phagocytic cell types, such as activated 
macrophage at the sites of inflammation and Kupffer cells in the liver, is made 
straightforward as these phenotypes readily take up circulating foreign bodies. SPIO have 
been used to exploit this feature in order to accumulate at and reveal sites of medical 
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interest; for example, at sites of injured endothelium (91), ischemic stroke (111) or to 
detect liver cancers (39, 173).  
 To a considerable degree, the most common cell type detected or tracked using 
SPIO have been macrophage. The accumulation of contrast agent by this immune cell 
type renders visualization by MR relatively straightforward, as little additional 
modification of as-synthesized nanoparticles (or even microparticles) need to be made. 
Cellular imaging of monocyte/macrophage activity has been employed in a variety of 
disease models where inflammation plays a critical role. In mice with experimental 
autoimmune encyphalomyelitis (EAE), a model for central nervous system inflammatory 
disorder multiple sclerosis, administered iron oxide accumulates at cerebral lesions (174). 
SPIO uptake at these inflammatory sites enables monitoring of progress and staging of 
disease (175, 176). The pre-clinical application of SPIO for detection of macrophage for 
the study and detection of organ transplant rejection (177, 178), ischemia (179, 180) and 
atherosclerosis (181-183) has also been achieved. Further, clinical work has attempted to 
use the particles to enable better understanding of lesion formation in cerebral models 
(184) as well as atherosclerosis (185).  
Inflammation plays a central role in the pathophysiology of virtually all disorders, 
and is thus of wide interest. It is also a complicated process involving many cellular 
players. To this end, cells of many different phenotypes beyond macrophage have been 
loaded with SPIO ex vivo in order to be followed once implanted. The tracking of 
inflammatory cells, such as T cells (186), NK cells (187, 188) and dendritic cells (189, 
190) has been accomplished. This is a powerful means to gain insight into the locations 
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of immune cells and their subsequent migrations in response to injury, disease or as 
therapeutic vehicles (for example engineered T cells or stem-cells (191)). 
 A focus of recent immunological research, dendritic cells (DCs) are able to 
stimulate or inhibit immune responses. The important role this cell type plays in 
marshaling the body’s defenses has made it attractive as a means to augment the native 
immune response against malignancies (189). A reputed problem with this therapeutic 
approach has been that the cells do not always localize or migrate to target organs as 
desired. In vivo imaging of DC migration may substantially aid in the design and 
administration of dendritic cell-based therapy. Initial studies have shown that when DCs, 
intended as a cancer vaccine for melanoma, were loaded with SPIO there were no 
unfavorable effect on phenotype, migration patterns or antigen-presenting functions 
(192). Further, the utility of tracking as few as 1.5x105 cell with the high anatomical 
resolution provided by MR has been demonstrated (190). Recently, this work has been 
translated into the clinic, where trials have established that SPIO enable accurate 
detection of small populations of DCs administered as therapy to late stage melanoma 
patients (193). 
 Natural Killer (NK) cells also hold promise for cell-based therapies as they 
exhibit high cytotoxic activity against multiple malignancies, while sparing normal cells 
(188). A genetically modified NK cell line, NK-92-scFv(FRP5)-!, has been directed 
against malignant cells over-expressing HER2/neu (a receptor over-expressed in many 
cancers, notably breast) (194). MR monitoring of NK cells loaded with SPIO led to 
distinct and long-lasting recognition of HER2/neu-positive NIH 3T3 mammary tumors in 
mice (195). Persistent labeling and detection was evident by MR for at least 5 days. 
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 Lymphocytes have been used to detect and treat several classes of malignancies. 
However, unlike the phagocytic uptake of SPIO by immature DC or macrophage (196), 
delivery strategies must be employed in order to label T and B cells with SPIO. This can 
be accomplished several ways including electroporation, lipofection agents and cell 
permeating peptides (CPPs) (197). CPPs such as HIV-Tat (82, 95), protamine (80) and 
polyarginine (198) have been used to greatly enhance cellular uptake, allowing for 
greater loading of SPIO in cells. CLIO-HD, a Tat-conjugated SPIO with high T-
lymphocyte uptake, has been used in a system where CD8+ T cells were able to 
specifically target an antigen expressing tumor upon which it could be clearly delineated 
by MR imaging (199). Furthermore, T-lymphocytes labeled with CLIO-HD did not lose 
their ability to kill cells both in vitro or in vivo. 
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1.8 - Summary 
 Cellular and molecular imaging holds great potential for the advanced detection 
and monitoring of disease in vivo. Magnetic resonance (MR) is a well-suited imaging 
modality to these ends as it provides high resolution anatomical information throughout 
an organism. MR cellular tracking approaches require the application of relaxitive 
contrast agents that alter MR signal in the vicinity of their accumulation.  
 One form of contrast agent found in widespread academic use are 
superparamagnetic iron oxide (SPIO) particulates. These materials are often in the form 
of polymer or polysaccharide coated iron oxide core nanopaticulates. These particles 
generate contrast by enhancing surrounding 1H atoms relaxivity, thereby generating local 
hypointensity on T2 and T2*-weighted images. The application of SPIO for the task of in 
vivo tracking of immune cells is expected to provide insight into disease and therapeutic 
mechanisms.  
 This thesis aims to identify SPIO synthesis and modification parameters that 
enable the production of particles with desirable properties for optimal labeling of 
immune cells. These include control over size, size distribution, magnetic and chemical 
surface characteristics. The developed contrast agents will then be applied in a series of 
in vitro and in vivo experiments whose objective it is to track immune cells in rodent 
disease and therapy models. 
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CHAPTER 2. Significance of Thesis and Specific Aims 
2.1 - Overview 
 The use of magnetic resonance (MR) imaging has become an important platform 
for investigating both basic biological and clinically relevant questions. The state of the 
art for MR preclinical research is divided along two paths. The first is centered on 
advancing the capabilities of scanners themselves by employing higher field strengths or 
pursuing multimodal detection approaches. The compilation of work that is this thesis 
concerns the second thrust of research - developing, characterizing and utilizing contrast 
agents (CA). These agents are used to enhance the unfortunately limited endogenous 
contrast in organisms between cells, tissues or specific sites of interest when visualized 
by MR.  
 It has been envisioned that high-resolution longitudinal distinction of immune 
cells can be of significant utility towards understanding and detection of disease as well 
as preclinical monitoring of therapeutic efficacy. This chapter first outlines the technical 
advances of efforts documented in this dissertation as well as the consequent applications 
that this research will have on the field. This concerns the role of SPIO characteristics for 
non-phagocytic cell loading and their use for the tracking of and targeting of B cells in 
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vivo. As well, it involves the identification of sites of neuroinflammation in a rat pain 
model. The particular goals detailed for each of these sections are then presented. 
2.2 - Significance of Research 
 The ability to image individual or populations of cells in vivo is of great 
biological and medical interest. The objective of this thesis is to develop and apply 
biocompatible nanometer-scale contrast agents for immune cell imaging in multiple in 
vivo and in vitro systems. Superparamagnetic iron oxide (SPIO) nanoparticles are 
perhaps the most widespread MR contrast in use for molecular and cellular imaging. The 
fundamental purpose behind the development and application of these agents is to enable 
earlier and enhanced detection of disease. The use of SPIO specifically for cell tracking 
and detection of immune cells is a significant component of that effort. This work 
centered on development and use of SPIO in two medically relevant biological 
paradigms: monitoring the efficacy of autoimmune therapy and detecting macrophage 
infiltration at sites of nerve root injury. 
 
2.2.1 - In vivo B Cell Tracking 
 Systemic lupus erythematosus (SLE) is a chronic, inflammatory autoimmune 
disorder. Symptoms include fatigue, polyarthritis, pericarditis and dermatitis. Treatment 
of this disease focuses on immunosupression to prevent organ damage and to combat 
flare-ups. Among these treatments are non-steroid anti-inflammatory drugs, 
corticosteroids and, applied in the more serious renal and nervous system manifestations, 
cytotoxic medicines such as cyclophosphamide (1).  
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 While the pathogenesis of SLE is not fully understood, B cells and B cell 
dysfunction have been implicated in its etiology (2). Their central role in immune 
processes has meant that they are a focus of research into the understanding and combat 
of SLE (3). Recently, monoclonal antibody B cell depletion therapy, which has been 
effective in treating B cell lymphoma, has been investigated as a therapy for autoimmune 
diseases including SLE (4). Results from preliminary studies had been promising (5), 
however under controlled study conditions it has been determined that antibody treatment 
is ineffective at combating the disease (6-8).  
 It has been hypothesized that imaging of B cell populations in vivo would be a 
powerful tool for the in vivo study of B cell response to depletion, particularly within 
secondary lymphoid organs such as the spleen where long-lived B cells reside and mature 
(9). We have shown that SPIO can be formulated for the specific task of non-toxic, high 
uptake in non-phagocytic, non-adherent cells. These SPIO were able to readily label 
primary murine B cells. Using these engineered particles, coupled with a cell membrane 
binding near infrared (NIR) dye, primary B cells were tracked using MR and optical 
techniques following in vivo administration. The data gathered from this work led to an 
appreciation of the underlying response of cells targeted by antibody depletion treatment 
and the issues associated with tracking them. Specifically, the work indicates that NIR 
can be readily used to follow the in vivo migration of cells with organ specificity and a 
degree of sensitivity such that localization of B cells to the spleen was readily visualized. 
Further the impact of the MR tracking approach, inherently noisy and seemingly 
interfering of B cell depletion, may help to mature the still nascent field of nanomaterial 
application in biology and medicine. 
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2.2.2 - In vivo Detection of Transient Nerve Root Injury 
 Cervical radiculopathy is defined as a neurological condition characterized by 
dysfunction of a cervical spinal nerve, the roots of the nerve, or both (10). It presents as 
pain, often debilitating, in the neck and one arm. This pain is also often accompanied by 
sensory loss, loss of motor function and diminished reflexes in the dermatome of the 
affected nerve root (11). The condition is relatively widespread, with studies showing 
incidence as high as 107 per 100,000 for men and 63.5 per 100,000 for women (12). The 
frequency of the disorder, coupled with its potential long term and severe impact on 
quality of life, results in a significant economic impact (13, 14).  
 The central nervous system (CNS) proximal to the cervical spine, consisting of 7 
vertebrae and 8 pairs of cervical nerve roots (in both rodents and humans) is susceptible 
to injury from a variety of causes. The most common cause of cervical radiculopathy is 
impingement of the spinal nerve through degenerative changes of the neuroforamen. 
Radiological evidence of these changes such as spondylosis, foraminal occlusion or disc 
protrusion is useful in determination of the pain-causing problem and for further decision 
making in patient management. However, in many cases there is no noticeable 
neuropathy associated with the report of pain symptoms (12). This presents a significant 
clinical and radiological challenge.  
 It has been hypothesized that transient nerve injury may lead to lasting pain 
without correlating radiological indication of permanent degeneration of vertebral 
architecture. In a rat model, persistent mechanical allodynia (behavioral sensitivity to 
otherwise benign stimulus) can be produced by unilateral transient compression of the 
nerve root (15). The transitory axial loading of the neck that this model seeks to mirror 
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include examples such as automobile accidents (16) and impact from contact sports (17, 
18). Inflammatory cells, such as activated macrophage, have been reported to correlate 
with pain in experimental models (19-22). Mechanical insult to the nerve root of 
sufficient compression leads to Wallerian degeneration and remodeling of the neural 
tissue (23). Macrophages are initially recruited to remove axonal and myelin debris and 
stimulate nerve growth factor synthesis by Schwann cells. A host of other immune cells 
are involved including microglia and the recruitment and activation of hematogeneous 
leukocytes to the site of nerve root compression  have been implicated in the etiology of 
chronic pain resulting in hypersensitivity (24, 25). Further understanding of the 
development of and the efficacy of treatment for transient nerve root injury would benefit 
significantly from a means to non-invasively detect the presence of injured nerve roots. 
 Sequestration of SPIO by macrophages at sites of inflammation in vivo has been 
demonstrated in a variety of disease models (26-28). This phenomenon has been 
exploited to image neurologically relevant processes such as cerebral inflammation (29-
31), spinal cord (32, 33) and nerve injury (34, 35). No study to date has correlated the 
uptake and MR detection of SPIO in vivo using a transient nerve root injury with a 
characterized behavioral response. In the pain producing transient compression model 
described above, the presence of persistent hypersensitivity has been associated with the 
infiltration of activated (CD68 expressing) macrophages.  
 In work described in this thesis, dextran coated SPIO were administered to rats 
after undergoing a transient nerve root compression to non-invasively detect macrophage 
infiltration after nerve root injury. It was demonstrated that detection of the site of the 
injury through accumulation of the SPIO by activated macrophage was possible. We 
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envision that application of SPIO for the noninvasive, longitudinal imaging of the cellular 
inflammatory response, correlated to the persistence of pain, will add valuable insight to 
our knowledge of the underlying dynamics of macrophage infiltration at sites of cervical 
radiculopathy. Furthermore, it may provide the foundation for enhanced clinical 
assessment and subsequent treatment of nanoparticle. 
 
2.2.3 - Technical Impact 
 We envision potential applications of the research described within this thesis will 
include: 
 - Study of the effect of size and surface properties on the non-phagocytic 
cell phenotype uptake of nanoparticulate materials. 
 - Facilitate the development and refinement of approaches to monitor 
lymphocytes in vivo. 
 - Detect the presence of otherwise occult nerve root inflammation resulting 
from transient compression.  
 - Identify sites for local administration of analgesic therapy. 
 - Non-invasively monitor the response to treatment of nerve root injury to 
treatment. 
We envision that the SPIO synthesized, modified and applied in this work will be 
a powerful and versatile tool for the study of a variety of biomedical problems. In 
particular they have significant utility in imaging immune cell types of interest in 
autoimmune and inflammatory processes through their efficient labeling of cells either in 
or ex vivo. 
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2.3 - Specific Aims 
 Molecular and cellular imaging (MCI) is an emergent field concerned with the 
non-invasive, quantitative, and repetitive imaging of biological processes in living 
organisms (36). Clinical end-goals include generation of image contrast for the purpose 
of achieving earlier disease detection, more accurate stratification and monitoring of 
response to therapy (37). Magnetic resonance (MR) is a powerful non-invasive, whole 
body imaging modality used in numerous MCI approaches. When used in conjunction 
with recently developed in vivo contrast agents, MR allows for the concomitant 
acquisition of anatomically detailed images and molecularly specific information.  
 The overall purpose of this dissertation was to develop and apply nanometer-scale 
contrast agents for immune cell imaging in multiple in vivo and in vitro systems. 
Superparamagnetic iron oxide (SPIO) nanoparticles are T2* contrast agents consisting of 
an iron oxide core surrounded by a polysaccharide coating. In this document we describe 
the synthesis, modification and evaluation of SPIO for a variety of physical and chemical 
properties. Further, the interaction of SPIO with cellular systems and animal models was 
investigated.  Initial work focused on development and differentiation of NP populations 
for non-phagocytic cell uptake. Subsequently, these NPs were applied in vivo to two 
disease models. The first of these systems concerned the ex vivo loading of contrast agent 
into B cells for their subsequent tracking in mice with and without B cell depletion 
therapy with implications for systemic lupus erthematosus (SLE) treatment. The second 
animal model appraised the ability of systemically injected iron oxide nanoparticles to 
specifically label sites of neuroinflammation correlated to persistent pain for diagnostic 
purposes. 
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2.3.1 - Aim 1. Synthesis, modification and optimization of SPIO probes for cellular 
labeling 
 
1.1 Synthesis and characterization of iron oxide nanoparticles – Nanoparticle synthesis 
parameters were varied to develop a library of particles with a wide range of physical and 
chemical properties. SPIO surfaces were cross-linked and functionalized with amines. 
The chemical and magnetic properties of these particles were analyzed along with an 
evaluation of their internal core morphological features. 
 
1.2 Optimize SPIO loading of lymphocytes – We determined a nanoparticle formulation 
for maximum SPIO loading in cultured lymphocytes, while concurrently avoiding cell 
toxicity. Flow cytometry, optical and MR techniques were utilized to examine particle 
uptake. Factors such as particle size, surface properties, loading times and SPIO 
concentration were isolated in order to determine their respective effects on 
internalization and viability. 
 
1.3 Evaluate effect of SPIO on B cell activation – SPIO loading conditions leading to 
activation of primary B cells were assessed. The roles of surface charge, particle 
diameter, concentration and time of incubation with cells were investigated. Further, B 
cell activation following SPIO internalization was tested to determine any interfering 
contrast agent influence on normal B cell function and subsequent depletion. 
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2.3.2 - Aim 2.  B cell tracking in SLE autoimmune therapy model 
 
2.1 Refine imaging of SPIO-loaded B cells – Imaging parameters and a logistical protocol 
were optimized for the detection of SPIO-loaded and NIR dye labeled B cells injected 
into mice for both MR and optical (fluorescent) modalities. Following imaging, 
immunohistological evaluation was utilized to ensure co-localization of SPIO and 
fluorescent dyes with B cells. 
 
2.2 Image B cell distribution following therapeutic depletion - Anti-CD79 therapeutic 
depletion of systemically administered SPIO- and near infrared dye-loaded B cells was 
investigated by MR and optical imaging in mice. Analysis of the dynamics of distribution 
with and without therapeutic intervention, through loss of local hypointensity for MR and 
loss of fluorescent signal by optical, was performed. 
 
2.3.3 - Aim 3. Imaging the post-injury dynamics of macrophage infiltration 
3.1 Optimize MR sequence and injury localization – Localization of transient nerve root 
compression was carried out. Initially this involved posthumous subjects to resolve 
animal handling during imaging and MR sequence issues. Living subjects were then 
introduced to determine feasibility of imaging protocol. Delivery and optimization of 
SPIO contrast by MR was also performed by varying scanning parameters for sequence 
configuration.  
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3.2 Imaging transient nerve root injury – Visualization of macrophage infiltration at the 
injury was evaluated across injured and sham subjects at time points prior to and 
following administration of contrast. Histological analysis of excised spinal cord and 
nerve root were used to verify SPIO accumulation at sites of macrophage infiltration. 
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CHAPTER 3. Synthesis, Modification and Characterization of SPIO  
3.1 - Overview 
3.1.1 - Preface 
 A promising new direction for contrast-enhanced magnetic resonance (MR) 
imaging involves tracking the migration and biodistribution of superparamagnetic iron 
oxide (SPIO)-labeled cells in vivo. Despite the fact that a number of cell labeling studies 
have been performed with SPIO particles of differing size and surface charge, it remains 
unclear which SPIO configuration provides optimal contrast in cells of interest. One of 
the central goals of this thesis was to accomplish immune cell tracking in multiple disease 
models. To that end, an engineering approach to manufacture and characterize nano- and 
microparticles was undertaken. The initial aim  was to develop good manufacturing 
processes for a SPIO formulation that enabled efficient delivery of contrast agent to cells 
in an ex vivo loading regime. 
 The present and following three chapters are connected components of a single 
research thread. The overall goal was for the use of SPIO nanoparticulates to enable 
imaging of lymphocyte trafficking in vivo. SPIO were developed and their interaction 
with cells investigated for that purpose (see Chapter 4). The specific application was to 
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track B cells in the mouse and monitor their in vivo distribution following administration 
of a B cell depleting therapy (see Chapter 5).  
 It can be seen that there are two general strategies for SPIO-enabled visualization 
of a population of cells; 1) loading the cells ex vivo with SPIO and 2) specific targeting 
of cells of interest in the organism. In the former, higher sensitivity for cell tracking is 
afforded as the ex vivo loading of cells with SPIO is high. Thus high contrast per cell can 
be achieved. However, cells must first be isolated. 
 In the latter system, cells need not be removed or exposed to an ex vivo 
environment. Targeting of the SPIO to cells of interest would involve their modification 
with a ligand for cell specificity, for example antibodies, and enable repeated 
administration of such an agent (see Chapter 6). As a result, loading efficiency is lower 
following this approach and there is the likelihood of greater background uptake (for 
example by the reticuloendothelial system).  
 The present chapter is concerned with the basic processes of manufacture and 
characterization of the nanoparticles used throughout this thesis. Production of particles 
with desirable features (including size, distribution, surface and magnetic properties). The 
following chapter utilizes these particles to address the problem of labeling non-
phagocytic cells, such as T and B cells. Subsequently, the application of this work was 
undertaken in an animal model for the non-invasive spatiotemporal visualization of 
murine B cells loaded ex vivo and injected into host mice. 
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3.1.2 - Abstract 
 The high efficiency delivery of SPIO to cell types that do not actively internalize 
foreign material has presented a significant problem within the field of cell tracking. In 
phagocytic cell types, such as macrophage, achievement of loading levels on the order of 
tens of picograms of iron per cell is not difficult. Facile incubation in culture for a period 
of several hours is all that is required (1). For non-phagocytic cells the intracellular 
loading levels needed for MR visualization are most often realized through application of 
potentially toxic biological or chemical modifications to the SPIO or the use of disruptive 
treatment of the cells (such as electroporation) (2).  
 Despite the size of this body of work, it remains unclear what configuration of 
SPIO provides optimal contrast for non-phagocytic cell types. The presence of 
contradictory findings, elaborated upon below, can be attributed to a significant degree to 
variability and imprecise control over particle size or surface charge and the limited 
number of particle configurations examined in any given study. In the present chapter, we 
have manipulated the synthesis procedure for SPIO nanoparticulates as well as 
systematically characterized these and commercially available NP. Dextran coated iron 
oxide particles in a continuum of sizes were generated with low polydispersity. These 
materials were subsequently cross-linked for stability and functionalized with surface 
amine groups. Control of the density of these amines was demonstrated. The core 
structure of the particles was also evaluated and surprisingly revealed that the ultrasmall 
and standard SPIO (USPIO and SSPIO, respectively) were multi-core in nature.  
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3.2 - Background 
 The growing field of nanoparticle (NP) research includes a plethora of different 
types of materials. These include (but are not limited to) particles composed of metals 
and metal oxides (such as gold, silver and SPIO), lipid and polymeric micelles or vesicles 
and protein complexes. Further, many are composites of several classes of materials, 
notably the polysaccharide and metal-oxide SPIO particles used throughout this 
dissertation. Characterization of these materials involves considerable effort as it is their 
nanoscopic physical and chemical features that drive interest in their design, fabrication, 
modification and application.  
 Traditional materials characterization technologies that rely on sampling bulk 
properties, while still important, are just the beginning of the descriptive route when 
working with nanoparticulate matter. This section seeks to provide the reader with an 
understanding of the field of materials characterization as it applies to NPs and 
specifically SPIO. This is significant because material properties optimization and 
manipulation are substantial elements of this thesis as we investigate the application of 
SPIO to ex vivo and in vivo cellular systems.  
 
3.2.1 - Size and Mass Measurement 
 Techniques that are applied widely in the field of colloidal nanoscale research 
begin with size measurement. There are several methods to characterize a NP's size, most 
notably atomic force microscopy (AFM), electron microscopy (EM) and dynamic light 
scattering (DLS). Other solutions based methods that are less common include 
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sedimentation velocity and size exclusion chromatography. Conceptually the simplest 
method, AFM sees the deposition of a NP solution to an ultra-flat surface (usually 
cleaved mica), which is then rastered using micron-sized cantilevered-beam with an 
atomically fine (usually silica) tip. In many ways the system can be thought of as the 
needle of a phonograph that is sensitive to the pits of a record. A laser beam is directed to 
the cantilevered-beam. When moved across the surface containing the deposited particles, 
interaction of the atomic tip with the deposited material deflects the beam which is 
measured by changes in the laser reflection (3). The result is non-destructive topology of 
the materials on the surface, measured in either air or water, that can extend all the way to 
atomic (attometer) resolution (4).  
 With one notable exception (the measurement of SPIO interaction with 
telomerase as an enzymatic nanosensor (5)) SPIO are not often measured using AFM. 
Instead DLS and transmission EM (TEM) techniques are often employed. The reason for 
this is that this NP configuration of polymer-coated iron oxide core is both stable in 
solution and possesses an electron dense core. This means that additional information, 
generally in higher throughput, can be obtained regarding their size distributions than is 
possible with AFM. 
 DLS probes particulates on the 1 - 1000 nm scale. NP in solution are placed in a 
cuvette and irradiated with the polarized light of a laser. The vast majority of light passes 
through the sample, however some is scattered to a detector. The intensity of scattered 
light, detected at some fixed angle (usually 90˚ from the incident laser) is dependent on 
the diffusive motion of the particles in the solution (6). An autocorrelation function 
applied to the scattered light intensity of the nanoparticles reveals the Brownian motion 
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(diffusivity) of the particles, which can be used to calculate their size (following the 
Einstein-Stokes relationship).  This autocorrelation of the intensity is why the technique 
is sometimes referred to as photon correlation spectroscopy. The autocorrelation function 
employed influences the final results. Most assume the presence of monodisperse 
spherical particles. While that is not often a true representation of the physical reality, 
comparison of several sizing models, standards and verification by other methods (for 
example TEM) has shown them to be quite accurate (7). Sample preparation for DLS is 
extremely easy, and requires only that particles remain in suspension throughout the 
measurement (often on the order of several minutes). DLS measures the hydrated 
particulate diameter as the sample is in solution. This is relevant for SPIO 
characterization because it reports the composite particles' inclusive size. 
 Transmission electron microscopy (TEM) provides some of the most detailed 
views of matter. Passing a focused high voltage beam of electrons through a sample is the 
basis for this technique. Sample preparation is onerous and time consuming, requiring 
particulate samples be carefully dried onto specialized 10 mm diameter grids. Ideally the 
sample is dried into a monolayer, as the working distance of this microscopic technique is 
limited to several hundred nanometers. The grid upon which they are placed is usually a 
metal mesh (often copper, titanium or nickel) that is then sparsely coated with thin layers 
of carbon or silicon. The presence of a particle that absorbs much of directed electron 
beam on this thin (minimally absorbing) layer allows for the distinction and measurement 
of the particle size. In the case of the many NP materials composed of or containing 
electron-transmitting substances (usually carbon-rich materials such as polymers, lipids 
or polysaccharides) absorbent material such as gold or carbon must be coated onto the 
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particles. In the case of non-metal coated SPIO this is actually an advantage for 
characterization purposes. For example, with the NPs synthesized and applied in this 
thesis, the electron-transparent dextran is generally not detectable rendering the iron 
oxide cores visible. This enables the direct measurement of the magnetic cores of the 
particles. When combined with data gathered from DLS measurements, information 
about the core composition and size, the entire diameter and the thickness of coating can 
be compiled. 
 These methods give information regarding particle dimensions, however it should 
be noted that none give a direct measurement of the mass of the particles. Acidic 
degradation of iron oxide particles can be used to spectrophotometrically assess the iron 
content in a solution, but without an understanding of the mass per particle, this gives no 
correlating information to the particle concentration in solution. Determination of core 
size from TEM can be used to compute the mass per particle (assuming an appropriate 
atomic packing factor and geometry). This estimation method is however limited to a 
small sample size (as cores must be measured one-by-one). Other methods exist for mass 
quantification of particulate samples. One is to take a quantity of sample and dry it at 
high temperature (8). The recovery of iron residue from the sample can be assessed by 
weight to estimate the iron per particle. This method depends on the assumption that all 
iron is present as iron oxide that the DLS measured volume is monodisperse and is 
heavily dependent on assumptions regarding the mass of any coating material. A third 
method for the determination of core size relies on the viscosity of a solution that 
contains suspended particles. A relationship exists between the viscosity of a dilute 
solution of nanoparticles and the volume fraction of particles in that solution. 
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Determination of this volume fraction of particles in solution, again coupled with DLS 
information regarding the entire particle diameter (and therefore volume), enables 
calculation of the number of particles in solution. In turn, spectrophotometric analysis of 
a solution of nanoparticles provides the iron concentration, which when divided by the 
number of particles of an equal volume provides an estimation of core size (9). The 
assumptions employed in this approach are that the particles are spherical and that the 
contribution of mass of iron greatly outweighs that of the coating material.  
 
3.2.2 - Chemical Surface Profiling 
 Equally important as the size and mass of NPs for their in vitro and in vivo 
application is their surface makeup. There exist several methods to assess the physico-
chemical properties on particle surfaces. Fourier transform infrared spectroscopy is a 
relatively inexpensive technique that relies on long wavelength light interference by dried 
or aqueous materials. Atomic bonds absorb this low energy electromagnetic radiation in 
specific spectral domains. This method is only somewhat quantitative but has been used 
to determine the presence or absence of specific chemical species on iron oxide NP 
surfaces (10, 11).  
 Spectrophotometric methods (UV/Vis) have been widely used to determine 
nanoparticle surface functionalization. Quantitative surface group assessment can be 
accomplished in several ways: 1) through the direct detection of small molecules on 
particles surfaces through specific absorption bands, for example to detect folate (10) or 
2) the reaction of surface groups with secondary absorbent (or fluorescent molecules) 
(12). An example of the latter that has been used with great success to determine the 
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amine surface content of SPIO has been the use of the thiol cleavable agent succinimidyl 
3-(2-pyridyldithio)propionate (SPDP). SPDP can be used to react with surface amines 
which, following cleavage and purification, yields the 2-pyridinethione chromophore. 
This molecule absorbs 343 nm light once cleaved allowing for determination of its 
quantity in solution. SPIO are reacted with SPDP and the excess chemical is removed 
from solution. The SPDP is then cleaved and the 2-pyridinethione is quantified. The 
concentration of this molecule divided by the concentration of particles in solution is a 
sensitive estimate of the number of amines per particle (13, 14).  
 The catalog of SPIO surface compositions is nearly endless. Different polymer or 
metal coating materials have been used that present, or are subsequently modified to 
possess, nearly every conceivable functional group. Only a small subset of these, 
including amines, carboxyls, thiols and azides are discussed in this thesis. 
 
3.2.3 - Magnetic Properties 
 The advantages of cellular and molecular imaging using MR are considerable. It 
allows for determination of the presence and in some cases the state of chemical, 
biological and cellular items of interest. This information is conveyed with high  
spatiotemporal distinction non-invasively. The use of contrast agents are in many cases 
required for this imaging. The characterization of relaxivity of materials, a description of 
their concentration dependent affect on local magnetic field, was introduced in section 
1.5. Material magnetic properties may be assessed either in dedicated instruments (such 
as superconducting quantum interference magnetometers) or directly in MR imaging 
systems. Dilutions of sample are prepared and read, and the requisite curves are 
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computed. The linear portion of the 1/T1 of 1/T2 versus iron concentration yields the R1 
or R2 measurement, respectively. 
  Another characteristic of magnetic materials is their saturation 
magnetization. This refers to the magnetic field strength at which no greater enhancement 
of material magnetic field can be generated. This is a useful defining characteristic of 
magnetic materials for applications such as electronics and specifically data information 
storage. Assessment of NP magnetization hysteresis curves and saturation values are 
often drawn from a superconducting quantum interference device (SQUID) or vibrating 
sample magnetometry (15). Extremely accurate measurements, even of single particles 
using SQUID can be made (16). However, the field strengths of MR imaging are of 
sufficient strength (approximately six orders of magnitude greater than the earth's 
magnetic field) that all magnetic materials are saturated. 
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3.3 - Materials and Methods 
3.3.1 - Nanoparticle Synthesis 
Three different formulations of dextran-coated superparamagnetic iron oxide 
nanoparticles were prepared using the co-precipitation method (17). All three 
formulations were prepared following the same procedure, as described below, with the 
only difference being the amount of FeCl2 and FeCl3 added. Specifically, 25 g of dextran 
T10 (GE Healthcare; Piscataway, NJ) was dissolved in 50 mL of dH2O and heated to 80˚ 
C for 1 hour. The solution was allowed to return to room temperature and continued to 
mix overnight. Subsequently, the dextran was cooled to 4˚ C on ice and degassed with N2 
for 1 hour. FeCl2 (0.7313 g, 1.5 g, or 2.2 g) and FeCl3 (1.97 g, 4 g, or 6 g, respectively) 
were each rapidly dissolved in 12.5 mL of degassed dH2O and kept on ice for 
approximately 10 minutes. The iron solutions were added to the dextran simultaneously 
and allowed to mix for 30 minutes. Keeping this mixing solution at 4˚ C, 15 mL of 
ammonium hydroxide was added. The resulting black viscous solution was then heated to 
90˚ C for 1 hour then cooled overnight, followed by ultracentrifugation at 20k rcf for 30 
minutes. Pellets were discarded and the supernatant was continually diafiltrated using a 
100 kDa MWCO cartridge (GE Healthcare) on a peristaltic pump (E323, Watson 
Marlowe Bredel; Wilmington, MA). The particles were exchanged into 0.02 M citrate, 
0.15 M sodium chloride buffer until all unreacted products had been removed. Aminated 
silica-coated iron oxide micro-particles were purchased from Bioclone Inc. (San Diego, 
CA). Amine functionalized styrene-copolymer coated iron oxide particles (Adembeads) 
were purchased from Ademtech SA (Pessac, France). 
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3.3.2 - Modification of Particles 
Amination and cross-linking of the coating on the dextran-SPIO was 
accomplished through reaction of the SPIO with 25% 10 M NaOH and 33% 
epichlorohydrin (18). After mixing for 24 hours, the particles were transferred into 
regenerated cellulose dialysis membranes (8-14 kDa MWCO, 50 mm flat width) and 
dialyzed against 0.02 M citrate for 10 minutes. After transfer back into glassware, 
additional ammonium hydroxide was added to the solution, bringing the volume fraction 
to 25% ammonium hydroxide, and the reaction was allowed to proceed for another 24 
hours. The particles were then exhaustively purified via diafiltration. The resulting 
particles were amine functionalized cross-linked iron oxide. 
All SPIO particles were labeled with FITC at a FITC-to-iron molar ratio of 
19.2:1. FITC (389.4 g/mol) was dissolved in dimethylformamide and added (10% v/v) to 
SPIO. SPIO concentration was determined spectrophotometrically (following 6 M HCl 
decomposition in the presence of 3% H2O2) against a standard curve to yield molar iron 
values. FITC was reacted with particles for 4 hours followed by two rounds of gel 
purification, once on a NAP-5 column and then on a PD10 column (GE Healthcare), both 
equilibrated with PBS. The FITC-labeled SPIO were subsequently reacted with various 
volumes of glycidol (0.01% to 50%) to produce populations of particles with different 
surface amine content. The particles were cleaned of excess glycidol through repeated 
precipitation in isopropanol and resuspension in phosphate buffered saline (PBS). Amine-
blocking was also attempted with particles 200 nm and greater, however this 
modification impelled immediate particle insolubility. 
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3.3.3 - Overall and Core Size Measurements 
The hydrodynamic diameter of the dextran-coated and commercial iron oxide 
particles was measured using a Zetasizer Nano-z (Malvern Instruments, Malvern, UK) 
through dynamic light scattering (DLS). The dextran-coated SPIO particles were diluted 
in PBS to a concentration of approximately 0.5 mg/mL and read in triplicate. The 
commercial particle diameters were read in the same manner, but only after undergoing 
three washes by precipitation in the presence of a strong magnet and resuspension in 
PBS. The values reported for all samples are the intensity peak values. 
Transmission electron micrographs of all iron oxide particles were taken using a 
JEOL 2010 at 200 kV. Samples were prepared for imaging by evaporating the particles 
onto a carbon-coated copper grid (Holey carbon - mesh 200, Structure Probe Inc., West 
Chester, PA). Salt was removed from all of the samples prior to evaporation by 
exchanging the particles into dH2O. Images of particle cores were analyzed using ImageJ 
(National Institutes of Health, Bethesda, MD). Since many of the particles were found to 
be composed of a cluster of multiple iron oxide cores, the average diameter of each core 
and the average number of cores per particle were determined. Assuming each core to be 
spherical, the amount of iron per particle type was determined from the aggregate core 
volume. 
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3.3.4 - Magnetic Characterization Assays 
The longitudinal (R1) and transverse (R2) relaxivity of each particle was 
calculated as the slope of the curves 1/T1 and 1/T2 against iron concentration, 
respectively. T1 and T2 relaxation times were determined using a Bruker mq60 MR 
relaxometer operating at 1.41 T (60 MHz at 40˚ C; Bruker Optics Ltd, Billerica, MA). T1 
measurements were performed by collecting 12 data points from 5.0 to 1000 msec with a 
total measurement duration of 1.49 minutes. T2 measurements were made using ! = 1.5 
msec and 2 dummy echoes, and fitted assuming monoexponential decay. 
 
3.3.5 - Chemical Assessment 
 The number of amines per particle was determined following the general 
procedure described by Zhao et al. (14). Briefly, iron oxide particles at a concentration of 
2 mg Fe/mL were reacted with excess N-Succinimidyl 3-(2-pyridyldithio) propionate 
(SPDP, Calbiochem, San Diego, CA) for 4 hours. SPIO were washed of excess SPDP 
through repeated precipitation in isopropanol and resuspension in PBS. The particles 
were then run through a 50 kDa MWCO centrifugal filter (YM-50, Millipore, Billerica, 
MA) either with or without the addition of disulfide cleavage agent tris(2-
carboxyethyl)phosphine (TCEP). The difference of the absorbance of these two samples 
at 343 nm was used to determine the concentration of 2-pyridinethione in the filter flow. 
Adjusting for dilution, the number of amines per particle was determined, assuming one 
100% conjugation of one SPDP per amine. The stability of cross-linking of dextran was 
measured by heating the particles in a dry bath to 80˚ C for several days. Samples were 
run through a 50 kDa MWCO filter at different time points. The presence of freed 
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dextran was colorimetrically revealed using the phenol:H2SO4 sugar method (19). The 
concentration of flow-through dextran was compared to a standard curve of dextran in 
dH2O. 
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3.4 - Results and Discussion 
3.4.1 - Particle Synthesis and Modification 
 Three different formulations of dextran-coated superparamagnetic iron oxide 
nanoparticles were prepared via co-precipitation. All three syntheses utilized a ratio of 
approximately 3 ferrous to ferric iron chloride; however, the total amount of iron was 
increased by whole numbers, i.e. 2x and 3x iron respectively. This deviation in the 
amount of iron present during synthesis allowed for the manufacture of SPIO with a 
range of different sizes and properties.  
 A wide range of synthesis conditions were assessed in order to determine a 
working procedure that enabled repeatable production of stable, superparamagnetic, high 
yield nanoparticles. Parameters in the synthesis that were altered in order to determine 
their role in nanometer SPIO production included; 1) reaction temperature, 2) 
atmosphere, 3) molar ratio of iron salts, 4) type of base, 5) rate of base addition, 6) 
stirring speed, 7) post-precipitation heating time, and 8) ratio of iron to complexing agent. 
The complete characterization of the SPIO was not attempted until high quality 
nanomaterials were first produced, and thus the results of the initial engineering of the 
SPIO were predominantly observational rather than quantitative.  
 Several of the reaction components were deemed to be critical towards production 
of useable magnetopharmaceutical. First, an inert atmosphere was found to be required to 
produce magnetite and maghemite. This observation was based on the color of the 
complexes formed during reactions conducted at both 4˚ C and 25˚ C in the presence of 
polymer (dextran) or surface complexing ions (such as citrate). The formation of a red or 
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orange complex followed by detection of large iron precipitates was noted when reactions 
were initiated in air. This color is indicative of the presence of iron oxyhydroxides that 
are diamagnetic (20, 21). Reaction under N2 was found to prevent the oxidation of 
material during the synthesis, as reported generally in the literature (22). 
 Critical parameters were the temperature of the reaction and the rate of base 
addition. It was assessed that these two elements of the procedure were intimately related. 
The reduction of the thermal energy present in the aqueous reaction was mediated 
through the presence of an ice bath and the addition of base at a slow rate. The slow 
addition of base (regardless of type, sodium hydroxide or ammonia) and the effective 
dissipation of heat produced from acid/base titration was critical. Together, they 
controlled the heterogeneous nucleation of the iron oxides (in the presence of polymer) 
delaying the ripening of particles (23, 24). This is illustrated schematically in Figure 3.1. 
This finding may also apply to the observation that larger reaction volumes were not 
effective for production of particles with sufficient polydispersity. Although only a 
limited number of larger (250 mL) reaction batches were attempted, it is hypothesized 
that the lack of a thermal jacket or more specialized cooling equipment resulted in 
inadequate temperature control. 
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Figure 3.1 - Nucleation and Growth of Nanoparticles. 
 
Controlled synthesis of particles, mediated primarily by presence of solute and 
temperature, allowed for the segregation of the nucleation and growth phases of the 
nanoparticles. During the nucleation phase (at 4˚ C) the iron ions do not spontaneously 
form stable nuclei of NP as the reaction conditions are conducted below saturation 
concentration of metal ions. However, upon the addition of base there is the 
heterogeneous nucleation of NP on dextran polysaccharides. By keeping the thermal 
energy in the mixture minimal, while still allowing for efficient mixing, a very large 
number of small particles are formed. These are then grown into larger particles with the 
application of heat, likely through a ripening process, to produce fairly uniform particles. 
Adapted from Sugimoto et al., (25). 
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 Post-precipitation heating, at levels of between 80˚ and 100˚ C was found to be 
required for contrast applicable magnetic properties. The reason for this is not exactly 
known, as the temperatures used here are far below that required for the conversion of 
iron oxides to maghemite and magnetite (24). It is likely that high relaxitive properties 
result solely from growth of pre-nanoparticle nuclei into actual nanoparticles, however it 
is also possible that relatively low temperature (90˚ C) heating of an iron oxide 
nanomaterial may provide sufficient thermal energy for a crystal structure phase change. 
It should be noted that further heating for greater than the (often used) 1 hour did not 
produce larger SPIO. This may be because the formation of particles of a defined size are 
sterically stable. Therefore, agglomeration at a SPIO-size plateau is reached after some 
size apparently dependent on initial synthesis parameters. 
 When altered, several parameters provided little observable difference in the 
products of synthesis. The concentration of the iron salts was found to be of little 
importance and several reactions were run with lower concentrations (and corresponding 
lower concentration of dextran) that resulted simply in production of less final product. It 
had been hoped that lowering the concentration (dilution) of the initial material would 
result in smaller or more monodisperse particles. Further, despite observations in the 
literature that change in the molar ratio of the salts, for example a 3:1, 2:1, 1:1 or 1:2 ratio 
of Fe2+:Fe3+, having an effect on the final product, all apparently yielded nanoparticles. 
 Another factor of little significance was stirring speed. Effort was expended to 
determine if stirring speed of the solution could result in, again, smaller or more 
monodisperse particles. The hypothesis here was that better mixing conditions would 
ensure that minimal heat would be evolved from acid-base titration and that greater 
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mixing in general would provide a more homogeneous reaction. Difficulties were 
encountered using external (non-magnetic stir bar) top down stirrers. While faster mixing 
was attainable, it was at the cost of a less well contained inert atmosphere. Results were 
not highly consistent between batches using top down mechanical stirring apparatus, and 
there was little apparent difference between using magnetic stir bars.  
 Besides the rate of base addition, the parameter that had the greatest effect on the 
geometric and magnetic properties of the nanoparticles was the molar ratio of the 
complexing agent to the iron salts. A wide variety of concentrations of both of these 
components were used (keeping the Fe2+:Fe3+ ratio at 3:1). Increasing the ratio by means 
of more dextran relative to a fixed iron amount quickly resulted in a viscous reaction 
volume that inefficiently mixed. Thus, a fixed amount of dextran was used with varying 
amounts of iron salts. It was found, as discussed in detail below, that increasing SPIO 
size and magnetic properties resulted from increasing the ratio of iron to dextran. When 
the total amount of iron was increased beyond 8.2 g, the co-precipitation solution became 
extremely viscous and yielded highly dispersed aggregates that precipitated out of 
solution.  
Core analysis of the particles was carried out in order to study the internal 
structure of the variously synthesized particles and to correlate these features to bulk 
colloidal properties. It was revealed by characterization that individual component cores 
between all particles were similar and it was the number of cores that differed. This 
suggests that the phenomenon leading to greater size and relaxivity was not greater size 
of particle nuclei but greater agglomeration during the growth phase. 
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 Finally, the chemical surface features were analyzed. It was found that 
modification of the particles, due to the excess of reactants used, was a highly consistent 
process in all of the cross-linking, functionalizing and blocking procedures. At the time 
that the cross-linking and amination procedures were undertaken here there was no 
defined literature on the subject. Subsequently, an excellent source method, from Pittet, et 
al. (18), has been published that closely mirrored the finalized protocol used here. The 
only major difference occurs during the transition step just prior to adding ammonia for 
the amine-functionalization of the particles. We found that a brief dialysis step, followed 
by addition of fresh NaOH, allowed for a more consistent product. We can only speculate 
that the result of this quick wash removed some (primarily spent) epichlorohydrin from 
the volume and enable more efficient amination with the diamine ammonia. The glycidol 
blocking of amines was also conducted in very high initial excess conditions. The SPIO 
were not greatly affected in even 50% volume of glycidol (they remained in solution; a 
rare phenomenon when mixing the particles with non-aqueous media at that volume 
ratio) allowing for conversion of the required ratio of amines. 
 
3.4.2 - Shell and Core Characterization 
 Characterization of the SPIO size was accomplished using optical scattering and 
TEM measurements. These techniques determined the overall diameter and core diameter 
of the particles, respectively. The DLS of the SPIO, following cross-linking and 
amination of the dextran coating, indicated an average hydrodynamic diameter of 33.4, 
53.5, and 107 nm respectively, with the larger nanoparticles corresponding to syntheses 
that utilized greater iron to dextran ratio. Nanoparticles ranging from 200 nm to 1 !m in 
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diameter were acquired from commercial sources in order to supplement the as-
synthesized particles (which were limited in size beyond an initial iron concentration due 
to viscosity of the solution becoming too great). Specifically, superparamagnetic iron 
oxide particles of 200 and 300 nm diameter with an amine functionalized styrene-
copolymer coating  (Amino-Adembeads) were purchased from Ademtech, while amine 
functionalized silica coated 1!m diameter particles were purchased from Bioclone. This 
allowed particle sizes across nearly three orders of magnitude to be compared. 
The particle sizes as determined by DLS, as peak intensity values, are compared 
in Figure 3.2. The 33.4 nm, 53.5 nm and 107 nm dextran-coated SPIO samples were fully 
soluble at physiological conditions. Conversely, it was found that the large size of the 289 
nm and 1430 nm particles led to precipitation.  
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Figure 3.2 - Hydrodynamic diameter of SPIO. 
 
The hydrodynamic diameter of SPIO particles was determined by DLS. Intensity 
measurements are reported and the peak intensity is provided for each distribution. 
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Analysis of the iron oxide core size and structure of the magnetic particles was 
conducted using TEM. Representative micrographs are shown in Figure 3.3. Aggregation 
of particles in salt free solution was a problem during TEM sample preparation; however, 
reduction in sample concentration allowed for imaging of discretely distributed particles 
after solvent exchange to water. Iron cores were easily distinguished from carbon coated 
copper grids, while dextran and styrene copolymer were not visible because of their low 
electron density. The edge of the holey grids is evident in image panels D, E and F. 
An interesting and unexpected feature of the dextran-coated nanoparticles was 
that each particle consists of a cluster of one or more iron oxide cores. Furthermore, each 
core was found to be approximately equal in size. Specifically, the distribution of cores is 
centered at approximately 6 nm for all three dextran-coated nanoparticles (Figure 3.4); 
however, the average number of cores per particle increases with overall hydrodynamic 
diameter. In contrast, the larger 207 nm and 289 nm styrene copolymer-coated particles 
exhibited a single large spherical iron oxide core, while the 1.43 !m silica-coated 
particles exhibited an amorphous iron oxide core of no discrete size or shape.  
It had been initially assumed that a larger particle diameter as determined from 
solution based DLS would contain a larger single core. It had been predicted that the iron 
cores would be imperfect magnetite or maghemite crystals, due to the fact that the 
crystals were produced using an agitated aqueous solution reaction approach. Discovery 
of the multicomponent core indicates that under the reaction conditions used, nuclei size 
of approximately 6 nm is produced independent of the ratio of iron ions to dextran. This 
ratio affects the ultimate size and core composition by altering the number of these nuclei 
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per particle. Core diameters from a large sample of TEM measurements were used to 
compute the average diameter as well as undertake a determination of the mass per 
particle. Using a packing factor of 0.68 and assuming a spherical geometry (9), the 
number of iron atoms per core and particle is given in Table 3.1. 
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Figure 3.3 - TEM of SPIO Cores. 
 
High magnification transmission electron microscopy images of the iron oxide particles 
were obtained with a JEOL 2010 operating at 200 kV. Structure analysis revealed the 
multiple core nature of the (A) 33.4 nm, (B) 53.5 nm and (C) 107 nm dextran-coated 
SPIO. Larger particles were composed of single cores; (D) 207 nm, (E) 289 nm and (F) 
1430 nm. All scale bars are 50 nm, excluding (F) 1 !m. 
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Figure 3.4 - Size Distribution of SPIO Core Diameters. 
 
TEM measurements of the SPIO core diameter for (A) 33.4 nm, (B) 53.5 nm, (C) 107 nm 
and (D) all cores. The core diameters were analyzed assuming that they were spherical 
and the frequency and cumulative distributions are plotted. Particle size appears to be 
determined by the number of cores per particle rather than the size of those constituent 
cores. 
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3.4.3 - Surface Chemistry 
 The SPDP assay was used to spectrophotometrically determine the concentration 
of surface amines on the synthesized and modified particles. Consistent with 
expectations, the number of amines per particle increased with increasing diameter and 
therefore surface area. The values of the functional groups per particle for fully aminated 
particles is found in Table 3.1, summarizing the physical and chemical attributes of all 
investigated particles.  
 
 
Table 3.1 - Physical and Magnetic Properties of SPIO 
 
* R1 values for 207, 289, and 1430 nm particles may be underestimated due to 
precipitation during measurements. 
** Measurement of Fe (atoms) / particle for the commercial particles was made using the 
company provided relative iron mass per particle data, rather than the core size 
determination from TEM. 
 
 Blocking of the functional groups was accomplished through crude reaction with 
glycidol. Previous use of glycidol in the literature for use with NPs had centered on 
Chapter 3  125 
attempts to use it to reduce the charge-dependent cytotoxicity of polymer NP such as 
dendrimers (26). This approach was adopted with the iron oxide NP and facile mixture 
with the agent consumed amines. Further, purification of the nanoparticles from excess 
spent or still-reactive glycidol was possible through the addition of isopropanol. Removal 
of the organic phase was complete after several washes.  
 Stability of the dextran shell was determined by an examination of the dextran 
that could be detected in solution (no longer complexed to SPIO) following residence in 
harsh conditions. The conditions used were meant to simulate accelerated lifetime of the 
particles in vivo, 80˚ C over roughly 100 hours. Two groups of samples from the same 
batch of SPIO, one having been cross-linked the other not, were run through a filter at 
various time points over the course of the heating. Using a colorimetric assay for the 
detection of polysaccharide, it was possible to determine the concentration of dextran that 
was being dissociated from the nanoparticle. The results, as shown in Figure 3.5, show 
that particles that had not been cross-linked gave off more dextran over time. 
Examination by eye also revealed that the non-cross-linked solution became cloudy after 
approximately 2 days of heating, while the cross-linked particle solution did not change. 
These results indicated that the cross-linking of the dextran shell significantly enhanced 
the stability of the particles. 
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Figure 3.5 - SPIO Stability. 
 
The stability of the cross-linked (CLIO) and as-synthesized (MION, non-cross-linked) 33 
nm SPIO is shown. Particles were filtered and the flow through volume was assessed for 
the presence of dextran. As-synthesized samples were found to continually release 
dextran, which is hypothesized to be from degenerating nanoparticles. Free dextran in the 
solution of cross-linked particles was detectable to some degree. It is possible that this is 
a background level of non-cross-linked dextran electrostatically-associated with a particle 
and/or  free dextran not purified from the synthesis solution. 
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3.4.4 - Magnetic Properties 
The magnetic characteristics of an MR CA are key to their application as in vitro 
and in vivo contrast agents. The R1 and R2 data (Figures 3.6A-B), indicate that there is a 
trend of increasing R2 and decreasing R1 with size up to the 107 nm particles. For 
particles of greater size, the single large core of the 207 nm and 289 nm particles does not 
result in proportionately higher R2. This likely reflects lower crystallinity of the larger 
single iron oxide cores in comparison to smaller crystals (27). Furthermore, according to 
the Solomon-Bloembergen theory, which relates the relaxation rate to particle properties, 
the total volume of the particle is not critical to the magnitude of R2 as the susceptibility 
effect falls off from the surface with an exponential (r6) dependence (28, 29).  
It is hypothesized that as water has limited surface access, especially in the 
diffusive time span over which magnetic measurements (and images) are taken, such size 
is detrimental to dephasing of proximal protons. It should be noted that the R1 values 
reported for particles greater than 200 nm are likely underestimates due to precipitation 
of the particles during T1 measurements. For instance, determining T1 relaxation times 
required more than 100 seconds per sample, which was ample time for the micrometer-
sized particles to precipitate out of suspension.  
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Figure 3.6 - Relaxivity Measurements of SPIO. 
 
SPIO of various size were diluted in PBS to iron concentrations between 1 and 200 !g 
Fe/mL for measurement at 1.41 T and 40˚ C. T1 (A-B) and T2 (C-D) values were then 
obtained. The inverse of the relaxation times, in seconds, was linearly fit against 
concentration to yield the particle R1 and R2. Non-linearity of 1430 nm particles in T1 and 
T2 measurements was a result of sedimentation during magnetic measurement. 
A B
C D
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3.5 - Conclusion 
 Iron oxide nanoparticles were prepared using a chemical coprecipitation 
synthesis. At the outset, reaction conditions were varied to determine a suitable protocol 
for the production of SPIO following good manufacturing processes. High quality 
particles, possessing attributes such as limited polydispersity, high transverse relaxivity, 
small size and long term colloidal stability were sought. In order to probe the effects, if 
any, of the modification of reaction conditions on the resultant particles detailed 
macroscopic and nanoscale characterization was performed. Measurements included the 
hydrodynamic and core size and mass, surface chemical functional density and magnetic 
relaxivity.  
 It was found that synthesis conditions could be reliably varied to produce particles 
over roughly an order of magnitude of size and multi-component core number. To 
complement our understanding of particle characteristics over a larger size domain, 
commercial particles were used to supplement the synthesized group. The number of 
surface amines and the iron per particle increased with greater particle diameter over the 
size scale from 33 nm to 1430 nm. Comparison of core and magnetic properties revealed 
that initial assumptions that greater size, and therefore greater iron content per particle, 
would result in larger NP cores and greater T2 relaxivity were incorrect for the entire 
range of particle sizes. The number of cores, and thus the amount of iron per particle, was 
found to significantly influence the relaxivity of the laboratory-synthesized particles, but 
not the larger, commercially obtained, samples. For dextran-coated SPIO the number of 
cores was found to increase with hydrodynamic radii and ratio of iron to dextran, while 
constituent core size remained relatively constant. The transverse and longitudinal 
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relaxivities were greatest for the particle with the greatest number of cores and not the 
particle with the greatest iron content. 
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CHAPTER 4. Size, Charge and Concentration Dependent Uptake of SPIO by Non-
Phagocytic Cells 
4.1 - Abstract 
We have evaluated the cellular uptake of superparamagnetic iron oxide (SPIO) in 
non-phagocytic T cells over a continuum of particle sizes ranging from 33 nm to nearly 
1.5 !m, with precisely controlled surface properties. Further, this has been accomplished 
without the need for potentially cytotoxic transfection agents. SPIO labeling of T cells 
was analyzed by flow cytometry and contrast enhancement was determined by 
relaxometry.  
SPIO uptake was dose dependent and exhibited sigmoidal charge dependence, 
which was shown to saturate at different levels of cationic surface functionalization. 
Efficient labeling of cells was observed for particles up to 300 nm, however micron-sized 
particle uptake was limited. We have shown that an unconventional highly cationic 
particle configuration of aminated 107 nm diameter standard-SPIO (SSPIO) particles 
maximized magnetic resonance (MR) contrast of T cells. These SPIO surprisingly 
outperformed the widely utilized ultrasmall-SPIO (< 50 nm) configuration and 
demonstrated sufficient loading for subsequent in vivo visualization. 
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4.2 - Introduction  
Continuing advancements in the fields of cell-based and cell-targeted therapy, 
such as engineered cytotoxic T cells or cell depleting antibodies, respectively, hold great 
promise for combating disease. Future development of these methods require greater 
knowledge than is currently available regarding the cellular distribution of the therapies 
and targets in vivo. This has led to the emergence of cellular imaging as a strategy to 
track the migration and biodistribution of target cells in living organisms. Pre-clinical 
studies have shown that cellular imaging can be used to evaluate stem cell distribution 
and homing in cell-based regenerative therapies (1, 2).  Recently, cellular imaging has 
also allowed for improved assessment of functional efficacy and applicability of 
immunotherapeutic treatments in disease models for cancer (3-5) and AIDS (6). These 
studies have shown that the ability to determine the cellular effect of treatment, 
quantitatively and over long periods of time, using non-invasive approaches can have a 
significant impact on the development of therapeutic protocols. 
In addition to evaluating cell-based therapies, cellular imaging has the potential to 
provide a great deal of insight into diverse physio- and pathological phenomena. 
Interesting applications include the observation of monocyte recruitment to 
atherosclerotic lesions for the mapping of disease development and therapeutic 
intervention (7), imaging embryonic stem cell movement during embryonic (8) and organ 
development (9) and the monitoring of metastatic cellular extravasation and tissue 
invasion (10, 11).  
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Tracking of labeled cells has been accomplished with a variety of imaging 
modalities including optical methods, positron emission tomography (PET), single 
photon emission computed tomography (SPECT), and MR (12-14). MR imaging presents 
a particularly promising approach because of its high spatial resolution in three 
dimensions and exquisite soft tissue contrast, which can be acquired concomitantly with 
the contrast-enhanced cellular distribution.  
MR detection of cells in vivo is often accomplished following labeling with 
superparamagnetic iron oxide (SPIO) particles. SPIO are negative contrast agents that are 
typically composed of an iron oxide crystal core surrounded by a polymer or 
polysaccharide shell (15). A variety of manifestations of SPIO have been used to track 
cells, which can be broadly categorized as:  
1)  Ultrasmall-SPIO (USPIO) with an overall diameter of 30 - 50 nm (16) 
2)  Standard-SPIO (SSPIO) with a diameter of 50 - 250 nm 
3) Micron-sized paramagnetic iron oxide (MPIO) having a diameter 
approaching or greater than 1 !m (17).  
To date, USPIO have perhaps been the most widely utilized SPIO configuration 
for cell labeling. Although they provide less contrast enhancement per particle as 
compared to SSPIO and MPIO, large numbers of particles can be loaded into each cell, 
allowing for large magnetic susceptibilities to be generated (18, 19). Cationic surfaces 
have been shown to facilitate cellular internalization (20, 21), and thus USPIO are often 
modified with polycationic cell permeating peptides (CPP) such as HIV-Tat (22) or 
protamine (23). Other transfection techniques such as electroporation, sometimes in 
concert with CPPs, have also been used (24, 25). 
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An exciting new direction for cell tracking involves labeling cells with MPIO (26, 
27). The large iron oxide cores present in these particles provide enough contrast for 
single cells to be imaged by MR. However, work with such large particles generally 
confines application of iron oxide-labeling to phenotypes such as macrophages (18), 
dendritic cells (28) or hepatocytes that actively internalize foreign material. MPIO uptake 
in non-phagocytic cells has been accomplished, however several non-trivial 
modifications to the particles were required. The additional conjugation steps and 
associated cost of using the antibody-mediated loading of MPIO is likely prohibitive to 
many for cell tracking purposes (29). As well, any such antibody targeting approach 
renders the contrast agents species specific and may induce adverse cellular events. 
Recently, several studies have attempted to define an optimized particle 
configuration for iron oxide labeling of both phagocytic and non-phagocytic cell types. 
These attempts are part of a maturation of the nascent nanomedicine field to understand 
how NPs interact with biological systems. Most of this work has been directed at the role 
of NP chemical and physical attributes with respect to tumor targeting (30, 31). With 
respect to phagocytic monocyte loading, it was found that these cells are more effectively 
labeled with SSPIO (150 nm) compared with USPIO (30 nm) although MPIO was 
excluded from all of these studies (18, 32). Further, it was found that ionic 
carboxydextran-coated SSPIO (i.e. ferucarbotran) performed better than non-ionic 
dextran-coated SSPIO (i.e. ferumoxide) (18). It remains unclear how MPIO compares 
with these agents. It should be noted that the ability to conduct single cell detection using 
MR imaging systems has been achieved in phagocytic cells with both SPIO 
configurations (33, 34). 
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The optimal SPIO configuration for labeling non-phagocytic cells has been much 
more elusive and findings have been contradictory. For example, in one study it was 
found that the delivery of carboxydextran SPIO and dextran-labeled SSPIO into non-
phagocytic cancer cells and leukocytes (with the assistance of lipofection agents) was 
similar in terms of iron uptake (21). Both particles led to higher iron uptake than 
carboxydextran-coated USPIO. This indirectly suggests that larger particles with ionic 
coatings are superior to non-ionic USPIO. However, in a different study it was found 
that, in the presence of poly-L-lysine, ionic (aminated) USPIO exhibited significantly 
higher iron uptake in non-phagocytic cells compared with SSPIO. These data suggest that 
smaller ionic particles are internalized into non-phagocytic cells more efficiently (35). 
These contradictory findings likely stem from the variability and imprecise control over 
surface charge and the limited number of particle configurations examined, particularly 
with respect to diameter (ranging only from ~17 to 150 nm).  
This chapter systematically evaluates the cellular uptake of SPIO in non-
phagocytic T cells over a continuum of particle sizes ranging from 33 nm to nearly 1.5 
!m and with precisely controlled surface properties, as detailed in the previous chapter. T 
cells were selected as a model non-phagocytic phenotype since visualization of their 
distribution is expected to be of importance for adoptive T cell therapy for cancer and T 
cell homing in autoimmune diseases. Extremely fine control was exerted on the surface 
properties of SPIO by direct chemical modification of particle surfaces rather than 
attempting to modulate the density of supplemental transfection agents. The main reason 
for this approach was to avoid the interfering and generally detrimental effects posed 
through use of charged peptide or cell membrane destabilization technologies.  
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Beyond the role of surface modification, concentration effects and incubation 
time were also tested in the interest of isolating the role particle size exerts on individual 
cell uptake and overall contrast enhancement. Our work shows that in a space between 
USPIO and MPIO exist configurations of relatively small particles (~100 nm) that 
efficiently label non-adherent, non-phagocytic T cells and generate higher relaxivity (per 
cell) relative to particles of other sizes. 
Chapter 4  140 
4.3 - Materials and Methods 
4.3.1 - Nano- and Microparticle SPIO 
 Rigorous characterization of the iron oxide contrast agents utilized in this in vitro 
study were detailed in Chapter 3. To recapitulate; nano- and microparticles of six 
different size configurations were analyzed for their hydrodynamic diameter, core size 
and composition, magnetic and surface properties. The particles are referred to by their 
overall (hydrodynamic) diameter throughout this chapter and include the laboratory 
synthesized 33.4 nm USPIO, 53.5 and 107 nm SSPIO and the commercially obtained 207 
and 289 nm SSPIO and 1430 nm MPIO. All particles were functionalized with cationic 
amine groups. Further, we have demonstrated the ability to control the surface amine 
content of the laboratory-synthesized particles. Additional details regarding synthesis and 
modification protocols as well as characterization can be found in Chapter 3. 
 
4.3.2 - Cell Culture and Labeling 
Immortalized human T cells, Jurkat Clone E6-1 (ATCC), were maintained at 37˚ 
C in 5% CO2 in RPMI 1640 (Mediatech, Manassas, VA) media supplemented with 10% 
FBS (Hyclone, Logan, UT) and penicillin/streptomycin (Mediatech). T cells were labeled 
with iron oxide particles (between 0 and 200 !g Fe/mL) by incubating the commercial 
and lab-made particles with 2 x 106 cells in 400 !L of fully supplemented media for 1 or 
4 hours, at 37˚ C in 5% CO2. Cells were washed of non-internalized particles through two 
methods. Synthesized dextran-coated particles were washed from cells using 
centrifugation. Specifically, cells were pelleted at 0.5k rcf for 5 minutes and resuspended 
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in PBS. This was repeated three times. The dextran-coated particles are highly soluble in 
aqueous solvents and do not precipitate at these centrifugation speeds. Removal of non-
internalized commercial particles was accomplished through a density gradient. The cells 
and particles were diluted to 1 mL with PBS and overlayed on 4 mL of room temperature 
Ficoll-Paque PLUS (GE Healthcare). The sample was centrifuged at 0.4k rcf for 40 
minutes. Cells loaded with particles were retrieved from the interface layer.  
To determine if particles were internalized or merely adsorbed on the cell 
exterior, surface receptor cleavage enzyme trypsin was used. Following particle 
incubation, as described above, cells were exposed to 0.025% trypsin-EDTA (Invitrogen) 
for 5 minutes. Purification of non-internalized particles was carried out as detailed. No 
statistical difference was seen in either flow cytometry or relaxometry between groups 
washed with or without enzyme. 
 
4.3.3 - Assessment of Labeling 
Immediately after non-internalized iron oxide particles were removed from T cell 
samples, flow cytometry was performed on a Guava Easycyte (Guava Technologies, 
Hayward, CA). For labeling and viability experiments, forward and side scattering were 
used to identify the entire population of cells. Data analysis of flow cytometry data was 
accomplished with FlowJo (TreeStar, Ashland, OR). Viability of T cells was determined 
using the LIVE/DEAD cytotoxicity kit for mammalian cells (Invitrogen, Carlsbad, CA) 
according to the manufacturer’s instructions. Specifically the proportion of dead cells was 
determined using the membrane-impermeant ethidium homodimer-1. This dye labels 
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nucleic acids of membrane-compromised cells with red fluorescence. In order to evaluate 
the decrease in T2 relaxation time of iron oxide internalized in T cells, purified cells were 
lysed for 30 minutes in 0.1% SDS in PBS at 37˚ C. Samples were diluted to 0.5x106 
cells/mL in 300 uL and T2 relaxation times were measured using a benchtop Bruker 
mq60 MR relaxometer operating at 1.41 T (60 MHz at 40˚ C; Bruker Optics Ltd, 
Billerica, MA). All flow and magnetic resonance measurements were made in triplicate 
on at least two separate occasions. 
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4.4 – Results 
4.4.1 – Cell Loading 
The extent to which T cells internalize iron oxide particles is dependent upon 
more than mere particle size. Various other particle characteristics and cell loading 
conditions, including surface charge, particle concentration, and incubation time play a 
role. Thus, before it could be determined which particle size or configuration led to the 
highest relaxivity per cell, it was first necessary to identify conditions whereby cell 
loading was independent of these other parameters.  
In the current study, all SPIO samples were fluorescently labeled with an 
equivalent amount of FITC/iron. The use of fluorescently labeled iron oxide particles 
combined with flow cytometry provided a facile method by which particle uptake could 
be systematically assessed in a high-throughput manner.  Following the exploration of 
concentration, time and charge dependent uptake parameters, the contrast enhancement as 
analyzed by magnetic relaxivity was determined. 
 
4.4.2 - Concentration Dependence 
In order to confirm that iron oxide particles were present in sufficient quantity for 
maximum cellular uptake, T cells were incubated with increasing iron concentrations 
until a saturating level was reached. As shown in Figure 4.1, dextran-coated particles 
were efficiently internalized, all reaching a plateau at iron concentrations below 50 !g 
Fe/mL. Greater than 100 !g Fe/mL was required to saturate the loading of the 207 nm, 
289 nm and 1430 nm particles. The necessity for these higher iron concentrations may be 
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attributed to the fact that the number of particles per unit of iron is far less than the 
smaller agents. Further, there is likely less contact between the larger particles and 
suspended cells because of their continual sedimentation. This was perhaps most evident 
with MPIO, where cell labeling was poor across all particle concentrations. Even at 1000 
!g Fe/mL (data not shown) labeling with MPIO did not reach the loading levels achieved 
by the dextran-coated USPIO and SPIO.  
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Figure 4.1 - Dependence of SPIO Loading on Particle Concentration. 
 
Fluorescently labeled SPIO of various size and across a range of concentrations were 
incubated with 2x106 T cells/mL at 37˚ C for 4 hours (excluding the 107 nm particle as 
indicated). SPIO uptake was then measured by flow cytometry. Each experiment was 
conducted in triplicate on at least two separate occasions and each data point represents 
the average value for the mean fluorescent intensity (MFI). Note the difference in x- and 
y-axes for (A) and (B). All particles were maximally aminated (for values see Table 3.1). 
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4.4.3 - Role of Particle Charge 
Surface charge is important for intracellular delivery of exogenous material. This 
principle has been described for a variety of nanoparticles (examples include gold (36), 
polymer (37, 38) and silica (39)) and biologicals (for example delivery of DNA with 
cationic proteins, lipids and polymers (40)) contexts. It stems from the realization that 
charged peptides enabled non-receptor mediated viral uptake (41). The aminated surfaces 
of the particles used in this study provide an inherent surface charge, facilitating cellular 
interaction. However, in order to study the role this property has in the intracellular 
delivery of iron oxide contrast agent, it was necessary to manipulate the magnitude of the 
surface charge. To do so we have applied glycidol, a hydroxyl terminating epoxide, to 
generate subsets of particles with a gradient of surface amines.  
Glycidol has been used previously in dendrimer chemistry to reduce the 
chemotoxicity of highly-positively charged dendrimers (42). The tight control of surface 
properties produced by consuming amines with glycidol allows for isolated examination 
and evaluation of the role of surface charge on SPIO. 
The summary of particle uptake on a per cell basis is shown in Figure 4.2A-C. 
Each data point represents the normalized mean fluorescence intensity (MFI) of T cells 
that were incubated with iron oxide particles at a saturating concentration (previously 
determined) for 4 hours. Under these incubation conditions, it was found that particles in 
their natural (fully aminated) state are maximally internalized. Any further increase in the 
positive surface charge will not further augment SPIO loading. In other words, the 
efficiency of cell labeling has become independent of surface charge. In all cases, uptake 
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and internalization of the particles was rapid. Representative uptake of the 107 nm 
particles as a function of time is shown in Figure 4.2D.  
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Figure 4.2 - Dependence of SPIO Loading on Surface Charge. 
 
T cell uptake of fluorescently labeled SPIO as a function of surface charge was examined 
by modulating the number of amines per particle for the (A) 33.4 nm, (B) 53.5 nm and 
(C) 107 nm particles. A gradient in the degree of functionalization was produced by 
glycidol blocking of amines. SPIO were incubated with T cells at saturating 
concentrations, 50 !g Fe/mL, under identical conditions.  Flow cytometry was then 
performed to assess the relative uptake of each SPIO. Each data point represents the 
mean fluorescent intensity (MFI). The loading of SPIO was rapid; (D) shows the 
representative uptake of fully-aminated 107 nm particles as a function of time. 
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4.4.4 - Cell Viability 
 The impact and potential cytotoxicity of each iron oxide particle on T cells was 
measured using a fluorescent cell viability marker. Negligible to low levels of cell death 
were observed (Figure 4.3) for all particles at diminished and saturating concentrations of 
iron oxide (10 and 50 !g Fe/mL, respectively). The exception was for the 107 nm SPIO, 
which exhibited some adverse cell influence even at 10 !g Fe/mL. This effect was 
exacerbated at increased concentrations. When the amines on the 107 nm particle were 
completely blocked, cell death was reduced to negligible levels; however, internalization 
was also reduced to negligible levels (Figure 4.2C).  
 T cell death is likely attributable to the high positive surface charge possessed by 
the SPIO. Similar results have been seen with amine-terminated poly(amidoamine) 
dendrimers (43). The extremely high driving force for cell internalization imparted by 
positive SPIO surface charge can lead to cell death. We speculate this occurs through 
non-reversible membrane degeneration resulting in either fatal cytoplasm leakage or 
active cell death in response to highly charged foreign bodies.  
In order to minimize the toxicity of the 107 nm particles, the incubation time with 
T cells was decreased to 1 hour. As shown in Figure 4.2D, particle uptake is still 
saturated within this time frame; therefore exposing T cells to excess SPIO for longer 
periods of time was deemed unnecessary. No toxicity was observed with the 107 nm 
particles after just 1 hour of incubation. 
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Figure 4.3 - Viability of T Cells Incubated With SPIO.  
 
SPIO were incubated with T cells at various iron concentrations: 10 !g/mL [black], 50 
!g Fe/mL [white], and 100 !g Fe/mL [grey]. After 4 hours (unless otherwise noted), 
viability was measured and normalized to cells grown in the absence of any particles 
(blank). All SPIO exhibited negligible impact on cell survival after 4 hours, excluding the 
107 nm diameter particles. Reducing incubation time of these particles to 1 hour 
eliminated adverse effects at both low and saturating concentrations. 
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4.4.5 - Contrast Enhancement 
 Flow cytometry was utilized to determine the saturating conditions for each SPIO; 
however, these single cell measurements were conducted with some variation between 
the number of fluorescent labels per particle making it difficult to accurately quantify the 
number of particles per cell. Also, after labeling cells with superparamagnetic tracking 
agents the critical assessment of ability to track cells is their relaxivity. Therefore, a 
benchtop NMR spectrometer, near to the clinical field strength of 1.5 T, was utilized for 
evaluating in vitro loading. As shown in Figure 4.4, T cells loaded with particles showed 
a dose-dependent, negative contrast enhancement.  
As befits their widespread application in the literature, the USPIO proved 
effective at lowering the spin-spin relaxation time (T2). Despite delivering only a small 
payload of iron per particle, the large numbers of 33.4 nm and 53.5 nm particles that 
accumulate in the cells allows for a strong aggregate effect, producing an average T2 
signal of 126.05 msec and 51.5 msec under saturating conditions, respectively. These 
reduced signal values correlate to an 8.04 and 19.68 times reduction in signal from T 
cells without any contrast agent (T2 = 1013 msec). 
Performance of particles greater than 200 nm was ranked inversely with diameter. 
Greater concentrations of large particles continued to reduce the T2 signal; however, 
when the iron concentration was increased above 500 !g Fe/mL the methods used to 
distinctly separate loaded-cells from free particles became less reliable. It should be noted 
that this drawback does not exist for the flow cytometery measurements, as the particles 
themselves could be excluded from the cells based on forward and side scatter. At 150 !g 
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Fe/mL, the spin-spin relaxation signal from the 207 nm, 289 nm and 1430 nm particles 
were 149.75 msec, 224.3 msec and 398 msec, respectively. These finding suggest that 
despite their high R2 values and large iron content, particles greater than 200 nm seem to 
have limited applicability in labeling non-phagocytic cells.  
The highly-aminated SPIO with a diameter of 107 nm produced the greatest 
contrast enhancement. These particles combined the high degree of internalization of the 
USPIO with the superior relaxivity of larger particles. At the 1 hour loading time, to 
avoid any longer term cytotoxic events, these SSPIO were able to reduce signal by 
approximately two orders of magnitude, providing T2 signal of only 12.25 msec, or a 
82.74 times reduction in signal from control. This reduction in signal was approximately 
5 and 10 times greater than that produced by the 53.5 nm and 33.4 nm SPIO (for the same 
concentration). 
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Figure 4.4 - Contrast Enhancement. 
 
T2 Relaxation times of T cells labeled with SPIO.  T cells were labeled with SPIO of 
various size and across a range of concentrations.  The T2 relaxivity of 0.5x106 SPIO-
loaded T cells/mL in 300 µL was measured on a Bruker mq60 MR relaxometer operating 
at 1.41 T (60 MHz). The signal decrease observed following internalization of SPIO is 
dose dependent and saturation correlates well with values determined by flow cytometry. 
The 107 nm SSPIO produced maximum signal decrease. 
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4.5 - Conclusions 
 In this work, efficient iron oxide labeling, without the use of cell penetrating 
peptides or transfection agents, was accomplished in a clinically relevant non-phagocytic 
cellular system. The level of SPIO loading in T cells was determined by flow cytometry 
and verified through evaluation of MR contrast enhancement. Using conditions under 
which cell loading was independent of particle concentration, chemical surface 
modification, and incubation time, particle size was isolated as an attribute to affect nano- 
and microparticle loading.  
 Large particles, over 200 nm in diameter, possess much greater amounts of iron 
per particle, and thus theoretically require few or single particles per cell in order to be 
detected. However, they suffered from gravitational sedimentation, decreased efficiency 
of cell labeling, and in some cases free particles were incompletely removed from cells. 
This may not be a problem with adherent and/or phagocytic cell systems, but 
significantly hampered their use as magnetic probes for non-phagocytic suspended cells.  
 The vastly greater number of USPIO that accumulate within the cells made up for 
their weaker R2 values. While a general trend correlating increased or decreased particle 
size with labeling was not observed, it was clear that the 107 nm SPIO manifestation led 
to the largest T2 signal decrease. The observation that SSPIO provide maximal contrast 
amongst the SPIO configurations tested here is surprising given the ubiquity of USPIO 
and current vogue of MPIO in the literature. These results may have a significant impact 
on the SPIO configuration used to label and subsequently track non-phagocytic cells in 
vivo. 
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CHAPTER 5. B Cell Tracking in SLE Autoimmune Therapy Model 
5.1 - Overview 
 Antibody mediated B cell depletion has been applied successfully to treat non-
Hodgkin's lymphoma (1). This strategy has been extended in trials to treat systemic 
autoimmune diseases which also have B cell related pathologies. When applied to 
systemic lupus erythematosus (SLE), a disease in which loss of B cell tolerance plays a 
central role (2-5), B cell depleting antibody therapy has not yet demonstrated clinical 
efficacy (6-8). Appreciation of the biological response to treatment would be beneficial 
for greater understanding of underlying disease mechanisms and insight towards 
development of effective therapies (9). Cellular and molecular imaging approaches to 
track the in vivo distribution of B cells would allow for the repeated, non-invasive, and 
quantitative determination of the extent of B cell depletion therapy effect and duration in 
an intact animal. 
 We have made use of an ex vivo labeling approach to enable small animal 
magnetic resonance (MR) and fluorescence imaging to accurately determine B cell 
distribution in vivo. Superparamagnetic iron oxide (SPIO) and CellVue 815 near infrared 
(NIR) dye were loaded into B cells and subsequently administered to mice. Distribution 
of cells over a time course of 15 days, with and without the introduction of B cell 
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depleting anti-CD79, was ascertained. The presence of the cells in the spleen was 
observed longitudinally, and quantitatively analyzed between treated and non-treated 
groups. Ex vivo fluorescence of organs of interest as well as immunohistology of the 
spleen was performed in order to describe the fate of the B cells in this system. It was 
seen that the cells loaded with SPIO and CellVue 815 were less responsive to 
immunotherapy, as compared to cells labeled with CellVue 815 alone. Ultimately, it was 
determined that SPIO were interfering with the depleting function of the antibody, 
despite their apparent lack of effect in vitro on cell viability and function.  
 This chapter begins with an introduction to the motivation behind our work on 
tracking lymphocytes and the clinical issues associated with the application of B cell 
depleting antibody to SLE. Methods of lymphocyte tracking are detailed, with an 
emphasis on optical and MR strategies. The development of our approach, the applied 
scheme and techniques are comprehensively discussed. Following this introduction, the 
results and implications of this work are discussed. 
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5.2 - Background; Depletion Therapy 
5.2.1 - Anti-CD20 and Non-Hodgkin's Lymphoma 
 Rituximab is a chimeric anti-CD20 monoclonal antibody used to effectively treat 
B cell non-Hodgkin’s lymphoma (1). The antibody consists of the human IgG1 and kappa 
constant regions along with mouse variable regions from a hybridoma directed at human 
CD20. The mechanism of action of the antibody for therapy is to target and deplete the 
CD20+ sub-population of B cells in the patient (10, 11). The exact biological role of 
CD20 has not been defined (12, 13), however it is suspected to play a role in signaling 
(14). Further, the means by which the antibody binding of this membrane-surface protein 
is able to deplete the cells in vivo has not been fully elucidated, although the consensus 
view is that cell death occurs by more than one mechanism (12, 15).   
 The primary methods through which B cells are depleted by anti-CD20 include 
apoptosis, complement dependent cytotoxicity (CDC) and antibody dependent cell 
mediated cytotoxicity (ADCC). Following administration of rituximab, the in vivo 
activation of caspase-3 and -9 have been noted in the blood leukemia cells of patients 
(16). It has been shown that this effect is dose and time dependent (17). CDC activity has 
been observed as an antibody mediated means of cell disposal. CDC activity, including 
complement activation (18), has been correlated to tumor cell death (19) and 
translocation of CD20 to lipid rafts (20). Finally, ADCC events mediated by Fc!R have 
been shown to be important for B cell depletion. Rituximab has been shown to bind 
activation receptors for effector cell mediated cytotoxicity (21). Other means by which 
the antibody could deplete the cells, such as antiproliferative effects, have also been 
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suggested (22). The success of rituximab for treatment of B cell lymphoma has 
encouraged its application in other B cell pathogenic diseases. 
 
5.2.2 – Rituximab and SLE 
 B cells are a key component of the adaptive immune system and are responsible 
for the maintenance of cellular and humoral protective memory. Autoimmune diseases, 
including rheumatoid arthritis, systemic lupus erythematosus (SLE) and multiple 
sclerosis, are associated with the presence of B cell hyperactivity and/or dysfunction (23). 
Their role is central; it has been shown that autoimmune prone mice that lack B cells do 
not develop characteristic autoimmune features such as kidney destruction, vasculitis or 
autoantibodies (24).  
 SLE is a systemic autoimmune disorder characterized by autoantibody 
production, not restricted to a single organ system, and inflammation of the joints, skin, 
kidneys, heart, lungs, blood vessels and central nervous system. B cells are critical actors 
in the immunopathogenesis of SLE even beyond the production of autoantibody (25, 26). 
Pathogenesis is believed to be mediated through the B cells’ multiple roles as an antigen 
presenting cell, involvement in T cell activation and production of cytokines (27, 28).  
 Rituximab is able to reduce B cells from the peripheral blood nearly completely 
on the order of months and has been tested as a treatment for SLE (29). Early results were 
promising (30-32), however clinical trials of the antibody have been disappointing (6-8). 
For example, a collaborative Genetech and Biogen Idec multicenter Phase II/III trial in 
2008 did not meet any of six endpoint goals demonstrating Rituxan (rituximab; Roche 
Genentech, Inc, South San Francisco, CA and IDEC Pharmaceuticals, San Diego, CA) 
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efficacy over placebo as measured by the British Isles Lupus Assessment Group 
(BILAG) index. This metric is a validated clinical measure of lupus disease activity. 
 
5.2.3 – Beyond Rituximab for SLE Immunotherapy 
 Additional approaches to B cell depletion as a treatment for SLE are in 
development. These include other B cell cytotoxic antibodies that target process critical 
to B cell function. For example, belimumab is a human monoclonal antibody that binds to 
and inhibits the biologic activity of BLyS, which is essential for B cell survival (33, 34). 
The fully human nature of the antibody reduces some safety concerns associated with 
rituximab over long treatment regimes (81), which may lead to production of human anti-
chimeric antibody (35). Pre- and clinical results to date show that belimumab and 
epratuzumab (another humanized monoclonal antibody; targeting CD-22 (36)) can reduce 
the levels of circulating CD20+ B cells (34). However, the circulating B cell depletion is 
apparently less effective than rituximab (37). Another depleting antibody, anti-CD79, 
targets the signaling complex of the B cell receptor (38). In mouse models of 
autoimmune disease, it has been shown that B cell depletion was extensive and 
contributed to enhanced survival (39). 
Counts of peripheral blood lymphocytes are commonly used to assess anti-CD20 
therapeutic effect. This method provides a quantitative cellular measurement of global 
circulating B cells. However, it is insufficient in determining true therapeutic impact as 
depletion from lymphoid tissues has been shown to be highly variable (40, 41). Failure to 
deplete in these tissues may well lead to relapse of, or unabated disease. It has become 
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apparent that the overall biological impact of the therapy, during the course of treatment, 
must be better understood (9).  
 In animal models, it is possible to harvest spleens and lymph nodes for 
lymphocyte subset analysis. However, such an approach is inherently limiting as it 
presents an ex vivo, terminal view of these organs. We hypothesize that methods to 
measure B cell depletion repeatedly in the intact patient or animal would be of great pre- 
and clinical interest. Such techniques would allow for the determination of effectiveness 
of a treatment at the cellular level and correlation to clinical benefit without sacrifice. The 
next section will provide a detailed account of attempts to track lymphocytes, and B cells 
in particular, across a range of imaging modalities. 
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5.3 - Background; Lymphocyte Tracking 
 A variety of methods have been used to study the in vivo distribution of 
lymphocytes in animal models and human patients. These include radioactive tracers, 
biological reporters, fluorescent moieties and magnetic resonance (MR) contrast agents. 
This section will provide a description of these techniques. 
 
5.3.1 - Radioactive Lymphocyte Tracking 
 A convenient method for the general overview of the distribution of injected 
lymphocytes is through the use of radiotracers. Indium-111 labeled lymphocytes were 
used to image biodistribution of radiation treated cells over 20 years ago (42). The most 
commonly applied clinical radiolabel, [18F]fluoro-deoxy-glucose (FDG), has been used in 
a limited number of studies to track lymphocytes, following incorporation in vitro (43).  
Major drawbacks associated with this approach are the low incorporation of radiotracer 
and, as with all radioactive based imaging, the loss of positron-emitting substance (FDG) 
over time (as much as 20% over 1 hour) (44). This limits the duration over which 
imaging of distribution can be performed. Further, there are radioactive health related 
concerns for both the animals and scientists involved in such studies 
 
5.3.2 - Biological Reporters 
 Several molecular biology constructs have been employed to enable in vivo 
visualization of lymphocytes. These include fluorescent and bioluminescent proteins 
which have been used to reveal information about T and B cell development, interaction 
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and distribution (45, 46). Bioluminescent imaging (BLI) is a particularly attractive 
platform for such molecular imaging applications due to its simplicity, sensitivity and the 
ability to obtain temporal information (47). Relevant to the greater understanding of the 
use of anti-CD20 antibodies, the luminescent approach has recently been used to quantify 
the dose dependent effect of rituximab on luciferase-expressing lymphomas (48). 
However, use of such constructs is hampered by the need for extensive animal model 
development, depth penetration issues and general limitation to rodent models. 
 
5.3.3 - Optical Methods 
 Optical tracking methods for the determination of lymphocyte distribution have 
been practiced for over two decades (49). Dyes used for B and T cell tracking can be 
classified into general categories; DNA-binding (50), cytoplasmic (51, 52), covalently 
coupled (53) and membrane-inserting dyes (54, 55). A table, listing commonly used 
lymphocyte tracking dyes is provided in Table 5.1. Initially, ex vivo dye-labeled cell 
populations' distribution was resolved using microscopic techniques at specific time 
points of interest. This approach is inherently limiting as it only allows for proliferation 
and migration to be studied in a terminally invasive fashion (52, 56). In a related 
approach, flow cytometry can be utilized for the detection of fluorescently labeled cells 
from the blood (or tissues processed into single cell suspensions). This technique 
provides an optical means to quantitatively determine, with high sensitivity, lymphocyte 
proliferation characteristics (57).  
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Abbreviation Absorption Emission Category 
H33342 355 460 DNA 
Thiazole Orange 501 547 DNA 
Calcein 496 520 Cytoplasmic 
BCECF-AM 505 545 Cytoplasmic 
FDA 489 514 Cytoplasmic 
CFDA 489 517 Cytoplasmic 
CFDA-AM 489 517 Cytoplasmic 
CFSE 491 518 Cytoplasmic 
FITC 494 519 Covalent 
TRITC 544 572 Covalent 
DiO 484 501 Membrane 
DiI 549 565 Membrane 
PKH 2 490 504 Membrane 
PKH 26 551 567 Membrane 
CellVue NIR780 743 776 Membrane 
CellVue NIR850 786 814 Membrane 
Table 5.1 - Fluorescent Dyes Used for Lymphocyte Tracking 
Common names of dyes used for T and B cell studies in vivo and in vitro. Expanded by 
Thorek, from (49). 
 
 A powerful advantage of optical methodologies is that multiplexing is possible. 
This is especially advantageous given the large library of dyes, as seen in Table 5.1. The 
labeling of cells with distinct dyes enables subsequent visualization of distinct 
populations at the same time (58). In one such approach reported by Roy, et al., two near 
infrared dyes were used to concomitantly image distinct lymphocyte populations in 
mouse lymphoid and brain tissues (54). An issue that accompanies all dyes is that their 
persistent staining is difficult to accomplish. This can be an advantage for proliferation 
Chapter 5  169 
studies, where the loss of signal (read from a daughter cell) can be used to estimate the 
number of divisions from the labeled cell (59, 60). More often though, the loss of signal 
hinders long experimental duration. This also complicates interpretation of results as it is 
difficult to discern if reduced signal is from loss of cells or loss of dye. Furthermore, 
many of the dyes do not maintain their brightness over longer study lengths and may also 
have toxicity issues (57, 61).  
 
5.3.4 - MR Imaging of Lymphocytes 
 Radioactive methods suffer from poor spatial resolution and the requirement of 
additional safety precautions. Optical imaging offers the advantage of high resolution, but 
suffers from tissue penetration depth issues. An alternative is magnetic resonance (MR); 
an attractive modality with translational capabilities for the long term tracking of cell 
populations. High-resolution images over long periods of time, without harm to the 
subject, can be performed. To track cells of interest, it is required that contrast agent used 
be labeled to the lymphocytes. This is more difficult than the labeling of innate immune 
cells, such as macrophage which, as part of their function in the immune system actively 
uptake foreign particles. Several strategies have been developed in order to track 
populations of lymphocytes in vivo by MR which can be categorized as either 1. In vivo 
targeting or 2. Ex vivo loading. 
 In vivo imaging using to T and B cell targeted-SPIO has previously been 
accomplished. Cell selective labeling in vivo with SPIO-antibody conjugates targeting 
cells directed by antibody (anti-CD-8, anti-CD-4 and anti-Mac1) enabled specific 
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labeling of lymphocytes in a CNS inflammation model (62). Anti-CD20 has also been 
coupled to USPIO for in vivo detection of CD20 expressing tumors (63).  
 In an effort to avoid conjugation of targeting ligands to nanoparticles, charge 
based strategies have been pursued to load contrast. Functionalization of SPIO, 
covalently or through electrostatic attraction, with cationic materials has been shown to 
enable lymphocyte uptake. T cells have been labeled with SPIO particles using poly-L-
lysine (64) as well as protamine and the HIV-tat peptide (65). The cationic material 
mediated loading of particles takes place in vitro and cells are subsequently injected into 
another (or back into the cell donating) mouse for subsequent imaging and analysis.  
 Labeling of lymphocytes without the use of cationic mediators has also been 
demonstrated in several ex vivo loading studies. Conjugation of SPIO to a T cell receptor 
specific ligand enabled high levels of uptake of these probes through endocytosis into T 
cells (CD8+). In vivo delivery of these cells demonstrated longitudinal imaging of 
migration to the pancreas in a mouse diabetes model (66). However, the use of cell 
specific ligands is restrictive as it involves additional chemical conjugation and 
purification steps that result in drastically lower yields.  
Visualization of T cells labeled with ultrasmall SPIO (USPIO) has been achieved 
ex vivo, without resorting to cationic or targeted labeling means (67). These citrate 
coated particles were loaded into tumor directed T cells ex vivo and subsequently 
implanted to allow for the high spatial and temporal tracking to the target and non-
specifically to the spleen. Positive contrast detection of lymphocytes, likewise targeted to 
tumors, has been demonstrated using manganese salts (the most common T1-w contrast 
agent after gadolinium) (68). 
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 It was shown in Chapter 4 that contrast agent accumulation in non-phagocytic 
lymphocytes (cultured human T cells) is possible for a variety of particle formulations. It 
was thus possible to determine the loading factors and SPIO characteristics that lead to 
optimal cell labeling for MR contrast enhancement (69). We hypothesize that this in vitro 
approach can be extended for the sensitive detection and tracking of lymphocytes in vivo. 
The robust contrast agent loading of lymphocytes possible using the developed ex vivo 
protocol will enable longitudinal, non-invasive in vivo tracking. 
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5.4 - Study Design 
 Our motivation was to determine whether SPIO enhanced MR could be used to 
monitor the efficacy of B cell antibody depletion therapy in a mouse model. We sought to 
visualize - with high spatial resolution over long times - the migration of B cells using 
magnetic resonance (MR) imaging and optical approaches. Four groups of mice were 
studied, as indicated in Table 5.2. Each possessed different conditions, with respect to the 
combination of contrast employed and/or treatment administered.  
 
Group GFP B cells NIR dye 
(contrast) 
SPIO 
(contrast) 
Anti-CD79 
(treatment) 
PBS 
(treatment) 
i ! ! ! - ! 
ii ! ! ! ! - 
iii ! ! - - ! 
iv ! ! - ! - 
Table 5.2 - Study Groups. 
 This framework enabled us to determine if any interfering effects of the SPIO 
existed regarding initial distribution or response to treatment. All contrast agents were 
loaded into purified GFP B cells in vitro, as illustrated in Figure 5.1A. Validation of the 
non-invasive imaging data was made possible through the histological co-localization of 
implanted cells, surface NIR dye and internalized SPIO. The use of GFP cells allowed for 
the immunohistological staining of B cells in the spleen to be specific for the introduced 
population.  
Specifically, C57BL/6 mice were imaged over the course of 15 days (Figure 
5.1B-C). The contrast-loaded cells were introduced following an initial precontrast 
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imaging session. One day following the B cell injection, a treatment of anti-CD79 or PBS 
was administered and the effect that each treatment had on the distribution and intensity 
of MR and fluorescent signal was quantitatively measured.  
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Figure 5.1 - Schematic. 
(A) SPIO particles functionalized with amines and subsequently Alexa 680, along with 
membrane intercalating near infrared (NIR) dye CellVue NIR815, were incubated with 
murine transgenic-GFP B cells. (B) The contrast loaded cells, tail vein injected at t=0 into 
C57BL/6 mice, enabled longitudinal imaging by MR and optical techniques. GFP 
markers in the implanted B cells allowed for histological correlation of signal and cells ex 
vivo. (C) Imaging (in vivo and ex vivo) time points are indicated. Treatment of either 
PBS or Anti-CD79 (as indicated) was administered following the t=1 imaging session. 
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5.5 - Materials and Methods 
5.5.1 - Nanoparticle Synthesis and Modification 
 Nanoparticles that enabled high levels of MR contrast agent loading into non-
phagocytic lymphocytes had been previously prepared (Chapters 3, 4). Briefly, 53.5 nm 
diameter iron oxide nanoparticles coated with dextran were synthesized using the co-
precipitation technique. All materials were purchased from Fisher Scientific (Hampton, 
NH) unless otherwise noted. To 50 mL of dH2O, 25 g of dextran T10 (GE Healthcare; 
Piscataway, NJ) was dissolved and heated to 80˚ C for 1 hour. After full polysaccharide 
dissolution, mixing overnight and cooling to 4˚ C on ice it was degassed with N2. Iron 
chloride salts, FeCl2 (1.5 g) and FeCl3 (4 g), were each rapidly dissolved in 12.5 mL of 
degassed dH2O and kept on ice for approximately 10 minutes and added to the dextran 
solution. After 30 min of mixing, 15 mL of ammonium hydroxide was added. The 
resulting black viscous solution was then heated to 90˚ C for 1 hour then cooled 
overnight, followed by ultracentrifugation at 20k RCF for 30 minutes. The supernatant 
was continually diafiltrated using a 100 kDa MWCO cartridge (GE Healthcare) on a 
peristaltic pump (E323, Watson Marlowe Bredel; Wilmington, MA). The particles were 
exchanged into 0.02 M citrate, 0.15 M sodium chloride buffer until all unreacted products 
had been removed.  
The dextran-coated SPIO were cross-linked in base (25% v/v 10 M NaOH) using 
epichlorhydrin (33%) (65). This solution was mixed for 24 hours. Prior to amine 
functionalization of the cross-linked dextran shell, a brief 10 minute dialysis into 0.02 M 
citrate buffer was performed (8-14 kDa MWCO, 50 mm flat width; regenerated 
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cellulose). Following the dialysis, additional ammonium hydroxide was added (25%) to 
the activated nanoparticles and mixed for 24 hours. The particles were then exhaustively 
purified via diafiltration, against 0.02 M citrate. The resulting particles were amine 
functionalized cross-linked iron oxide, SPIO. 
 Alexa Fluor 680 (Invitrogen; Carlsbad, CA) was dissolved in dimethylformamide 
and added to SPIO suspended in pH 9 sodium bicarbonate buffer. The final volume of the 
dye was 10% at a 10:1 molar labeling ratio of dye:SPIO. The solution was mixed 
overnight and then purified twice through a PD10 gel filtration column (GE Healthcare) 
equilibrated with phosphate buffered saline (PBS). Conjugation was verified by 
absorbance using a Cary-100 UV-Vis spectrophotometer (Varian; Palo Alto, CA). For 
preliminary experiments, fluorescein isothiocyanate (FITC, Pierce Biotechnology; 
Rockford, IL) was used in place of Alexa Fluor 680 under identical reaction and 
purification conditions.  
 The cross-linked cationic SPIO functionalized with fluorescent dye will be 
referred to as SPIO. This convention is adopted for simplicity and the fact that no other 
nanoparticles were utilized in this study. 
 
5.5.2 - Cell Acquisition 
 Splenocytes were obtained from C57BL/6-Tg(UBC-GFP)30Scha/J (GFP) and 
C57BL/6 mice. Animals were culled and their spleen's removed. The spleen was 
macerated through a 70 !m strainer placed in a shallow dish. A single cell suspension 
was made by running the cells, in Hanks Buffered Saline Solution (HBSS), repeatedly 
through a 70 !m screen. The cells were pelleted by centrifugation at 4˚ C, 0.6k rcf for 5 
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minutes and resuspended in ACK lysis buffer (Invitrogen), placed on ice for 5 minutes 
and centrifuged again.  
 When required, B cells were purified from splenocytes, derived from the GFP 
mice, using a negative selection (70). Harvested splenocytes were centrifuged and 
resuspended in PBS + 0.5% BSA + 2mM EDTA (90 !L for every 107 cells). The cells 
were then mixed and incubated with CD43 selection microbeads beads (30 minutes) and 
isolated using an autoMACS (Miltenyi Biotec; Hamburg, Germany). B cells were those 
that failed to bind (i.e. CD43 negative). 
 
5.5.3 - Cell Labeling 
 B cells were incubated with SPIO (50 !g Fe/mL) in fully supplemented RPMI 
1640 (ATCC; Manassas, VA) for 2 hours at 37˚ C, 5% CO2. The cells were washed of 
non-internalized SPIO and prepared for CellVue NIR815 dye (NIR, Molecular Targeting 
Technologies, Inc; Malvern, PA) labeling by precipitation at 0.5k RCF and resuspension 
in protein free media, in triplicate. NIR membrane labeling was conducted following 
manufacturers instructions; NIR was diluted from stock by 1/50 to 16 !M in Diluent C, 
an iso-osmotic solution with no physiological salts or organic solvents (provided by 
manufacturer). The cells were added to this solution rapidly, mixed thoroughly and 
incubated covered from light for 4 minutes. Cells were washed from free dye by repeated 
centrifugation and resuspension into serum-supplemented media and subsequently PBS. 
Fresh 15 mL conical tubes were used for each wash to avoid dye binding to the vessel's 
hydrophobic walls. For preliminary experiments, the dye PKH26 (Sigma; St. Louis, MO) 
was used under identical loading conditions. PKH26 is a similar lipophilic dye, from 
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which NIR was derived. 
 Success of loading cells with SPIO and dye was verified by fluorescence 
microscopy. An Olympus IX 81 motorized inverted fluorescence microscope was used, 
equipped with an Ixon (Andor Technology PLC; Belfast, Northern Ireland) monochrome 
digital camera, an X-Cite 120 excitation source (EXFO; Quebec, QC) and Sutter 
excitation and emission filter wheels. 
 
5.5.4 - Cell Activation 
 Activation of primary C57BL/6 B cells or splenocytes by incubation with SPIO 
was assessed by flow cytometry. In initial experiments to determine whether the SPIO 
loading would lead to activation of the B cells, the cells were cultured with SPIO (as 
above), washed and maintained in culture for 24 hours. Cells cultured with the SPIO for a 
total of 24 hours and cells cultured with increasing doses of PMA (phorbol ester, phorbol 
12-myristate 13-acetate; 0.1-10 !g/mL) served as positive control. Cells incubated 
without additives represented the negative control. Activation was measured by changes 
in surface marker expression. Specifically, fluorescently labeled antibodies against CD40 
(PE), CD86 (PE), CD80 (FITC) and MHCII (FITC) were used to label cells after 
triplicate purification from culture media to 0.1% BSA in PBS, on ice for 15 minutes 
(1/200). 
 The ability for B cell activation after SPIO loading was determined by loading 
splenocytes with SPIO, washing of excess nanoparticles and then incubating with LPS 
(E. Coli 055:b5; 0.01 – 10 !g/mL) in fully supplemented media. B cells were identified 
from the general splenocyte population by anti-CD19 (APC), and surface marker 
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expression was assessed as above. Flow cytometry was performed using a FACSCalibur 
(BD Biosciences; Franklin Lakes, NJ).  
 
5.5.5 - Animal Procedures 
 All procedures were carried out in compliance with the Guide for the Care and 
Use of Laboratory Animal Resources (National Research Council, 1996) and approved 
by both the University of Pennsylvania's Institutional Animal Care and Use Committee 
and the Small Animal Imaging Facility (SAIF) Animal Oversight Subcommittee. All in 
vivo fluorescence and magnetic resonance imaging procedures were conducted at their 
respective sub-cores at the SAIF at the Department of Radiology in the School of 
Medicine. 
 Four groups of 8 adult (8 week old) male C57BL/6 mice (all mice obtained from 
Jackson Laboratories) were placed on AIN-76A low-autofluorescence rodent diet, ad 
libidum (Research Diets, Inc.). Six days after food change, animals were tail vein injected 
with 20M primary B cells derived from GFP-transgenic mice loaded with either SPIO 
and NIR or just NIR.  
 Three subjects per group were imaged by MR and whole-body fluorescent 
imaging at each of the following time points; prior to administration of B cells and , 1 
hour, 1 d, 3d, 5d, 7d, 10d and 15 d post-injection. B cell depletion was conducted using 
an intraperitoneal injection of 250 !g of Anti-CD79" (HM79-16, Armenian hamster IgG 
(39, 71)) immediately following the conclusion of the day 1 imaging session. A 
peripheral blood lymphocyte measurement and necroscopy, for ex vivo fluorescent organ 
imaging, were performed on one mouse per time point, per group.  
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5.5.6 - In Vivo Fluorescence Imaging 
 Mice were induced with inhalation anesthesia, using in a 4% mixture of 
Isoflurane in oxygen. Mice were maintained at a 2% mixture of the gas and shaved on 
their left side. Intraperitoneally administered 2-2-2 Tribromoethanol (Avertin; 0.5 mg/g 
dose; approximately 200 !L) 10 minutes before imaging was used to keep animals 
motionless during acquisition. Spectral fluorescence images were acquired of recumbent 
mice, using a Maestro fluorescence imaging system (CRi; Woburn, MA).  The red filter 
set (excitation range 615 to 665 nm; emission, 700 nm longpass) was used to detect 
Alexa680-SPIO and the near infrared filter set (excitation range 710 to 760 nm; emission, 
800 nm longpass) enabled detection of the cell membrane bound NIR815. Each spectral 
image set was acquired using a 5 sec exposure with acquisition at 10 nm steps through 
the emission range. The spectral fluorescence images consisting of the two dyes and the 
autofluorescence spectra were then unmixed based on their spectral patterns using 
commercial software (Maestro software, CRi). Line intensities were generated through 
the long axis of the spleen. Mean intensities of the signal at this organ and background 
were computed and averaged for each image. 
 
5.5.7 - MR Imaging 
 Magnetic resonance imaging was conducted using a horizontal Varian 9.4 T small 
animal imaging system (Varian; Palo Alto, CA). Gradient coils were upgraded during the 
course of the study, going from a diameter of 14 to 12 cm and an applied field strength of 
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10 G/cm to 25 G/cm (both Varian). A dual coil, actively detuned system was employed; a 
70 mm receiver volume coil was paired with a 2.5 cm surface coil (InsightMRI, LLC; 
Worcester, MA). Mice were induced using inhalation anesthesia, 4% isoflurane, and 
maintained for the duration of image acquisition with 2% isoflurane. The animals were 
placed on their right side in a split top mouse chamber sled (m2m Imaging; Cleveland, 
OH) affixed to a custom built poly-(methyl methacrylate) patient bed. The surface coil 
was applied to the left side of the animal and fixed in position using surgical tape to both 
the mouse and bed. Temperature and electrocardiography probes were used to monitor 
the rats in the 37˚ C environment supplied by an air heating system (SA Instruments, Inc.; 
Stony Brook, NY). 
 Scout scans were used to identify the anatomy of interest. Following recognition 
of the spleen axial sections, 1 mm thick, were acquired in a 36x36 mm field of view. 
Acquisition sets consisted of np=256, nv=256, under T1-weighted and T2*-weighted 
parameters. For the former, a spin echo multi-slice sequence was employed (2 NEX and 
TR/TE 2000/40 msec). T2*-weighted scans were taken under two sets of conditions with 
increasing echo time (2 NEX, and TR/TE 200/6 (or 200/12) msec). Images were analyzed 
by defining an equal area ROI for the spleen and background (paraspinal) muscle. The 
relative intensity of the spleen was then calculated and statistical significance for the 
image analysis was p<0.05 using a two-tailed parametric analysis. 
 
5.5.8 - Ex vivo Fluorescence Imaging 
 At each time point, following MR and in vivo fluorescent imaging, one subject 
per group was sacrificed. A necroscopy was performed to harvest the spleen, liver, lungs 
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and heart. Dual channel (700 nm and 800 nm) fluorescence images were acquired of the 
organs on an Odyssey flatbed laser scanning system (LICOR Biosciences; Lincoln, NE). 
After imaging was complete, organs were immediately fixed in 4% paraformaldehyde. 
The fixation of only one half of the spleen was performed (see below). The mean 
fluorescence of each organ was calculated. This value was determined by outlining each 
organ from the background using the trace thresholding tool in ImageJ. The mean 
intensities of each organ at each time point, for each group, were quantitatively 
compared. 
 
5.5.9 - Immunohistology  
 The excised spleen was bisected prior to fixation (above) and the non-fixed half 
was embedded in Optimal Cutting Temperature medium (OCT, Tissue-Tek, Sakura 
Finetek Americas, Inc.; Torrance, CA) for cryostat sectioning. Sections (8 !m thickness) 
were initially coverslipped under cyanoacrylate ester glue and interrogated for GFP, 
NIR815 and Alexa680-SPIO by fluorescence microscopy or using the Odyssey in the 700 
nm and 800 nm channels at 21 !m resolution.  
The coverslip and glue were subsequently dissolved using an acetone bath for 48 
hours which also served to cross-link the tissue. The same slide that had been imaged 
using fluorescence microscopy was then imaged for the presence and co-localization of 
GFP and nanoparticles. Nanoparticles were revealed by development of samples in 
Prussian blue stain. Here, a wash of a 1:1 mixture of 2% potassium ferrocyanide and 2% 
HCl for 20 minutes produces blue aggregates at sites of iron oxide (SPIO) deposits.  
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5.5.10 – Efficacy of Depletion 
 Peripheral blood lymphocyte (PBL) counts were determined by flow cytometry. 
PBL were obtained from mice at time of organ harvest, purified of red blood cells with 
ACK and stained with anti-CD19-FITC (1D3, rIgG2a) and fixed with 4% 
paraformaldehyde. Fluoroescent populations (B cells) were assessed using a Guava 
Easycyte (Millipore). 
 The depletion of B cells in the spleen was determined in a similar fashion. A 
single cell suspension of splenocytes was obtained from the spleen of treated and 
untreated C57BL/6 mice (2 mice per group), 3 days after therapy. The number of B cells 
in the spleen was determined by labeling the splenocytes with anti-CD19 (APC) and 
measuring the population size on a FACSCalibur. 
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5.6 - Results and Discussion  
5.6.1 – SPIO Characterization and Cell Loading 
 Prior to imaging animals using fluorescently modified nanoparticles and dyes, the 
spectral characteristics of the cationic 53.5 nm superparamagnetic iron oxide 
nanoparticles derivated with Alexa 680 dye (SPIO) were measured. The concentration of 
Alexa 680 fluorophores per particle was determined from the difference in absorbance 
between labeled and unlabeled SPIO. A spectra of the nanoparticle absorbance 
normalized to that of an unmodified particle is shown in Figure 5.2A. Using a standard 
curve for nanoparticle concentration and the molar extinction coefficient of the dye 
(1840000 M/cm) the number of SPIO and of dye was determined for the absorbance 
sample. It was calculated that there were approximately 3 fluorescent molecules attached 
per particle. 
 Primary B cell activation was assessed ex vivo to determine if loading with 53.5 
nm SPIO would have a negative impact on the cells' in vivo viability, distribution or 
function. Flow cytometry was performed on cells after incubation with particles for 1 or 
24 hours and compared to non-labeled and phorbol ester (PMA) incubated B cells, Figure 
5.2B. The SPIO did not appear to activate the cells as no increase in CD40, CD86, CD80 
or MHCII was observed compared with that of unlabeled control, and expression was 
significantly less than activated with 1 !g/mL PMA. 
 Cells loaded with SPIO and NIR were examined by fluorescence microscopy to 
confirm their internalization and the prospects of their in vivo detection, Figure 5.2C-F. It 
was found that despite a high iron uptake of the cells (see below) that there was low 
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fluorescence from Alexa Fluor 680. It is speculated that this is due to a quenching of the 
dye due to its proximity to the iron oxide core of the particles. The labeling of NIR was 
rapid and robust, as detection of the cells was achieved with relatively short exposure 
time (200 msec). 
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Figure 5.2 - Fluorescence Labeling of Particles and Cells. 
(A) Normalized absorption spectra of the dye-modified (green) and unmodified (red) 
SPIO. The peak at 680 nm is indicative of the presence of the dye. (B) Particles did not 
activate primary B cells, as determined by surface marker expression. (C-F) SPIO and 
dye loaded primary B cells were imaged, immediately after labeling. (C) White light, (D) 
Alexa 680 nm-SPIO, (E) NIR815 and (F) composite. Both contrast agents effectively 
labeled cells, however particle-core quenching of the Alexa dye limited its fluorescence. 
NIR815 membrane labeling was homogeneous and comparatively bright. All at 20x 
magnification. 
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5.6.2 – Optimization of MR Imaging Protocol 
 MR imaging, initially using mouse cadavers, was carried out in order to develop 
the final imaging protocol described in Materials and Methods. Early live animal work 
involved both the intraperitoneal and tail vein injection of splenocytes loaded with SPIO 
and PKH26. Intraperitoneal injection as a means of administration was abandoned as 
migration of the cells to the secondary lymphoid tissues required days. From anecdotal 
references and initial imaging results, the slow accumulation of contrast in the spleen was 
difficult to verify. In contrast, tail vein injected cells were predominantly found in the 
spleen within 24 hours, as seen clearly seen below, in section 5.6.3.  
 Selection of sequence parameters, through which the T1, T2, T2* or proton-density 
weighting could be achieved, was critical for the detection of the contrast agent used. For 
SPIO enabled nanoparticle detection of neuroinflammation in a rat model of pain (see 
Chapter 6) a T2*-weighted gradient echo multi-slice protocol had been developed. Using 
these sequence parameters (echo time; TE = 5.5 msec and repetition time; TR = 200 
msec) as a starting point, values were varied in order to investigate effectiveness in 
imaging of SPIO-labeled B cells accumulated in the spleen, Figure 5.3. Increase in TR 
resulted in significant respiratory motion artifact. Increases in TE enhanced the T2* effect 
slightly, however noise increased dramatically. Contrast, determined as the difference in 
mean signal between the spleen and background muscle (surrounding the spine), was 
assessed for increasing TE. It was found that increasing the TE above 6 msec did not 
provide greater splenic contrast. Use of a gradient echo multi-slice sequence with TR/TE 
of 200/6, 2 averages, 1 mm thickness and a resolution of 256x256 produced images with 
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a CNR of 82.25 for SPIO-B cell injected mice and only 31.67 for PBS injected mice; a 
CNR increase greater than two times. 
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Figure 5.3 - Preliminary MR and Histology. 
(A, B) Representative image acquisitions in the sagittal plane of a mouse injected with 
SPIO-loaded B cells. The slices, 1 mm thick, were acquired with a gradient echo 
sequence with increasing TE as indicated at the base of each image. Right (rostral) to left 
(caudal) organs were identified; including the lungs (Lu), liver (Li), stomach (S), spleen 
(arrow and triangle) and kidneys (K) are clearly identified within an isointense region. 
Increasing TE produced greater signal decrease at the spleen. (C-H) Evidence of highly-
efficient loading of SPIO-FITC and PKH26 into primary B-cells, following their 
injection and homing to the spleen. (D, G) PKH26 fluorescence was specific to the 
injected animals (562 nm emission). Likewise, (E) FITC channel signal was limited to 
autofluorescence in PBS injected as compared to (H) the SPIO-FITC loaded B cells. 
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5.6.3 - In Vivo Fluorescence Imaging 
 Preliminary work confirmed our ability to label primary B cells with both SPIO 
MR contrast agents and fluorescent membrane dye. During initial experimentation FITC 
and PKH26 were used. These fluorophores are non-ideal for in vivo imaging as they 
function at a highly tissue-attenuated region of the light spectrum. For in vivo imaging, 
SPIO were subsequently modified with Alexa 680 nm and the cells were membrane 
labeled with NIR dyes. Both dyes possess red-shifted excitation and emission profiles 
that enable greater tissue penetration (72). The excitation and emission maxima are listed 
for each of the fluorescent molecules in Table 5.3.  
 
Fluorophore Excitation (nm) Emission (nm) 
PKH26 551 567 
FITC(SPIO) 494 518 
CellVue NIR815 786 814 
Alexa Fluor 680(SPIO) 679 702 
Table 5.3 - Dye Suitability for In vivo Imaging 
 
Fluorescent molecules for preliminary (top half) and in vivo (bottom half) 
experimentation, according to manufacturers (MTTI and Invitrogen). 
 
 Using in vivo imaging-suitable dyes, it was possible to detect and monitor the 
distribution of B cells in vivo Figure 5.4. All four groups of animals were imaged in the 
near infrared red (NIR) channel using a Maestro system. Acquisitions in the deep red 
(Alexa-SPIO) channel were also obtained for groups that included SPIO loading. All 
mice were placed on a low-autofluorescence diet approximately one week prior to the 
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start of the study. This was done to limit background in the deep red channel. However, 
even with this precaution, the autofluorescence from (exposed) skin was still significant 
in the SPIO channel prior to injection of any contrast, Figure 5.4B. Further, the 
quenching of the Alexa Fluor 680 nm fluorescence, through proximity to the iron oxide 
core of the SPIO, limited the enhancement of signal following B cell administration. A 
similar effect had been noted using in vitro fluorescent microscopy (Figure 5.2). 
 Prior to injection of cells (day 0) the levels of fluorescence in the NIR channel 
were equal to that of background for all groups. Immediately following injection cells 
were visualized in the spleen, however there was generally high variability of signal 
intensity at this '1 minute' time point. The spleen was easily identified at 1 day, with little 
fluorescence observed elsewhere except at sites of the site of the tail vein injection. Here, 
it is speculated that a small fraction of the cells and dye may have been injected 
subcutaneously and thus required a much longer time to migrate to the spleen or disperse.  
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Figure 5.4 - In vivo Fluorescent Tracking of B Cells. 
 
Representative whole animal fluorescence images of mice before and after injection of B 
cells loaded with SPIO and NIR contrast. Prior to injection (A-C), significant signal 
within the SPIO channel was evident at the dermis (B). Longitudinal imaging of this 
mouse, from group A (loaded with both NIR and SPIO; no knockdown), revealed rapid 
accumulation of the exogenous population in the spleen and at the sites of the tail vein 
injection (D-F). The signal decreased over time to the end time point of the study (J-L).  
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 To determine the effect of the B cell depleting antibody, anti-CD79, on SPIO-
labeled B cells the fluorescent signal intensity in the spleen was quantitatively compared 
across the four groups of animals, as outlined in Table 5.2. These groups were antibody-
treated and untreated mice with B cells loaded with either SPIO and NIR or NIR-alone: 
group i) untreated, NIR and SPIO, group ii) treated, NIR and SPIO, group iii) untreated, 
NIR-alone, and group iv) treated, NIR-alone. The mean fluorescent intensity of the 
spleen and background and signal-to-background ratio (SBR) were then calculated for 
each animal (Figure 5.5). These data revealed that B cells localized to the spleen, within 1 
day. In untreated animals that contained B cells membrane labeled with NIR alone, the 
signal gradually disappeared over the duration of the experiment (group D).  For this 
group SBR retention at day 3 was 81.3% of day 1 levels. Untreated mice injected with 
cells loaded with both MR and fluorescent contrast (group i) also exhibited a gradual loss 
of signal with a SBR on day 3 that was 81.5% of day 1 levels. The continuing loss of 
signal over the remaining 11 days for the two groups was also similar.  
 In animals labeled with NIR-alone and treated with B cell depleting antibody 
(group iii) the loss of signal ratio was rapid, with only 41.5% of day 1 SBR ratio 
remaining by day 3. While SBR did not return to precontrast levels, likely due to some 
residual, non-cleared B cells, the signal continued to decrease gradually over the 
remainder of the experiment. However, for mice treated with the B cell depleting 
antibody following injection of SPIO and NIR loaded cells (group ii), SBR only 
decreased to 68% of day 1 levels at day 3. Continued signal ratio loss occurred on a rate 
comparable to that of the non-treated controls.  
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Figure 5.5 - In vivo Fluorescence Quantitation. 
(A) For quantitative analysis, a user defined line of interest was placed on the (NIR 
channel) fluorescent image. (B) The signal intensity along the line was used to generate 
values for intensity of spleen signal and background. (C) The signal-to-background ratio, 
normalized to the day 1 value by group, demonstrated swift homing of contrast labeled B 
cells to the spleen. The ratio decreased gradually over the course of the experiment for 
non-knockdown groups (i and iv). In contrast, the metric decreased rapidly for the anti-
CD79 depleted group containing B cells loaded with only NIR (iii). However, no 
depletion was observed in mice injected with cells loaded with both dye and SPIO, as 
measured by fluorescence (ii). Groups; i – untreated, NIR and SPIO, ii – treated, NIR and 
SPIO, iii – untreated, NIR-alone, and iv – treated, NIR-alone. 
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5.6.4 - MR Imaging  
 The biodistribution of B cells labeled with both SPIO and NIR was also observed 
by MR (Figure 5.6). Changes in relative signal normalized to day 0 (pre-contrast) 
between the spleen and back muscle changed significantly following injection with 
SPIO-loaded B cells (groups i and ii). Over the following two weeks, the normalized 
signal ratio gradually increased towards pre-contrast values. There was no statistically 
significant change (p>0.05) in the normalized intensity ratio for mice given cells labeled 
with NIR-alone (groups iii and iv). Thus, detection of the migration of the exogenous cell 
population to the spleen required the presence of SPIO. However, it was observed that the 
normalized signal ratio for the spleen gradually decreased following treatment of SPIO-
free mice (group iii; NIR-only with anti-CD79 treatment). Possible changes to the MR 
T2*-weighted signal of the spleen, through antibody mediated depopulation of the organ, 
could have such an effect over time. To our knowledge, this observation has not 
previously been presented in the literature regarding rituximab treatment and imaging. 
 Similar to the observations and measurements of in vivo fluorescence, in animals 
with SPIO-labeled B cells, relative signal changes were small between antibody treated 
and non-treated groups. There was an observed difference in signal intensity ratio at 
approximately 9 days following antibody injection. Nevertheless, for all other time 
points, differences between depleted and non-depleted mouse specimens that could be 
detected were non-statistically significant. 
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Figure 5.6 - MR Imaging of B Cell Distribution 
(A-C) Representative axial T2*-weighted images of mice either pre-injection or on the 
indicated days following injection of SPIO-loaded B cells (group i). Signal in the spleen 
(arrow) decreased following cell introduction but gradually recovered over the duration 
of the experiment. (D) Relative signal intensity was calculated as the ratio of spleen and 
background muscle (an average) from user defined ROI. (E) Groups given SPIO-labeled 
B cells demonstrated rapid and pronounced relative signal changes normalized to pre-
contrast (i and ii). There was no significant change in spleen signal for groups devoid of 
SPIO (iii and iv). Echoing the fluorescent data, there was also only limited difference in 
the normalized relative signal between treated (ii) and non-treated (i) groups that 
possessed SPIO-loaded B cells. 
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5.6.5 - Ex vivo Fluorescence 
 Consistent with findings from whole body fluorescent and MR imaging, the 
distribution of B cells as determined by ex vivo fluorescence indicated that homing to the 
spleen was rapid. The normalized mean fluorescent intensity (MFI) for each group, 
normalized by organ, is shown in Figure 5.7.  
Homing of the re-administered B cells was almost entirely within the spleen, 
Figure 5.8A (non-normalized MFI). Some fluorescence in the liver, 1 day after cell 
injection, was also noted for all groups. In line with in vivo whole body fluorescent and 
MR imaging of the spleen, maximum signal was attained in the spleen (and all other 
organs) 1 day after injection and gradually decreased thereafter.  
 These organ specific fluorescent data also confirm that there is no significant 
difference between splenic signal in the treated and non-treated SPIO-labeled groups, 
Figure 5.8B. B cells were in some way inhibited from antibody-mediated depletion 
following intracellular loading of SPIO nanoparticulates. This effect was not a result of 
the B cell acquisition and purification protocol, as cells obtained and labeled with NIR-
alone were robustly and rapidly depleted from the spleen.  
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Figure 5.7 - Ex vivo Fluorescence; By Group. 
(A-D) The distribution of B cells by organ (spleen, liver, heart and lungs) for each group 
is shown, as determined by the mean fluorescence intensity (MFI) normalized to the day 
1 intensity of each organ. For groups in which SPIO-labeled B cells had been 
administered to mice, there was a gradual decrease in fluorescence over two weeks (ii) 
with or (i) without introduction of antibody therapy. This paralleled the slow decrease in 
organs of signal from (iii) NIR-only labeled, non-depleted mice. A rapid decrease in MFI 
was measured after (iv) anti-CD79 therapy of NIR-only labeled B cells. Here, groups i, ii, 
iii, and iv correspond to A, B, C and D. (E) A representative false-coloured organ scan in 
the 800 nm (NIR) channel. 
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Figure 5.8 - Ex vivo Fluorescence; Absolute and Normalized Splenic Comparison. 
(a) The non-normalized MFI, for group B, illustrates the predominance of spleen-targeted 
distribution. (B) Normalized MFI of the spleen alone, for each group, is plotted for the 
length of the experiment. Little difference was detected between the groups outside of 
antibody-treated, NIR-only (SPIO-free) group iii. 
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5.6.6 –Cytometric Analysis and Histological Correlation 
Through longitudinal MR and fluorescent imaging it was apparent that there 
existed a discrepancy between the signal changes of treated animals from SPIO-and-NIR 
loaded (group ii) and NIR-alone labeled B cells (group iii). In order to verify that the 
anti-CD79 immunotherapy was effective towards the depletion of B cells, blood was 
obtained from a mouse at each time point, for each group. The number of B cells, as 
detected by fluorescently-labeled anti-CD19, was assessed relative to the total 
lymphocyte count, Figure 5.9A. Further, the splenic B cells depletion by antibody was 
also investigated, Figure 5.9B. It was apparent from these data that the anti-CD79 was 
indeed effective at reducing the number of B cells throughout the organism, if only for a 
time. 
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Figure 5.9 – Assessment of Depletion. 
These figures indicate that the depletion of B cells was successful, using both a (A) 
global and (B-D) spleen-specific measure. (A) The peripheral blood lymphocyte 
quantification in untreated (i) and treated (ii) mice, into which SPIO and NIR loaded B 
cells had been administered. The arrow indicates the time of administration of 
immunotherapy (following day 1 image acquisitions). Within the spleen, B cell counts 
also decreased significantly following anti-CD79 therapy. (B) Unstained single cell 
suspension from spleen. (C) Anti-CD19 (APC) stained splenocytes from untreated 
animal. (D) Decreased number of B cells are detected following therapy. Average gated 
proportion of population for two mice 4 days after B cell introduction. 
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 B cells were successfully being depleted by the immunotherapeutic treatment and 
not by sham PBS injection. This led to supplementary investigation of what role SPIO-
loading had on the primary B cells, which apparently reduced their clearance, despite 
achieving this effect globally and within the spleen. Specifically, surface marker changes, 
as an indication of activation, were assessed to determine if the cells could be activated 
following loading by SPIO. LPS was used to activate the cells as a positive control. SPIO 
(non-fluorescently labeled, so as not to interfere with flow cytometry) were incubated 
with the cells under two conditions. The first was a recapitulation of the preliminary 
experiment to determine if the particles, when loaded during a two hour period, led to 
activation over the subsequent 24 hours (see section 5.6.1). To assess the ability of loaded 
B cells to become activated, SPIO were again loaded over 2 hours, but following washing 
away of excess particles, the cells were incubated with LPS for a 24 hour period. The 
results, shown in Figure 5.9, indicate that the SPIO do not inhibit the ability of the B cells 
to become activated, as assessed by surface marker differentiation.  
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Figure 5.10 – B Cell Function and SPIO Loading 
Surface marker expression was assessed to determine the ability of B cells, following 
SPIO-loading, to activate. The blank group are primary splenocytes cultured for 24 hours 
in fully supplemented media. Activated cells were seen following incubation with LPS 
over 24 hours (0.1 !g/mL). Loading of cells with particles, SPIO (2h), again assessed the 
ability of SPIO to incidentally activate the cells. To determine if B cells could be 
activated following SPIO-loading, as used for the in vivo imaging experiments, labeled 
splenocytes were incubated with LPS for 24 hours, SPIO (2h LPS). The loaded cells 
appear to be able to undergo LPS mediated activation. 
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 Histological analysis of the excised and axially sectioned tissue was also 
performed. These studies were undertake in order to confirm that SPIO, NIR and GFP 
signal correlated within the spleen over the course of the anti-CD79-depletion monitoring 
experiment. Co-localization of the contrast agents with the exogenous cells is an 
important control to verify that the signal (or reduction in signal for MR) detected was 
not due to non-specific distribution of the agents outside of the cells following injection. 
For example, an initial concern was that anti-CD79 mediated depletion through ADCC 
processes would lead to the accumulation of originally-B cell loaded agents in 
macrophages.  
In the initial examination, a relatively novel protocol was employed in order to 
examine fluorescent intensity data from all samples simultaneously, at the sub-organ 
scale (54). For our purposes, this allowed for the direct observation of splenic tissue 
fluorescence in all groups at multiple time points. Images of the NIR fluorescence 
indicated clearly that the signal intensity decreased as a function of time following loaded 
B cell injection. Disappointingly however, the lack of SPIO channel fluorescence made it 
impossible to directly correlate SPIO and NIR signal within the spleen. Fluorescence 
microscopy was also used to co-localize fluorescent signals, Figure 5.12. Despite high 
levels of autofluorescence in the GFP channel, correlation between sites of GFP, NIR and 
SPIO fluorescence could be made. Further, this signal was specific to GFP-B cell injected 
mice. 
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Figure 5.11 – Laser Scanning Histology 
An application of moderately high-throughput histological laser scanning of splenic 
tissues. The samples were embedded in OCT and fresh frozen. Following axial (or axial-
biased oblique) sectioning at 8 !m, the samples were placed directly onto an Odyssey 
laser scanner. With a resolution of 21 !m, it is possible to discern with moderately-high-
resolution the fluorescent signal from the spleen. (A-D) (A) No NIR signal is present in 
control tissues (mice without B cell injection). The decrease of NIR signal (800 nm 
channel) of group i samples (NIR- and SPIO-loaded) from (B) day 1 through (C) day 5 
and finally, (D) day 15. All images have identical brightness and contrast values. The 
flatbed scanning profile allows for acquisition of numerous samples at the same time, 
lower magnification (F). 
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Figure 5.12 – Histological Co-localization. 
(A-D)  Representative images of the spleen of a mouse without administration of B cells. 
(A) Despite the absence of any green fluorescent protein, there is still considerable 
fluorescence in this low wavelength channel. There is little detectable cellular signal in 
the (B) SPIO or (C) NIR channels, as shown on (D) the composite image. (E-F) 
Representative images of the spleen an untreated mouse 7 days after injection of B cells 
loaded with both SPIO and NIR, group i. (E) Despite the comparable background 
autofluorescence in the GFP channel, there were distinct, punctate areas of increased 
signal. These localized well with the (F) SPIO and (G) NIR fluorescence channels. The 
composite image shows that indeed there is considerable overlap of all three channels 
(arrows), apart from the background autofluorescence. All images taken at 40x 
magnification. 
 
A B C D
E F G H
Chapter 5  207 
5.7 - Conclusion  
The immune system is a dynamic and highly coordinated assemblage of proteins 
and cell types that protect the body from foreign invaders. Lymphocytes are the 
mediators of adaptive immunity and are able to migrate throughout the body as well as to 
specific sites of the lymphatic system including the thymus, lymph nodes and spleen. In 
order to analyze this complex series of events, procedures are required that can 
simultaneously track the migration of lymphocytes into different tissues. This is 
especially relevant when the system operates in an abnormal fashion.  
Autoimmune disorders, such as systemic lupus erythematosus present a host of 
clinical manifestations that impact quality and length of life (73, 74). Successful 
application of B cell depleting antibody, which has been shown to be effective in 
treatment of non-Hodgkin's lymphoma (1) and rheumatoid arthritis (75), to SLE has been 
elusive (9). Understanding the distribution of autoimmune disorder relevant populations, 
such as B cells, prior to and following attempted therapy would permit the determination 
of effectiveness of treatment with respect to duration and extent. Here, we investigated 
the use of non-invasive cellular and molecular imaging approaches for the repeated 
measurement of B cells longitudinally. 
We have shown the ability to effectively load superparamagnetic iron oxide 
nanoparticles (SPIO) into lymphocytes (69). This was accomplished without the use of 
potentially toxic exogenous agents (76-78). The 53.5 nm diameter aminated and cross-
linked dextran-coated SPIO nanoparticles were able to effectively label non-phagocytic 
lymphocytes and showed significant T2*-weighted contrast. When used to label primary 
murine B cells no significant activation, as determined by surface marker expression, was 
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noted. Cells labeled with these fluorescently-labeled agents could be identified under 
fluorescent microscopic observation, however the brightness of the fluorophore used, the 
Alexa Fluor 680 nm dye, was apparently quenched by the iron oxide core of the 
nanoparticle to some degree. Due to this effect, and a desire to have multimodal cell 
tracking capabilities, a second cellular marker was introduced, the CellVue NIR 815 nm 
membrane labeling dye (NIR). With NIR we demonstrated the ability to effectively label 
the primary B cells with the required concentration to enable in vivo fluorescent 
detection. 
Contrast loaded B cells homed quickly and specifically to the spleen. This was 
determined non-invasively in all groups by a specific signal increase in the spleen by 
fluorescence imaging. Here, a signal-to-background ratio of approximately 30 times was 
recorded for all groups. Hypointensity of the spleen in MR T2*-weighted imaging for 
SPIO and fluorescently labeled cells confirmed a multimodal capability to detect the 
presence of an introduced cell population. Relative to pre-injection values, there was an 
approximate 40% change in normalized signal intensity ratio 1 day after cellular 
administration. This correlated with fluorescent signal increases in both ex vivo imaging 
techniques, organ laser scanning and histological evaluation.  
For mice in groups that were treated with PBS there was a gradual loss of MR and 
fluorescent signal (in vivo and ex vivo) over time. By the final imaging time point, MR 
signal ratio had returned to within statistical error of the pre-injection values. Similarly, 
after 15 days only 40% of the fluorescent signal (determined by signal-to-background 
ratio) remained in the spleen relative to day 0 levels.  
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In treated groups, significant differences in the change in signal following 
treatment were seen between the MR-and-NIR and NIR-alone loaded lymphocytes, under 
all modalities of imaging. MR contrast generation in the spleen had been found to be 
specific for SPIO loaded cells; no contrast developed between the spleen and background 
muscle when lymphocytes with NIR-alone had been introduced. However, there was no 
significant change in signal intensity ratio between the two SPIO-loaded B cell groups; 
PBS and anti-CD79 treated. Using fluorescence whole body imaging, these results were 
essentially recapitulated. It was seen again that there was little difference in the splenic 
signal between the two SPIO-loaded groups.  
These results were quite distinct from the fluorescent spleen intensity over time in 
animals injected with B cells that had only been label with NIR dye. Unlike the gradual 
loss of signal trending towards the pre-injection level, a rapid decrease in signal-to-
background was observed in anti-CD79 treated mice. These results were confirmed by ex 
vivo organ and histologically prepared tissues for fluorescent measurements. It was found 
that signal from the organs, once resected, reported similar outcomes. Namely, the 
fluorescent intensity was specific to the spleen and decreased rapidly only for the anti-
CD79 treated NIR-only loaded mice. 
Flow cytometry of blood at terminal imaging time points was collected in order to 
determine the effectiveness of antibody treatment in depleting circulating B cells. From 
these data it was seen that depletion therapy was successful in removing a significant 
proportion of the circulating B cell population. This outcome was seen in both treated 
groups (dual-labeled and NIR-only), while the peripheral blood lymphocyte values varied 
little for the PBS injected animals. Further, splenic B cell quantification, also by flow 
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cytometry, indicated that the number of B cells decreased significantly following 
treatment, as compared to untreated control. With the knowledge that the antibody was 
indeed effective upon administration it was apparent that the SPIO nanoparticles were in 
some way influencing the depletion of the labeled, introduced B cells in the location to 
which they had accumulated, the spleen. Determination of the biochemical or physical 
means of this inhibition is extremely difficult. It is impossible to mimic the specific and 
complex microenvironment of this organ ex vivo. This would be required in order to 
discern the role that each chemical, mechanical and biological factor may have in the 
therapeutic efficacy of the antibody mediated depletion. However, in an initial attempt to 
determine the possible effect of SPIO loading on B cell function, a post-loading 
activation study was presented. Here, it was shown that B cells can be activated by LPS 
as determined by surface marker expression in flow cytometry. 
These results indicate clearly that detection and tracking of an introduced 
population of B cells is possible using SPIO nanoparticles. However, the outcome of little 
apparent signal ratio change in either MR or optical modalities indicates that the 
approach of ex vivo loading these contrast agents are inadequate to the task of monitoring 
therapeutic efficacy. This is a particularly interesting conclusion from the standpoint of 
the application of nanomaterials in biological, and especially biomedical, settings. It also 
serves to highlight a concern for the use of MR approaches to track lymphocytes in a 
similar fashion to the extant drawbacks associated with radiotracer and optical 
approaches. 
In a recent study comparing bioluminescent and SPIO approaches to non-invasive 
cell tracking, it was found that the SPIO used exhibited an extended residence lifetime in 
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vivo, regardless of the presence or state of the cells they were supposedly meant to track 
(79). This led to the conclusion that bioluminescent proteins were a better marker of 
myocardial cell survival kinetics than MR through SPIO. We have found that the change 
in signal from MR and optical techniques do not mimic the distribution profile of cells 
tracked without SPIO. It should be noted that the present study’s findings do not correlate 
exactly with the recently published work finding fault with SPIO. We were able to 
determine a co-localization of SPIO, NIR and B cells. And in fact, others have indeed 
shown that SPIO and bioluminescene are both effective imaging approaches to determine 
the presence of stem cell transplants to injured cardiac tissue (80).  
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CHAPTER 6. Comparative Analysis of Nanoparticle-Antibody Conjugations: 
Carbodiimide Versus Click Chemistry 
6.1 - Abstract 
 Ex vivo labeling of contrast agents into cells affords high levels of loading for 
subsequently sensitive in vivo detection. However, as we have shown in the previous 
chapter, the ex vivo loading of superparamagnetic iron oxide (SPIO) nanoparticles into B 
cells inhibited the cells ability to be depleted using an antibody therapy. In vivo targeting 
of cells offers an alternative approach; wherein the cells are labeled in vivo using 
systemically delivered particles. While achieving lower contrast delivery per cell, these 
methods still allow for non-invasive detection. The major advantage of this strategy 
applied for the monitoring of B cell response to immunotherapy would be to avoid the 
onerous requirements of extracting, purifying and loading B cells, and their possible 
dysfunction as a result.  
Typically, in vivo applications require functionalizing the nanoparticles directly 
with targeting agents. The ability to modify the physical, chemical, and biological 
properties of nanoparticles (NPs) has led to their widespread use as multi-functional 
platforms for drug delivery and diagnostic applications. Antibodies (Ab) remain an 
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attractive choice as targeting agents because of their large epitope space and high affinity; 
however, implementation of Ab-NP conjugate strategies are plagued by low coupling 
efficiencies and the high cost of reagents.  
 Click chemistry may provide a solution to the problem of Ab-NP probe 
manufacture with reported coupling efficiencies nearing 100%. While click chemistries 
have been used to functionalize nanoparticles with small molecules, they have not 
previously been used to functionalize nanoparticles with Ab. Concerns associated with 
extending this procedure to Ab is that reaction catalysts or the ligands required for cross-
linking may result in loss of functionality. Here, we document the evaluation of the 
efficiency of conjugations between Ab and superparamagnetic iron oxide NPs using click 
chemistry. Results were compared with conjugates formed through carbodiimide (EDC) 
cross-linking.  The click reaction allowed for a higher extent and efficiency of labeling 
compared with EDC thus requiring less Ab. Functional assessment of these probes in an 
in vitro cell labeling schema has also been performed. In comparison to EDC, conjugates 
prepared via the click reaction exhibited improved binding to target receptors. 
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6.2 - Introduction 
 Nanoparticles (NPs), commonly defined as organic or inorganic materials with at 
least one length dimension below 100 nm, are being widely investigated as drug delivery 
vehicles and/or imaging agents. Interest in NPs largely stems from their ability to carry a 
large therapeutic payload (or ample amounts of contrast agent), the ability to finely tune 
physicochemical properties, which can influence their pharmacokinetic and 
pharmacodynamic profiles, and the ability to functionalize their surface with molecularly 
specific targeting agents. For both diagnostic (1) and therapeutic (2) purposes, including 
immune cell relevant applications, it is becoming increasingly recognized that specific 
targeting of NPs is critical towards their effective use.  
 Ex vivo loading of a particulate agent is a proficient means to achieve high 
intracellular payloads of contrast or therapetic agents. An example of this approach was 
detailed for in vitro (Chapter 4) and in vivo (Chapter 5) applications. However, this 
method requires that the cells of interest be removed, often quite abrasively from an 
organism or patient, for example in the case of splenocyte purification. Such an approach 
is well suited for some applications, but not in situations when invasive attainment of a 
cell population would be detrimental to its further study.  
 In vivo targeting of NP is a more sophisticated approach wherein agents are 
directed with some engineered-specificity towards cells of interest. When targeted, 
reduced amounts of therapeutic and imaging agents are required compared with 
systemically delivered non-specific vehicle (3). Furthermore, targeting greatly reduces 
nonspecific background signal from accumulation of contrast agents at undesirable sites 
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when compared to non-targeted NP. Together, lower dose and greater specificity reduce 
undesirable toxicity and lead to improved efficacy of therapeutics.  
 Superparamagnetic iron oxide nanoparticles (SPIO) are a widely used NP system 
affording T2*-weighted contrast for magnetic resonance (MR) imaging applications (4). 
Recently, SPIO have been conjugated to a variety of targeting ligands to provide cellular 
and molecular specificity for in vitro diagnostic (5) and in vivo imaging (6) applications. 
Strategies for targeting SPIO most often include the use of peptides, endogenous ligands 
and monoclonal antibodies (7-9).  
 Despite their relatively large size (roughly 150 kDa) antibodies remain an 
attractive choice because of their combinatorially large epitope space (of approximately 
1015) and their high affinity for targets with Kd’s often on the order of nM (10). 
Antibodies also have the additional advantage of being widely pursued for use in pre- and 
clinical applications for the therapy of prevalent disorders. Antibody therapies for cancer 
such as Trastuzumab  (targeting Her2/neu) (11), for inflammatory disorders such as 
Infliximab (an anti-TNF antibody) (12) and antiviral antibodies such as Palivizumab 
(targeting respiratory syncytial virus) (13) are used to study and treat disease globally.  
 Currently, one of the greatest obstacles facing the use of NP-antibody conjugates 
is the low efficiency of Ab coupling to NPs, which can result in the need for large 
quantities of antibody and prohibitive costs (14). One example of a common approach 
used for conjugation of antibodies to NPs involves carbodiimide cross-linking (15). The 
zero length cross-linker 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride 
(EDC) reacts with carboxylated NPs in the presence of sulfo-N-hydroxylfosuccinimide 
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(sulfo-NHS) to form amine-reactive sulfo-NHS esters. Subsequent addition of antibodies 
results in coupling between the NPs and primary amines on the antibody via a stable 
amide bond. Unfortunately, the reaction is non-ideal as it is highly inefficient and thus 
requires a high excess of antibody.  Typically, only about 1-20% of the antibody used 
during the conjugation procedure will be coupled to the NP (9, 16, 17). 
 Click chemistry refers to modular chemical conjugations with an emphasis on 
simple reactions that can take place under a range of conditions with stereospecificity and 
high efficiency (18). Recently, the emergence and adoption of the click chemistry 
philosophy has had a large impact in drug discovery and materials synthesis. The rapid 
rise of click chemistry is evident from its novel use in a variety of disciplines including 
medicinal chemistry (19), materials and polymer science (20, 21) and molecular imaging 
(22, 23). The most widely adopted reaction of this type, the CuI-catalyzed terminal 
alkyne-azide cycloaddition (CuAAC), was developed by the Sharpless and Meldal groups 
independently in 2002 (24, 25).  
 Previously, it has been shown that the coupling of low molecular weight species 
such as peptides (26) and fluorophores (27) to SPIO can be accomplished with CuAAC. 
However, evidence that functional antibodies can be coupled to SPIO through CuAAC is 
lacking. Likewise, reference of large protein linkage to any NP system using a click 
approach is scarce. Gupta et al. have briefly described holo-transferrin bound viral 
capsids, although this was reported by way of TEM (transmission electron microscopy) 
micrographs (28). Lipases have been conjugated to gold nanoparticles and retained their 
function (29), however a major concern with using CuAAC for NP-antibody coupling 
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reactions is that the antibodies will be irreversibly degraded and/or modified during the 
reaction. For example, it has previously been shown that the CuAAC reaction can result 
in the irreversible degradation of viral capsids (30) and nucleic acids (31).  Further, 
antibodies could become non-functional due to modification of the innate protein with 
click reactive ligands.  
 In this work we evaluated the use of CuAAC for conjugation of SPIO to anti-
CD20.  Anti-CD20 is a clinically approved chimeric monoclonal antibody that has been 
therapeutically approved for use in treating B cell lymphoma. This antibody has also been 
used previously to target SPIO to CD20 expressing tumors (32). We have sought to 
comparatively assess the utility of the CuAAC reaction for antibody targeting of SPIO 
against an accepted method, that of carbodiimide conjugation. Particle labeling was 
assessed for both strategies by means of the efficiency and extent of protein-to-particle 
labeling and by functional cell-targeting assays. It is our expectation that determination of 
best practices for Ab-NP production will significantly impact their ability to be applied in 
biomedically relevant situations. 
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6.3 - Experimental Procedures 
6.3.1 - Materials 
 Azido-dPEG12 NHS ester and Propargyl-dPEG NHS ester were purchased from 
Quanta BioDesign Ltd., (Powell, OH). The nanoparticle coating material, dextran T10, 
was purchased from Amersham Biosciences (now GE Healthcare, Piscataway, NJ). 
Reagent grade IgG (Immunoglobulin G) from rat serum was acquired from Sigma 
Aldrich (St. Louis, MO), while anti-CD20 antibody, Rituximab, (Genentech, South San 
Francisco, CA) was a gift of the Eisenberg group. Human lymphoma B cells (Burkitt 
GA-10) were obtained from ATCC (Manassas, VA). Bathocuproinedisulfonic acid (BCS) 
was acquired from Acros Organics (Geel, Belgium). All other reagents were purchased 
from Thermo Fisher Scientific (Waltham, MA), unless otherwise noted. 
 
6.3.2 - SPIO Synthesis and Amination 
 SPIO were prepared by chemical co-precipitation, as previously described in 
Chapter 3 and reference (33). Briefly, 0.7313 g FeCl2 and 1.97 g  FeCl3  were each 
dissolved in 12.5 mL diH2O and added to 25 g dextran T10 in 50 mL diH2O at 4˚C. 
Ammonium hydroxide (15 mL) was slowly added to this mixture turning the light yellow 
colored solution black. This nanoparticle slurry was then heated to 90˚C for 1 h and 
cooled overnight.  
 Purification of SPIO was accomplished by ultracentrifugation of the mixture at 
20K RCF (relative centrifugal force) for 30 min. Pellets were discarded and the 
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supernatant was subjected to diafiltration against greater than 20 volumes of 0.02 M 
citrate, 0.15 M sodium chloride buffer, using a 100 kDa cutoff membrane filter (GE 
Healthcare). The purified particles were then cross-linked by reacting the particles (10 
mg Fe/mL) with 25% (v/v) 10 M NaOH and 33% epichlorohydrin. After mixing for 24 
hours, the particles were briefly dialyzed and then functionalized with amines by adding 
25% ammonium hydroxide. This reaction was allowed to continue for another 24 h 
followed by diafiltration as above.  
 
6.3.3 - SPIO Characterization 
 The hydrodynamic diameter of the nanoparticles was measured using a Zetasizer 
Nano-z (Malvern Instruments, Malvern, UK) through dynamic light scattering (DLS).  
SPIO particles were diluted in PBS to a concentration of approximately 0.5 mg Fe/mL 
and read in triplicate. The values reported for all samples are the intensity peak values. 
 The longitudinal (R1) and transverse (R2) relaxivity of each particle was 
calculated as the slope of the curves 1/T1 and 1/T2 against iron concentration, 
respectively.  T1 and T2 relaxation times were determined using a Bruker mq60 MR 
relaxometer operating at 1.41 T (60 MHz). T1 measurements were performed by 
collecting 12 data points from 5.0 to 1000 msec with a total measurement duration of 
1.49 minutes. T2 measurements were made using ! = 1.5 msec and 2 dummy echoes, and 
fitted assuming a monoexponential decay. 
 The number of amines per particle was determined following the general 
procedure described by Zhao et al. (34). Briefly, iron oxide particles at a concentration of 
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2 mg/mL Fe were reacted with excess N-Succinimidyl 3-(2-pyridyldithio) propionate 
(SPDP, Calbiochem, San Diego, CA) for 4 hours. SPIO were washed of excess SPDP 
through repeated precipitation in isopropanol and resuspension in PBS.  The particles 
were then run through a 50kDa MWCO centrifugal filter (YM-50, Millipore, Billerica, 
MA) either with or without the addition of the disulfide cleavage agent (tris(2-
carboxyethyl)phosphine) (TCEP). The difference of the absorbance of these two samples 
at 343 nm was used to determine the concentration of SPDP in the filter flow. Adjusting 
for dilution, the number of amines per particle was determined. 
 
6.3.4 - FITC Modification of SPIO 
 Fluorescein-isothiocyanate (FITC) was used to fluorescently label amine-
functionalized cross-linked SPIO by reacting at a molar ratio of 19:1 FITC to iron. The 
unbound FITC was washed from the FITC-SPIO using a PD10 gel filtration column (GE 
Healthcare) equilibrated with phosphate buffered saline (PBS). All particles were FITC-
labeled prior to subsequent modification, ensuring that all particles had equal fluorescent 
labeling. 
 
6.3.5 - Carboxylation of SPIO 
 A schematic outlining the carbodiimide cross-linking procedure is illustrated in 
Figure 6.1A - strategy i. FITC labeled, amine-functionalized NPs (as shown in Figure 
6.1B) were derivatized to acid residues following reaction with an excess of succinic 
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anhydride in basic solution. Specifically, 200 !L of NH2-SPIO (5 mg Fe/mL) in 0.02M 
citrate buffer, pH 8 was added to 10 !L of 1 M NaOH followed by 10 !L of 4 M succinic 
anhydride in DMF. The reaction was allowed to mix for 4 hours. Carboxylated-SPIO 
(COOH-SPIO) were subsequently precipitated three times in 4 volumes of isopropanol to 
remove free reactants.  
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Figure 6.1 - Schematic of Antibody-SPIO Conjugation Strategies.  
(A) Fluorescently labeled, amine functionalized SPIO were reacted along one of two 
routes to produce antibody-SPIO conjugates. In strategy (i) carbodiimide chemistry is 
utilized, following the conversion of the surface amines to COOH groups utilizing 
succinic anhydride. In strategy (ii), antibody-labeled SPIO are produced by employing 
CuI-catalyzed terminal alkyne-azide cycloaddition (CuAAC). Azide-modified SPIO are 
“clicked” to alkyne-labeled antibodies in the presence of copper. (B) Schematic 
illustrating the preparation of FITC-SPIO. (C) Schematic illustrating the alkyne-PEG 
modification of antibody, which was necessary for the CuAAC reaction. 
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6.3.6 - Carbodiimide Conjugations 
 Carbodiimide coupling reactions were accomplished with FITC labeled COOH-
SPIO in 2-(N-morpholino)ethanesulfonic acid (MES) buffer, pH 6.0. To 50 !L of SPIO 
(2 mg Fe/mL), 10 !L each of 200 mM EDC and 500 mM sulfo-NHS was added. 
Solutions mixed for one hour at 25˚C, were then precipitated in 500 !L of isopropanol. A 
resuspension of the NPs in 100 !L of 10 mg/mL antibody solution in PBS, pH 7.4 was 
allowed to react at 15˚C overnight. Purification was carried out using a MS magnetic 
column in PBS. 
 The BCA Protein Assay was used for protein concentration of conjugate 
solutions, after correcting for background with unlabeled SPIO. To determine number of 
protein per particle, the molarity of SPIO was assessed spectrophotometrically by 
dissolving the NPs and oxidizing the iron with 6M HCl and 3% H2O2. Absorbance at 410 
nm was compared to a standard curve and particle concentration was calculated assuming 
8924 Fe atoms per particle, as previously determined (33). 
 
6.3.7 - Azide Modification of SPIO  
 A schematic outlining the CuAAC cross-linking procedure is found in Figure 
6.1A - strategy ii. FITC-SPIO was reacted with the amine-reactive azido-dPEG12 NHS, 
diluted 10 times from stock in dimethyl sulfoxide (DMSO), in 0.1 M sodium phosphate 
buffer, pH 9. The linker was added at 100 times molar excess to the SPIO. After mixing 
for 4 hours, the SPIO were purified twice on PD10 columns equilibrated with PBS. 
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Azide-SPIO was then concentrated on an Ultracel 30k centrifugal filter (Millipore, 
Billerica, MA) in PBS. 
 
6.3.8 - Alkyne Functionalization of Antibodies 
 Alkyne functionalization of antibodies, for both IgG and Rituximab as seen in 
Figure 6.1C, was accomplished by addition of 10% v/v propargyl-dPEG-NHS in DMSO 
to 10 mg/mL antibody in 0.1M sodium phosphate buffer, pH 9. The concentration of 
propargyl-dPEG-NHS was varied to provide different degrees of labeling per antibody. 
Antibody was purified on a PD10 column equilibrated with PBS and then re-concentrated 
using Ultracel 30k filters. Antibody concentration post-purification was assessed 
spectrophotometrically at 280 nm using a molar extinction coefficient of 210000 M-1cm-1. 
 
6.3.9 - CuAAC Conjugation 
 SPIO was conjugated to alkyne functionalized IgG and anti-CD20 using the same 
procedures. FITC labeled N3-SPIO (3 mg Fe/mL) was mixed with varying volumes of 10 
mg/mL alkynated-antibody, 5 mM BCS, 1 mM CuSO4 and 5 mM sodium ascorbate. 
Final volumes of the reactions were brought to a constant level with the addition of PBS. 
The samples were mixed for 4 h at 15˚ C. Samples were cleaned of the reaction additives 
using an YM-50 spin column. The antibody-linked nanoparticles were then purified from 
unbound protein on a MS magnetic column (Miltenyi Biotec, Bergisch Gladbach, 
Germany). Protein per particle labeling was determined as above. 
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6.3.10 - Cell Labeling and Assessment 
 SPIO were incubated with 100 !L of 1x106 cells/mL Burkitt’s GA-10 lymphoma 
B cells for 30 minutes at 37˚C, 5 % CO2 in a 96 well plate. SPIO were added at final 
concentrations of 50 !g Fe/mL and 10 !g Fe/mL for carbodiimide- and click-conjugated 
SPIO, respectively. In the antibody inhibition experiments, 50 !g/mL (final 
concentrations) of free anti-CD20 was added prior to the addition of the antibody-
conjugated nanoparticles. The free, unbound particles, were purified from the cells 
through three PBS washes at 1k RCF for 5 minutes each. Cells were finally resuspended 
in 300 !L of PBS and placed in a 96-well plate to be read using a Guava Easycyte Plus 
system (Guava Technologies, Hayward, CA). Flow cytometry data was analyzed using 
FlowJo (TreeStar Inc., San Francisco, CA). 
 Click-conjugated particles at a concentration of 50 !g Fe/mL were incubated with 
cells as above, using 30x103 cells. Images were acquired with an Olympus IX 81 inverted 
fluorescence microscope using a LUC PLAN 40x objective (NA 0.6; Olympus) following 
fluorescein excitation by and an X-cite 120 excitation source (EXFO, Quebec, QC). 
Micrographs were taken using a back-illuminated EMCCD camera (Andor Technology 
PLC, Belfast, Northern Ireland). 
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6.4 - Results and Discussion 
6.4.1 - Antibody Modification 
 Antibodies were coupled to SPIO using either conventional carbodiimide 
chemistry or CuAAC, as shown in Figure 6.1A. The SPIO used throughout the present 
study possessed an average hydrodynamic diameter of 33.4 nm and R1 and R2 values of 
13.56 mM-1sec-1 and 71.00 mM-1sec-1, respectively. The SPIO were also aminated (~185 
NH2 per particle), making this probe well suited to modification with dye and proteins. 
Initially, all CuAAC conjugations were carried out using rat IgG so that the reaction 
parameters could be optimized in a cost-effective manner. Further, FITC dyes were 
bound to the particles prior to any subsequent protein modification. This served to 
eliminate interference of fluorescent labeling by proteins or click-ligands at a later stage. 
 A series of biochemical cross-linking experiments were performed in order to 
determine the optimal binding efficiency of antibody to SPIO using the CuAAC strategy. 
The first parameter to be varied was the number of alkyne groups introduced onto IgG. 
This was accomplished by varying the labeling ratio of alkynating reagent, CH-PEG-
NHS, to IgG from 15:1 to 100:1. In a separate reaction, azide-labeled SPIO were 
prepared by reacting aminated SPIO with a 100-fold molar excess of N3-PEG-NHS, as 
seen in Figure 6.2. Following appropriate purification procedures, alkyne-labeled IgG 
were coupled to the azide-SPIO through CuAAC in a catalytic copper solution.  For this 
reaction, the molar ratio of IgG per SPIO was held constant at 17.5:1.  After a 4 hour 
incubation, unbound IgG were removed by magnetically purifying the SPIO and the 
average number of IgG coupled to each SPIO was quantified.  It was found that the 
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number of IgG per SPIO increased with the degree of alkyne incorporation, to a 
maximum labeling of 10-13 IgG per SPIO for this series of reactions.  The maximum 
number of IgG per SPIO was achieved when IgG was reacted with >35-fold molar excess 
of CH-PEG-NHS. Therefore, all subsequent alkynating reactions were carried out 
utilizing these lowest saturating conditions. 
 It can be seen that there is significant variability in the reaction as we approach 
the saturation labeling plateau. This is a result of cross-linking of N3-SPIO and CH-IgG 
into large aggregates. The occurrence of this phenomenon was difficult to overcome 
because purification of excess protein is required in order to assess how much remains 
bound. Purification is not possible when the particles are no longer soluble. It was found 
that aggregation could be minimized through application of several careful steps during 
and after the reaction.  
 Specifically, immediate mixing of all reactants after each was added helped 
reduce aggregation. The order of addition was not important, however it was kept 
constant. Additional PBS was added prior to any purification, which appeared to aid in 
preventing the loss of all material if any precipitate had formed. Further, as noted in the 
materials section, a filtration step was added prior to the magnetic purification. It appears 
counterintuitive that sedimentation would help particles remain in solution, but it has 
been found that aggregation in solution is more likely to result in strong column binding 
during the magnetic purification step (even after removal from the magnet). Therefore, 
removal of such material (which will form a film on the filter), as well as excess 
reactants, prior to application to the magnetic column was beneficial. 
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Figure 6.2 - Effect of IgG alkylation on conjugation to SPIO.  
 
To determine the minimally required alkyne residues on IgG necessary to achieve 
maximum conjugation with SPIO, IgG was reacted with increasing amounts of CH-PEG-
NHS. The alkyne-IgG samples were then “clicked” to N3-SPIO and the degree of labeling 
was assessed. The degree of antibody labeling began to level off at an approximate 
starting labeling ratio of 35 CH-PEG-NHS:IgG.  
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6.4.2 - Saturation Labeling 
 An important reported advantage of pursuing CuAAC reactions has been the high 
efficiency of conjugations. This is a particularly desirable property when procedures 
involve large and expensive proteins such as antibodies. As such, we next determined the 
conjugation efficiency between IgG and SPIO for labeling ratios of alkyne-IgG to azide-
SPIO ranging from 2.5:1 to 35:1.  As shown in Figure 6.3, there was nearly a 100% 
coupling efficiency when the labeling ratio was less than ~20 IgG per SPIO.  At higher 
labeling ratios, the number of IgG per SPIO did not improve, likely because there was 
insufficient space on the SPIO surface for additional conjugations. Utilizing this 
information, subsequent conjugation of the clinically approved anti-CD20 was materially 
conserved, as a labeling ratio of only 15 antibodies per SPIO was used. 
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Figure 6.3 - Efficiency of CuAAC-Based IgG-SPIO Conjugations as a Function of 
IgG Concentration.  
 
The click reaction between protein and SPIO was performed with increasing molar 
excess of IgG to SPIO.  The labeling efficiency was ~100% for all conjugations up to a 
labeling ratio of 20 IgG per SPIO.  Higher labeling ratios did not result in any increase in 
the number of conjugated antibodies. 
 
Chapter 6   239 
   
6.4.3 - Bioconjugation Comparison 
 To this point all reactions had seen rat IgG coupled to FITC labeled SPIO by 
CuAAC. Prior to assessment of whether antibodies that have been coupled to SPIO 
remain functionally active following the CuAAC reaction, antibody (anti-CD20) was 
coupled to SPIO using CuAAC. For comparison, the same antibodies were also coupled 
to SPIO using carbodiimide chemistry.  Each step of the carbodiimide reaction was 
conducted under saturating conditions to maximize the conjugation efficiency.  
Specifically, carboxylated SPIO were reacted with an excess of EDC and sulfo-NHS in 
MES buffer, pH 6.0 for 1 hour in an attempt to achieve complete activation of all 
available carboxyl groups.  To minimize subsequent hydrolysis of the NHS-activated 
SPIO, unreacted cross-linking agents were removed as rapidly as possible (~2-5 minutes) 
by precipitating the SPIO with isopropanol.  The SPIO were then resuspended directly in 
an excess of anti-CD20 in PBS, pH 7.4 and mixed overnight.   
 As shown in Figure 6.4A, the copper catalyzed ligation of anti-CD20 to SPIO 
after 4 h yielded approximately 6.85 anti-CD20 per SPIO.  Carbodiimide cross-linking 
only resulted in 2.77 anti-CD20 per SPIO. The labeling efficiency for each conjugation 
strategy, defined as a percentage of conjugated protein per SPIO over total protein per 
SPIO is presented in Figure 6.4B. The click chemistry reaction achieved 45.6% 
efficiency, while the carbodiimide reaction resulted in a labeling efficiency of only 8.3%. 
It was surprising that despite a relatively high degree of labeling by the protein through 
CuAAC, this was significantly less than achieved with rat IgG.   
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 It is hypothesized that the reduced efficiency may stem from a lower 
incorporation of alkynes onto the anti-CD20 compared with IgG, perhaps due to subtle 
differences between the proteins. Nonetheless, CuAAC still resulted in a 5.5-fold 
improvement in the efficiency of labeling compared with carbodiimide chemistry.   
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Figure 6.4 - Comparison of SPIO Labeling with Anti-CD20 Using CuAAC and 
Carbodiimide Conjugation Procedures.  
 
(A) Extent of reaction as measured by final number of antibody per SPIO. Following the 
optimization of IgG-SPIO conjugation using CuAAC, anti-CD20 antibodies were 
“clicked” to SPIO. The average number of antiCD20 per SPIO was determined by BCA 
Protein Assay to be 6.85 molecules per particle. Labeling of SPIO by anti-CD20 was also 
accomplished using the classic carbodiimide method; however a lower final labeling ratio 
of 2.77 antibodies per SPIO particle was achieved, despite using more antibodies during 
the conjugation procedure. (B) Percent efficiency of reaction by conjugation method. 
Here, the ratio of final protein per NP with respect to the initial value has been plotted as 
a percent. For the CuAAC-mediated cross-linking of anti-CD20 the reaction approached 
50% efficiency, while the EDC conjugates reached almost 10%. 
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6.4.4 - Functional Application 
 Binding of anti-CD20-conjugated SPIO to CD20-positive B cells was assessed by 
flow cytometry. All SPIO were fluorescently labeled prior to the respective conjugation 
protocols to enable fluorescence detection. The same fluorescently labeled SPIO were 
used for both the CuAAC and carbodiimide reactions to ensure that total cellular 
fluorescence could be correlated to the extent of SPIO binding. Thus, it was possible to 
quantitatively compare the equally fluorescent EDC- and CuAAC-particle strategies.   
 As shown in Figure 6.5 (top row), it was found that at a concentration of 10 !g 
Fe/mL, anti-CD20-targeted SPIO prepared using click chemistry could be used to 
successfully target B cells. Specificity was confirmed by competitively inhibiting SPIO 
binding using an excess of free anti-CD20 antibodies.  Surprisingly, anti-CD20-targeted 
SPIO prepared using carbodiimide chemistry did not result in any appreciable B cell 
labeling using equivalent concentrations (10 !g Fe/mL; D-F).  In fact, similar levels of B 
cell labeling could only be achieved when the iron concentration was increased to 50 !g 
Fe/mL (Figure 6.5, bottom row). Again, for both concentrations of the carbodiimide-
conjugated targeted nanoparticles, specificity was confirmed by competitively inhibiting 
SPIO binding using an excess of free anti-CD20 antibodies. This data suggests that the 
anti-CD20-labeled SPIO prepared using click chemistry have a higher affinity for the 
CD20 receptors on B cells compared with analogous nanoparticles prepared using 
carbodiimide chemistry.  It is likely that this increase in affinity is due to the greater 
number of anti-CD20 per particle.   
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Figure 6.5 - B Cell Labeling with Anti-CD20-SPIO.  
 
Functional targeting of SPIO to B cells was accomplished for click- and carbodiimide-
cross-linked anti-CD20-SPIO conjugates. Top row shows the flow cytometric analysis of 
B cells that were incubated with 10 !g Fe/mL of CuAAC conjugated (A) IgG-SPIO, (B) 
anti-CD20-SPIO, and (C) anti-CD20-SPIO in the presence of excess free antibody. 
Labeling of cells with the EDC conjugated particles (10 !g Fe/mL) is found in the second 
row (D-F). Cells labeled with EDC conjugated particles at a higher concentration (50 !g 
Fe/mL) were analyzed in the final row (G-I). Antibody mediated binding was observed 
for anti-CD20 SPIO using both conjugation strategies; however, cell labeling with 
CuAAC nanoparticles was achieved with a significantly lower concentration of 
nanoparticles. Solid lines refer to unlabeled B cells, dashed to cells incubated with NP of 
type indicated by row and column. 
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 Overall, the data presented here provide strong evidence that CuAAC reactions 
can be used for highly efficient and effective labeling of nanoparticles with antibodies, 
without any noticeable loss in antibody functionality. Fluorescent micrographs of click 
conjugated SPIO particles incubated with B cells are also shown (Figure 6.6). Labeling of 
the cells was found to be specific, as IgG-SPIO conjugates do not bind to the cells, nor do 
anti-CD20-SPIO when inhibited with excess free antibody.  
 It should be noted that the incubation of anti-CD20-SPIO with the B cells, and 
especially in the presence of free anti-CD20, appeared to have a negative effect on the 
health of the cells, if only inferred from cell morphology. No cytotoxological studies 
were conducted using the constructs created in this work as this targeting agent is itself 
administered to deplete cells. Logically this could lead to a further functionality study 
wherein each conjugate, EDC and click, is viability tested for B cells in vitro or in vivo. 
This related study would be interesting; however, as the mechanism of anti-CD20 
mediated cell death is not fully understood, it is beyond the scope of this work.  
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Figure 6.6 - B Cell Labeling; Fluorescence Micrographs.  
 
Cells were incubated for 30 minutes with 50 !g Fe/mL of (A) IgG-SPIO, (B) anti-CD20-
SPIO and (C) anti-CD20-SPIO in the presence of excess antibody, and then washed in 
triplicate. The fluorescently labeled particles are found bind to cells specifically, as 
competition for ligand curtails cell signal. All images at 40x magnfication. 
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6.5 - Conclusion 
 Advanced applications in the areas of diagnostic imaging and drug delivery stand 
to benefit from antibody- or protein-based targeting of nanoparticle carriers. Preparation 
of such targeted nanoparticles can however be inefficient and costly. Here, we have 
shown that the utilization of the CuAAC for the production of antibody-nanoparticle 
conjugates permits materially efficient and functionally competent targetable probes. In 
comparison to classic carbodiimide-conjugates, CuAAC adds a valuable alternative to the 
toolbox of the bioconjugate chemist. This mechanistically simple and highly efficient 
reaction, which is generally insensitive to reaction conditions, is expected to allow for an 
expansion in applications for nanoparticle-targeted systems in the clinic.  
 The products of the click reaction were functionally specific for B cells in vitro, as 
demonstrated by inhibitory competition with free protein. A preferred targeting ligand for 
this work is a non-depleting antibody to a receptor that internalizes cargo once bound, 
and recycles to the surface. This work has implications towards the use of targeted 
nanoparticle conjugates following the choice of such a suitable targeting vector. This 
would allow for the intracellular accumulation of the contrast agent. Coupled to a NP for 
diagnostic or tracking purposes, such an agent would be a powerful means to image the 
distribution of specific cell types in vivo. 
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CHAPTER 7. SPIO Enabled Detection of Transient Cervical Nerve Root Injury 
7.1 - Overview 
 Cervical radicular pain is a widespread neurologic condition resulting from the 
compression of a cervical nerve root. The impact on quality of life and economic cost of 
persistent states of pain are massive. Current diagnostic imaging approaches fall short in 
their ability to accurately correlate pain symptoms to evidence of neuropathy.  
 This chapter focuses on our aim to utilize systemically administered SPIO for 
enhanced identification of injured nerve roots in a rat model. The chapter begins by 
detailing the salient epidemiological and economic impact resulting from back and neck 
pain. An introduction to the anatomic and biomechanical foundations of transient nerve 
root compression and the resulting axonal degenerative effects are also discussed. A rat 
model of neuroinflammation following transient nerve compression that has been 
previously shown to produce sustained states of hypersensitivity is outlined. In order to 
visualize neuroinflammation in vivo it was necessary to develop a magnetic resonance 
(MR) imaging protocol suited to the task of utilizing SPIO as contrast. Preliminary 
experiments were conducted to ensure that a high-field strength small animal MR system, 
a surface-receive coil and a T2*-weighted gradient echo sequence would enable detection 
of cell loaded SPIO.  
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 The sequence parameters and animal handling protocol were initially optimized to 
enable detection of accumulated SPIO. These settings were then utilized for detection of 
neuroinflammation from a painful transient compression of the C7 nerve root following 
SPIO administration. Pre- and postcontrast scanning sessions were conducted following a 
6 day recovery period from surgery. Imaging at the site of C7 nerve root injury using 
SPIO resulted in an average postcontrast enhancement of 72.9±31%, measured as the 
difference in normalized relative signal intensity (nrSI) between ipsilateral (compressed) 
and contralateral roots. This was significantly greater than the 5.3±12.9% difference in 
nrSI of injured animals precontrast. Finally, implications of this work regarding future 
development of imaging in pre-clinical pain models as well as clinical relevance for 
patient management are discussed. 
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7.2 - Introduction 
7.2.1 - Epidemiology and Impact  
 Low back pain and neck pain are among the most common physical conditions 
requiring medical care globally. The healthcare burden for treating spinal pain is 
considerable, making it the most common physical condition for which a patient elects to 
see his/her doctor in the United States (1).  
 The affected portion of the population is large as cervical neck pain has a lifetime 
prevalence reported to be as high as 71% (2, 3). Further, there is no specific 
epidemiological demographic; four out of five neck pain diagnoses (81%) were for 
persons between the ages of 18 and 64 (4). The corresponding economic impact is 
equally large, with estimates of annual societal costs of $29 billion (5) and work days lost 
to back pain has been estimated at 186.7 million for 2004 in the US (1). 
  
7.2.2 - Relevant Cervical Anatomy 
 The central nervous system (CNS) proximal to the cervical spine, consists of 7 
vertebrae and 8 pairs of cervical nerve roots (in both rodents and humans). The purpose 
of the vertebrae are to contain and protect the spinal cord, support the skull and enable 
diverse head movement. The spinal cord passes through the spinal canal and is 
surrounded by a protective dural sheath. The spinal cord consist of tracts of white and 
grey matter. The white is responsible for conveyance of information to and from the 
brain, while gray matter houses cell bodies and unmyelinated axons. The first two 
cervical vertebrae have a unique structure in comparison with other components of the 
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spine, however the lower (C3-C7) vertebrae are similar. The vertebra progress in size 
from cephalad to caudad with C7, the vertebra prominens, possessing a spinous process 
larger than the process associated with the first thoracic vertebra (6). 
 In the schematic of the fifth cervical vertebra (C5; Figure 7.1A), the space 
through which the C6 nerve roots exit are labeled as the transverse foramen. It should be 
noted that the nerves of the cervical spine take the name of the pedicle above which they 
exit (unlike nerves in the thoracic and lumbar spine). The exception is the eighth cervical 
nerve root, which exits between C7 and T1. The nerve roots of the cervical spine pass 
laterally at each level to exit from the spinal canal at the same foraminal level as their 
origin from the spinal cord, Figure 7.1B.  
 Each level sees six to eight rootlets exit the spinal cord to be joined together and 
surrounded by the dura to form the nerve root (Figure 7.1C). The dorsal nerve roots are 
approximately three times as thick as the corresponding ventral roots, except at C1 and 
C2, because of the greater amount of sensory fibers. The roots of a particular level 
contain axons whose cell bodies reside in the corresponding dorsal root ganglion (Figure 
7.1C). Each dorsal root level enervates a specific area of skin. These often overlapping 
areas are the dermatomes. A dermatome map for the cervical and first thoracic nerve root 
levels is shown in Figure 7.1D. Although variability differences can complicate diagnosis 
(7), pain in a particular dermatome can enable distinction of the compromised nerve root 
level in an injured patient (8). 
 The upper quarter of the foramen is filled with areolar tissue and small veins. In 
addition, small arteries arising from the vertebral arteries and the sinuvertebral nerves 
traverse the canals (6). The intervertebral foramen is also in close proximity to the 
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uncovertebral and the apophyseal (facet) joints (anteromedially and posterolaterally, 
respectively). These features, the somewhat dense vasculature and adjacency of joints, 
are noted because they are potential causes of canal (neuroforamenal) restriction. There 
exist a host of causes that produce neck pain including degenerative conditions, strain 
injury and direct trauma (9, 10). Cervical radicular pain is distinguished as pain derived 
from insult to the nerve roots (11). The incidence of either a lesion or contact by the 
uncinate processes, facet joint or pedicles will result in compression of the nerve roots or 
spinal nerve which may result in this painful injury, as will be discussed in the following 
section.  
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Figure 7.1 - Cervical Neural and Vertebral  Anatomy. 
 
(A) Description of the cervical vertebral architecture. (B) Schematic of the spinal cord 
with nerve roots passing laterally through the neuroforamen to enervate the body. (C) 
Schematic of the rootlets as they branch together to form the roots and subsequently the 
spinal nerve. (D) Anterior and posterior dermatomes of the cervical spinal nerves and 
first thoracic level. 
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7.2.3 - Cervical Radicular Pain 
 Cervical radicular pain is a neurologic condition characterized by dysfunction of a 
cervical spinal nerve, the roots of the nerve, or both. It usually presents with pain in the 
neck and one arm often severe enough to compromise patients' functional abilities (12). 
Impact on the quality of life of patients exhibiting symptoms can be severe (13). The 
condition manifested as pain, sensory loss and motor weakness in the affected dermatome 
(14) and these symptoms can last for as long as months or even years (15). 
 Chronic neck pain caused by nerve root injury is common as these roots are at 
particular risk for mechanical insult (see above). Their risk of compression due to the 
foraminal shape changes that may occur during some vertebral motions is high (16). 
Cervical radiculopathy may result from herniation of the nucleus pulposus, however this 
is less frequent than in the lumbar spine (17). Prevalent causes of such trauma leading to 
persistent pain include rear-end automobile accidents (18) and contact-sports injuries (19-
21). Extensive, large sample population studies have been conducted to determine the 
effect of suspected risk factors on predisposition to cervical radiculopathy. These are 
thought to include tobacco-use, psychological health, trauma, sex, age and degenerative 
disc changes (15). However, the condition also can arise in patients devoid of putative 
risk factors (17). 
 The most commonly reported injured spinal nerve or nerve root level is that of 
C7, at the C6-C7 vertebral level. One study revealed that in a population of 561 patients, 
the frequency of surgically confirmed cervical radiculopathy at C7 alone was 46.3% (17). 
Injury at this level produces pain distributed on the affected side along the shoulder, 
posterior of arm and forearm and along the third finger of the hand (22).  
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7.2.4 Imaging Techniques in Nerve Root Injury 
 Clinical criteria for diagnosis of cervical radicular pain lacks a universal standard 
(23). Application of guidelines following a physical examination are used to screen 
patients' symptoms from life-threatening pathologies (such as spinal tumors or cerebral 
infections) (24, 25). These tests, which help confirm or eliminate clinical diagnoses, also 
serve to localize the injured spinal level by analyzing the affected dermatomal area.  
 Clinical imaging modalities of all types are employed in determination of the 
cause of severe and chronic neck pain. The first line of diagnostic tests to evaluate 
suspected radiculopathy are often conventional radiographs. These may be helpful in 
assessing for abnormalities such as fractures or instability. However, this technique is of 
limited utility as it lacks soft-tissue distinction and the degenerative hard-tissue changes 
in geriatric cases further complicate diagnosis (26, 27). While not immune from 
asymptomatic findings, magnetic resonance (MR) imaging is the modality of choice for 
cervical radiculopathy (28, 29). This is a result of the excellent soft-tissue contrast 
achievable through application of different sequence protocols.  
Radiological evidence of neural impingement, such as disc collapse and/or 
protrusion, spondylosis, or foraminal occlusion, is seen in as many as 44% of lower back 
pain (30) and 68% of neck pain cases (17). However, in most of the remaining cases, no 
noticeable neuropathology is detectable.  
 The challenge of diagnosing this clinical syndrome is exacerbated by the high 
rates of positive radiological findings in asymptomatic subjects (31-33). It has been 
estimated that the prevalence of cervical spondylosis for men above 75 is approximately 
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95% (34, 35). Patients who report no pain symptoms are commonly found to have 
degenerative spinal features, which may include nerve root impingement (12). This 
further impairs the utility of current clinical imaging approaches as it is difficult enough 
to determine the presence of injury, let alone distinguish extent or response to treatment 
over time.  
 It is also possible that this pain is the product of a transient mechanical injury or 
presence of chemical factors that are not apparent through conventional diagnostic 
radiology. Nerve root insult originating from these sources may not result in cervical 
neural or musculoskeletal deformation that can be detected using conventional 
radiographic approaches. We have hypothesized that the application of a cellular MR 
imaging strategy leveraging the accumulation of systemically injected SPIO to generate 
inflammation specific contrast can be used to identify the site of a pain producing injury.  
 
7.2.5 - Neuroinflammation 
 It is generally accepted that radicular pain results largely from mechanical or 
chemical insult of the nerve roots (36-38). Trauma to the neural tissues results in both 
pain and Wallerian degeneration (39-42). In lumbar radiculopathy models of pain, 
behavioral hypersenstivity is immediate and has been correlated to axon cytoskeletal 
damage, cytokine production and glial activation (43-46).  Contributing to persistent pain 
is the neuroinflammatory cascade that sees recruitment of macrophage to the injured 
region to phagocytize myelin debris (40, 47, 48) followed by further production of small 
molecule pain mediators (45, 49-51).  
Chapter 7    260 
 Sustained neuroinflammation can be induced by even transient mechanical 
injuries to neural tissues (36, 45) and may explain the lack of correlation between 
radiologically evident pathology and pain. In a rat model of cervical radiculopathy, 
transient compression of the C7 cervical dorsal nerve root produced persistent behavioral 
sensitivity, as measured by mechanical allodynia (sensitivity to an otherwise non-painful 
mechanical stimulus) (52-54).  
 Similar to transection and crush models, transient compression produces 
Wallerian degeneration, along with the hallmarks of neuroinflammation, including 
increased upregulation and expression of neuropeptides, growth factors, and cytokines, 
and sustained inflammatory cell activation at the injury site and in the spinal cord (45, 50, 
55). Infiltrating macrophage ingest axonal debris at the injury and have been shown to be 
a principal element in development of pain (48, 56, 57). The inflammatory response 
associated with pain states incited by transient neural tissue trauma may provide an 
opportunity for identification and diagnosis of injury in subjects that present no 
radiological abnormalities. 
 
7.2.6 - SPIO Accumulation at Sites of Inflammation 
 Superparamagnetic iron oxide (SPIO) nanoparticles are a widely used T2*-
weighted MR contrast agent. They enable detection of sites of their accumulation through 
enhanced proton dephasing (darkening), as they function as strong magnetic 
inhomogeneities in vivo (58). They have been applied in numerous academic and clinical 
studies in a wide range of models for the detection of inflammation. Imaging of these 
sites using SPIO has been previously shown to rely upon the accumulation of the 
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particles at sites of activated immune cell activity; specifically they are sequestered by 
monocytes (59-61). Following sufficient accumulation in foreign-body phagocytosing 
macrophage, SPIO have enabled detection of otherwise radiologically indistinguishable 
inflammatory processes. These include pathologies such as soft-tissue infection (59, 62, 
63), implant rejection (64) and atherosclerosis (60, 65-68).  
The agents have also been widely used in several central nervous system disorders 
for the detection of inflammatory cells. One of the most widely studied applications is the 
detection of cerebral lesions in multiple sclerosis (69-72). In humans, sites of 
inflammation following stroke have also been visualized through SPIO contrast (73). 
Peripheral and central nerve injury models have been investigated as well. The 
distribution of macrophages into a mechanically crushed sciatic nerve in a rabbit were 
tracked following SPIO administration (74, 75). SPIO have been used in the cord injury 
models to enable visualization of either macrophage in vivo or to track ex vivo loaded 
macrophage or stem cells to the injury (76, 77).  
There are currently no reports of in vivo cellular imaging studies investigating the use of 
SPIO to identify and/or localize the anatomical location of pain resulting from transient 
neural injury. As indicated above, a painful cervical nerve root compression model has 
demonstrated that transient compression of sufficient force is able to produce a sustained 
inflammatory response (36, 45). It is the aim of this chapter to utilize SPIO to exploit the 
phagocytic activity of macrophage infiltrating the injury site as schematically illustrated 
in Figure 7.2. Prior to the application of SPIO, it was necessary to determine optimum 
MR scanning logistical and sequence parameters for cell-accumulated SPIO detection.
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Figure 7.2 - Schematic of SPIO Uptake. 
 
It is hypothesized that systemically injected long circulating dextran-coated SPIO will be 
able to accumulate in phagocytic macrophage at the site of nerve root compression. 
Transient compression (red clip) of the C7 dorsal nerve root has previously been shown 
to lead to neuroinflammation and the presence of activated macrophage (purple). SPIO 
(black) have been widely used to visualize sites of tissue injury through accretion of 
nanoparticulate contrast within macrophages. 
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7.3 - MR Protocol Development 
 The noninvasive high-resolution imaging of living subjects is a primary advantage 
in utilizing MR imaging for preclinical studies. A major difficulty, and the underlying 
motivation for the application of contrast agents, is inherently low signal-to-noise (SNR). 
This is often the reason for long scan duration in the clinic, as an initially long acquisition 
must be averaged several times to reduce background noise from otherwise useful 
information. The aim here was to visualize the accumulation of nanoparticulate contrast 
agents at sites of neuroinflammation, a difficult task from an SNR standpoint. This was 
due in large part to the complex biomechanical function of the cervical spine.  
A precise assemblage system of bone, cartilage, ligaments, tendons, nerves and 
muscles all exist to enable both a high degree of flexibility and protect the spinal cord 
from injury. To perform successful neuroinflammatory imaging, the relevant structures 
need to be defined with adequate resolution. The substantial artifact that can arise from 
the presence of bone is also a significant concern. Finally, the spinal nerve roots are 
located at some distance from the back of the neck in the rat. The further the structure of 
interest is from the receiver coil, the more signal that is lost for image formation. In order 
to ensure that equipment parameters were properly configured for SPIO detection 
sequence, high field strength, sequence selection and the use of specialized coils were 
examined. 
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7.3.1 - High Field MR 
 A constant feature throughout the history and development of magnetic resonance 
imaging systems has been implementation of greater field strengths. Industrial production 
of clinical scanners have progressed from 0.2-0.3 T systems to 1.5 T and now the current 
standard of 3 T. Higher field strength produces images of better quality as a result of 
improved signal-to-noise. This is a result of the the differing effects on signal and noise 
with increasing field strength (B), as they have different magnetic field-dependencies 
(78). 
 Strength of signal from a voxel is proportional to voxel volume. The SNR is 
proportional to voxel volume multiplied by the square root of the acquisition time. 
Attainment of greater SNR, using higher magnetic field strength, thus results in reduced 
time and means that voxel volumes can be reduced to achieve the same signal as at a 
lower field strength for the same amount of time (79). The resulting features of higher 
strength fields are faster scans and higher resolution. Faster scans have the added 
advantage of reducing artifacts from patient motion, as the likelihood of movement 
increases with duration. Thus, all of the work in this thesis (excluding contrast agent 
characterization) was conducted at high field strength, using a 9.4 T small animal 
imaging system (Varian; Palo Alto, CA). 
 
7.3.2 - Coils 
 When surface coils are applied it is often the case that separate coils are used to 
excite the subjects’ protons and to receive signal for detection. These two coils are 
referred to as the transmitting-volume coil and the receiving-surface coil. Surface coils 
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function as antennas to achieve greater SNR in MR imaging. The closer proximity to the 
tissue of interest to be imaged allows for less signal to be lost. The reduced field of view 
also serves to reduce noise from surrounding tissues in the volume excited by the body 
coil.  
 In this work a custom built surface coil was utilized in conjunction with a volume 
coil. The volume coil was a transmit-and-receive design built by Insight Neuroimaging 
Inc. (now InsightMRI), Worcester, MA. This coil was used solely in the transmit mode. 
The dimensions were 7 cm in inner diameter and approximately 9 cm in length. The 
surface coil was applied directly to the surface of the rodent proximal to the tissue of 
interest. This receive-only coil and was detunable with a linear, single-loop coil with 
remote tuning and matching. The dimensions of the surface coil (antenna only) were 2.54 
cm in long axis, curved to a 1.5 cm radius.  
 
7.3.3 - Sequence Selection 
 The usefulness of MR imaging in the clinical and research spheres is greatly 
enhanced by its ability to visualize and distinguish many different tissues. This capacity 
is derived from the application of radiofrequency pulses and magnetic gradients in order 
to provide distinction of tissues and tissue states of interest. The direction, strength and 
timing of the pulses and gradients used to acquire an image is referred to as a sequence. 
Sequences are essentially exercises in choosing between speed, contrast and SNR in 
order to visualize items of interest. This is relevant here as choice of the sequence in 
order to emphasize the presence of susceptibility generating contrast agents is often 
necessary. Determination of favorable parameters for detecting intracellular SPIO 
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contrast agents was thus required prior to any attempt to visualize transient nerve root 
compression. 
 Initialization of a susceptibility enhancing sequence, and all subsequent imaging 
was performed on the University of Pennsylvania Department of Radiology small animal 
31 cm diameter 9.4 T MR system (Varian, Palo Alto, CA). Initial results, using the 
volume/surface coil setup detailed above, indicated high SNR at sufficient tissue depth 
(maximum visualization of approximately 3.5 cm). A gradient echo multi-slice (GEMS) 
sequence was selected as multiple animals were to be imaged in each group (requiring 
efficient scan duration) with thin slice selection (0.5 - 1 mm) along with the desire for a 
susceptibility bias. In other words: fast, selective and T2*-weighted.  
 The fast scanning time results from several GEMS features including a non-90˚ 
flip angle and absence of a 180˚ rephasing pulse (as is utilized in spin echo imaging). 
This angle (!), selected as 20˚, is used to decrease the time required to return to 
equilibrium magnetization. This is the result of the decreased magnitude of the transverse 
magnetization, as compared to a 90˚ or hard flip wherein the entire magnetization vector 
is (at least initially) in the xy-plane. The shorter recovery period allowed for repetition 
and echo times (TR and TE, respectively), as shown in Figure 7.3. This has the advantage 
of minimizing acquisition time and limits breathing and other motion artifacts. As long as 
a non-steady state longitudinal magnetization does not interfere with imaging (a possible 
interfering side effect of <90˚ flip angle when the TR < T2) the slice thickness chosen can 
be as thin as the gradient allows (on the system used the minimum was 0.5 mm).  
 A final advantage of the GEMS sequence is that T2*-weighting is present. There 
is only a single radiofrequency pulse delivered (to flip) and no 180˚ refocusing pulses (as 
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there would be in, for example, a spin-echo sequence). Thus, relaxation process from 
magnetic field inhomogeneities (such as SPIO) are not corrected for. The trade-off of 
such a feature is that a dephasing gradient needs to be applied prior to the readout 
gradient. This process, in addition to the lack of rephasing pulses, results in some loss of 
signal.  
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Figure 7.3 - Gradient Echo Sequence. 
 
The radiofrequency (RF) pulse used in the gradient echo sequence to flip the net 
magnetization vector into the xy-plane is by some (non-90˚) angle !. The value used for 
all imaging was 20˚. This limits the time for recovery of longitudinal magnetization 
allowing shorter TR and TE to be used. No 180˚ refocusing pulse is applied, which 
further speeds scanning time and also does not correct for magnetic inhomogeneities. 
This results in T2* rather than T2-weighting. In the absence of a refocusing pulse the echo 
is created by applying a dephasing gradient during slice selection (GSS) before the signal 
is read during application of the readout gradient (GRO). This generates an echo when the 
the data is acquired by the analog to digital converter (ADC). The phase encoding 
gradient (GPE) is varied in order to fill the k-space. Adapted from the Vnmrj user manual. 
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7.3.4 - GEMS Parameter Optimization 
 The GEMS sequence was selected as a partial flip angle reduces acquisition time 
and enhances susceptibility artifacts. However, there exists a significant compromise in 
the application of gradient echo protocols with the TE parameter. The T2*-weighting 
produced due to the lack of rephasing pulse means that signal loss is rapid and there is a 
low SNR. To maintain the advantage of a fast acquisition time, it was undesirable to 
resort to reliance on extensive averaging to recover lost image quality. In order to 
determine a sequence parameters that balanced T2*-w and image quality a mock SPIO-
intracellular-accumulation experiment was conducted.  
 Initial experiments had indicated that sufficient signal could be obtained from the 
dual-coil setup with TR in the range of 100-200 msec. Longer TR resulted in extensive 
breathing artifacts (see Figure 7.4F). Very short TR were not feasible because of the thin 
slice selection requirement; adjacent thin slices interfered with each other with short TR 
due to presence of remnant magnetization. After qualitative experimentation, a TR of 200 
msec was chosen for the following experiments. 
 As TE optimization was intended to maximize distinction of the presence of 
SPIO, a simulated in vivo SPIO-cell experiment was devised and analyzed. Specifically, 
cationic, cross-linked and aminated SPIO (33 nm diameter, R2 of 72 mM-1Sec-1) at 100 
!g Fe/mL were incubated with confluent human embryonic kidney (293T, ATCC) cells 
for 1 hour. These cells have previously been shown to be excellent candidates for 
transfection through relatively efficient uptake of nanoparticles during incubation (80, 
81). The cells were washed of excess SPIO after the 1 hour incubation, trypsinized and 
washed twice in PBS. The cell suspension, containing approximately 2.5x106 cells, was 
Chapter 7    270 
delivered by injection intramuscularly to the back of the rat neck, at a depth of 
approximately 1 cm. 
 The anesthetized animal was placed into a custom-built stereotactic restraint 
device after induction at 4% isoflurane in oxygen. The surface coil was fixed proximal to 
the general area of the injected cells. A coaxial delivery and vacuum system was used to 
maintain the animal at 1 L/min of a reduced (2%) gas mixture. The animal was then 
placed on a custom-built patient bed and centered in the 7 cm inner diameter volume coil.  
 Initial scouting scans were acquired in all three directions in order to determine 
the relative position of the injected SPIO-loaded cells. Sagittal scans (13 slices) were then 
acquired using the following parameters under the GEMS sequence: TR = 200 msec, np 
= 256, nv = 256, N = 4, a field of view of 60 mm2 and a flip angle of 20˚. A span of TE 
values from the minimum (2.72 msec; bounded by bandwidth constraints) to the 
maximum (11.25 msec; bounded by TR)  were then used for acquisitions. Representative 
images of the scanning results are found in Figure 7.4A-E. 
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Figure 7.4 - TE Optimization Using SPIO-Cell Implant. 
 
The determination of an echo time (TE) for the applied gradient echo sequence was 
necessary. This parameter allows for distinction of the presence of iron oxide 
nanoparticle labeled cells, while balancing other affects that impact image quality. 
Images (A-E) are of the same animal with increasing TE and the following parameters; 
256x256, 4 averages and TR = 200 msec. The TE was varied from 2.77, 3.88, 5.00, 10.00 
and 11.25 msec. Contrast to noise measurements were conducted to determine the 
optimal TE. Longer TR times, for example 400 msec (as shown in F) resulted in 
significant artifact from animal respiration. 
A B C
D E F
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 Quantitative analysis was undertaken to determine the TE value that provided 
T2*-weighting with sufficient image integrity. Using ImageJ (NIH; Bethesda, MD) the 
images were converted to a useable lossless format in the Multi FDF Opener plug-in 
(Shanrong Zhang, University of Texas Southwestern Medical Center). A constant area 
(15 pixel diameter) circle ROI was placed on the injected cells, adjacent back muscle and 
in a noise-field surrounding the animal, as illustrated in Figure 7.5A. The contrast-to-
noise ratio (CNR) was computed for each of the acquisitions.  
 The results indicated that a TE between 3.88 and 10 msec provided the greatest 
CNR, Figure 7.5B. Longer TE times (Figure 7.4D-E) were qualitatively the most striking 
as greater time for susceptibility artifact generated hypointensity of the spinal vertebral 
column as well as the bones of the rat forepaw. It should be noted that T2*-weighted 
inhomogeneities are generated by both bone and SPIO contrast. Thus, increasing the 
effect for one serves to enhance the other. Bone's artifact generating properties are a 
result of several factors including a lack of water, a sharp interface with soft-tissue and 
radiofrequency penetration and reflectance. This presents a dilemma to the operator or 
radiologist as images of anatomical features that may be highlighted with nanoparticles 
which are close to or bounded by bony structures may suffer from interference and 
degraded image quality. Gains in contrast enhancement between the SPIO and 
surrounding tissue is offset by the distortion and artifact generated by the bone.  
 Lower TE times provided sharper distinction of tissues as there was less signal 
lost, however the midrange TR applied (200 msec) coupled with a very short TE (for 
example 2.7 msec) limits the T2-weighting of the scan. Using a TE of approximately 5-6 
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msec in practice enabled excellent soft-tissue distinction, acceptable bone susceptibility 
artifact and sensitive SPIO-cell detection.  
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(A) 
 
(B) 
 
Figure 7.5 - Analysis of TE Adjustment. 
 
(A) An illustration of the ROI used to calculate the CNR for determination of acceptable 
values. Three ROI, of equal area, were placed on each image; SPIO-loaded cells (dotted), 
a background tissue (solid) and the noise (double-lined) ROI are shown. For each image 
the placement was nearly identical however small changes in the location of features 
resulted from animal movement and TE choice from scan to scan. (B) The results of CNR 
are plotted, as a function of TE. CNR values were found to be maximum between values 
of 3.88 and 10 msec. 
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7.4 - Materials and Methods 
7.4.1 - Nanoparticle Synthesis and Characterization 
 SPIO were prepared using the chemical co-precipitation technique (82). All 
chemicals and equipment were purchased from Fisher Scientific (Pittsburgh, PA), unless 
otherwise noted. Briefly, a solution of iron salts, 1.97 g of FeCl3 and 0.7313 g of FeCl2 
(each in 12.5 mL of dH2O) were dissolved in the presence of 25 g dextran-T10 (GE 
Healthcare; Waukesha, WI) in 50 mL dH2O under nitrogen gas. The vessel was cooled to 
4˚ C and 15 mL of ammonium hydroxide was added. This solution was then heated to 90˚ 
C for 1 hour, cooled overnight and then purified from aggregates by ultracentrifugation at 
20 kRCF. The supernatant containing nanoparticles was diafiltrated against greater than 
20 volumes of 0.02 M citrate, 0.15 M sodium chloride buffer, using a 100 kDa cutoff 
membrane (GE Healthcare). Finally, particles were exchanged into pH 7.4 phosphate 
buffered saline (PBS), 0.2 !m syringe filtered and stored at 4˚ C.  
 SPIO were characterized by dynamic light scattering (DLS) to determine 
hydrodynamic diameter using a Zetasizer Nano-S (Malvern Instruments; Malvern, UK). 
The transverse relaxivity, R2, of the particles was calculated as the slope of the 1/T2 
against iron concentration. T2 relaxation times were determined using a Bruker mq60 MR 
relaxometer (Bruker; Milton, Ontario) operating at 1.41 T (40˚ C) using a standard Carr-
Purcell-Meiboom-Gill mulitecho sequence (!=1.5 msec and 2 dummy echoes) fitted 
using a monoexponential decay. 
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7.4.2 - Animal Care and Surgical Procedures 
 Male Holtzman rats (Harlan Sprague-Dawley; Indianapolis, ID) were housed 
under USDA- and AAALAC-approved conditions with free access to food and water. All 
experimental procedures were approved by the University of Pennsylvania Institutional 
Animal Care and Use Committee and carried out under the guidelines of the Committee 
for Research and Ethical Issues of the International Association for the Study of Pain 
(83). At the time of surgery all rats weighed between 275-332 g, Table 7.1.  
number date type weight (grams) 
    
48 12/10/08 compression 298 
49 12/10/08 compression 298 
52 12/10/08 sham 298 
53 12/10/08 sham 290 
74 4/2/09 compression 302 
75 4/2/09 compression 303 
76 4/2/09 sham 275 
77 4/7/09 sham 280 
90 4/15/09 compression 300 
91 4/15/09 compression 308 
Table 7.1 - Participating MR Imaged Rats. 
 
Rat subjects used in this study are labeled by their chronological surgery number (by 
neurosurgeon Christine Weisshaar). The date of surgery (day 0; see Figure 7.6) is given. 
All compressions were as described; 15 minutes at 10 gmf. The weights reported are 
immediately prior to surgery. 
 
 Surgical procedures were performed under inhalation anesthesia using 4% 
isoflurane for induction and 2% for maintenance. The transient unilateral nerve root 
compression injury has been previously described and reliably induces sustained 
Chapter 7    277 
behavioral sensitivity that lasts for nearly 3 weeks (16, 40, 84, 85). Briefly, a 
hemilaminectomy and facetectomy were performed at the C6-C7 level of the right side to 
expose the C7 roots. For painful injury, a microvascular compression clip (World 
Precision Instruments, Inc.; Sarasota, FL) was used to apply a 10 gmf compression to the 
dorsal nerve root for 15 minutes (n=6; Figure 7.6A). Identical surgical procedures were 
carried out for the sham group except that the nerve root was exposed only, without any 
compression (n=4). The surgery site was sutured and closed with surgical staples. Rats 
were continuously monitored following surgery. 
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Figure 7.6 - Experimental Design. 
 
(A) The painful injury is provoked by transient compression of the right-side C7 dorsal 
nerve root. A haemostatic compression clip (*) is applied proximal to the dorsal root 
ganglion (DRG), following the disclosure of the nerve root. The ventral ramus (VR) and 
dorsal ramus (DR) are also indicated. (B) The timeline for the experiment shows that 6 
days following surgery precontrast images of the animals are acquired in a 9.4 T MR. 
SPIO are tail-vein injected following the pre-contrast imaging session and a postcontrast 
scan is performed 24 hours later. 
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7.4.3 - MR Imaging 
 All experiments were performed using a 9.4 T horizontal small animal MR 
equipped with a 25 G/cm gradient insert (Varian; Palo Alto, CA) at the Small Animal 
Imaging Facility in the Department of Radiology at the University of Pennsylvania. 
Imaging was performed using a dual-coil system; a 7 cm diameter volume coil was 
actively detuned for use with a 2.5 cm loop receive-only surface coil (InsightMRI; 
Worcester, MA). 
 Rats were anesthetized prior to imaging, as described above, and placed supine 
into a custom-built stereotactic restraint device that held the surface coil to the cervical 
spine. A coaxial breathing apparatus delivered anesthetic throughout the scan and 
removed CO2 and excess isoflurane. Temperature and electrocardiography probes were 
used to monitor the rats in the 37˚ C environment supplied by an air heating system (SA 
Instruments, Inc.; Stony Brook, NY).  
 Precontrast image sets were acquired at day 6 following surgery (Figure 7.6B). 
After the precontrast imaging session, 10 mg Fe/kg (approximately 300 !L) was 
delivered systemically by tail vein injection. Postcontrast image sets were acquired 24 h 
later, on day 7 following surgery (Figure 7.6B). Identical imaging procedures were used 
for both of the pre- and postcontrast imaging sessions. In vivo MR microscopy of the C6 
and C7 spinal cord and nerve roots was performed using the VnmrJ software (Varian). 
The MR imaging protocol consisted of several scout sequences to locate the C6 and C7 
nerve roots. This was followed by a T2*-weighted gradient echo multislice sequence (TR 
200 msec, TE 5.5 msec, 20˚ flip angle) in the axial plane. Greater T2*-weighting, while 
desired, was precluded due to proximity (and enclosure) of interrogated anatomy to bone. 
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Fifteen interleaved slices were typically acquired, with a thickness of 0.5 mm, NEX = 8, 
nv = 256, np = 256 and a field of view of 5 cm x 5 cm.  
 
7.4.4 - Image and Statistical Analysis 
 Image sets were analyzed using ImageJ (NIH; Bethesda, MD), following their 
conversion using the Multi FDF Opener plug-in (Shanrong Zhang, University of Texas 
Southwestern Medical Center). User defined ROI of equal area were set for the ipsilateral 
and contralateral (control) C6 and C7 nerve roots, as well as two background (paraspinal 
muscle) locations, under radiologist-blind (pre-, postcontrast, injured or sham) 
conditions. 
 On a slice-specific basis, the relative signal intensity, rSI, was calculated by 
division of the mean intensity of the ROI at each nerve root by that of the paraspinal 
muscle. For each subject, this value was then normalized to the rSI maxima of the C6 
nerve root to give the normalized rSI (nrSI) for ipsilateral and contralateral roots. 
Quantitative comparison of the pre- and postcontrast C7 nerve roots, as well as between 
injured and sham groups, was made possible by then computing the difference of the 
normalized rSI peak and immediately adjacent slices'. MR findings, the presence or 
absence of enhancement, were considered significant if  p < 0.01. A two-tailed Mann-
Whitney test was used. 
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7.4.5 - Tissue Harvest and Immunohistochemistry 
 Tissue was harvested from all rats immediately following the final imaging 
session on day 7 (Figure 7.6B). Transcardiac perfusion was performed using PBS and 
then a 4% paraformaldehyde-in-PBS mixture; the cervical spinal cord was exposed and 
the C7 level was bisected to enable removal of the nerve roots and spinal cord en bloc on 
each of the ipsilateral and contralateral sides separately. Tissue samples were embedded 
in paraffin to enable axial sectioning (10 !m thick). Nanoparticles were localized in the 
tissue by Prussian blue staining for iron oxide using a wash of a 1:1 mixture of 2% 
potassium ferrocyanide and 2% HCl for 20 minutes. Sections were rinsed in dH2O, 
dehydrated, cleared in Citrisolv and then cover slipped using Permount. Serial sections 
were also immunostained to co-localize macrophages with SPIO; activated macrophages 
were stained using an antibody against the CD68 receptor (ED-1, Serotec; Oxford, UK). 
A horse anti-mouse secondary antibody (Vector; Burlingame, CA) was used and 
developed using the ABC kit (Vector). Sections were dehydrated, cleared and then 
mounted. 
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7.5 - Results and Discussion 
 Precontrast images were acquired after 6 days of recovery from surgery. Dextran-
coated SPIO, with a 29 nm hydrodynamic diameter and R2 of 104 mM-1sec-1, were then 
injected at a dose of 10 mg Fe/kg. The following day imaging was repeated. The cervical 
nerve roots at the C6 and C7 NR levels were visualized with 0.5 mm thin axial slices in 
series using a T2*-w multi-slice gradient echo sequence. 
 Representative axial acquisitions from each group, pre- and postcontrast, are 
shown in Figure 7.7. Scans of the rat cervical spine show the spinal cord at the center 
surrounded by vertebral bone enclosed in muscle. Careful axial slice selection afforded 
visualization of both the ipsilateral and contralateral roots in the field of view, allowing 
for an inherent control (contralateral root) to be included throughout imaging. Bilateral 
roots can be readily identified in the precontrast images for both injured and sham 
groups. There is a clear loss of signal in the ipsilateral (compressed; Figure 7.7D) root in 
the postcontrast imaging session.  
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Figure 7.7 - Imaging SPIO-Induced Hypointensity at Injury. 
 
Representative MR acquisitions of spinal cord and nerve root level C7 (C6 vertebral 
level). Use of a dual coil arrangement afforded high resolution imaging at tissue depths of 
several centimeters. The spinal cord (SC), vertebrae (V; especially the anterior tubercle), 
disc (IVD), nerve roots (ipsilateral and contralateral; Ip, Co respectively) and wind pipe 
are clearly visible for each subject. Soft tissue filling of the void created upon 
hemilaminectomy bone removal to expose the nerve roots is present to differing degrees 
(indicated below symbol ! in A). The pre- and postcontrast images for the sham animal, 
A and B respectively, show little signal difference in nerve roots on the exposed side. In 
contrast, the pre- and postcontrast acquisitions for the injured subject, C and D, differ at 
the transiently loaded NR. Indicated by the arrow, a signal void is present at the NR 
following administration and accumulation of SPIO. 
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The placement of ROI used for quantitative analysis is given on a representative 
acquisition in Figure 7.8A. Here, the spinal cord with roots passing through the 
surrounding vertebrae at C7 is shown. The spinal level of interest was localized using the 
landmarks of soft-tissue injury and anterior tubercles. ROIs were drawn for each dorsal 
root as well as at sites in the surrounding back muscle. If no nerve root was visible, the 
ROI was placed in the linearly inferred position between successive roots. 
The flexibility of the rat neck in multiple directions meant that axial plane 
alignment of both ipsilateral and contralateral nerve roots was not always feasible, 
despite the use of a stereotactic restraint device. Therefore, to ensure that the signal loss 
at the injured root was a result of SPIO accumulation rather than from imaging artifacts, 
such as partial volume effects, a series of sequential slices were acquired for each rat to 
include nerve roots through the C6/C7 levels.  A representative series of such acquisitions 
is shown in Figure 7.8B-F. These five adjacent slices at C6 from a C7-compressed rat 
show that there is no evidence of signal loss in the ipsilateral root at one level above the 
injury. 
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Figure 7.8 - Nerve Root Injury Visualization. 
 
(A) A representative axial image  is presented, overlaid with ROI for the ipsilateral (Ri) 
and contralateral (Rc) roots as well as background paraspinal muscle (B1 and B2). The 
ROI are have been slightly enlarged for clarification. Analyses investigated relative 
signal through a series of sequential acquisitions to avoid artifactual errors, such as partial 
volume effects, from distorting the results. An example of 5 consecutive 0.5 mm slices 
through the C5 vertebral level (C6 nerve roots) are shown raustral to caudal in B - F. 
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  The normalized relative signal intensity (nrSI) computed for each imaging slice 
in the rostral-to-caudal direction of an animal are shown in Figure 7.9. The periodic 
maxima reflect the appearance of the nerve roots, while the minima reflect the presence 
of bone. Qualitatively, it is evident that there is little discrepancy between the ipsilateral 
and contralateral nrSI in the precontrast series. An example of slight offset of roots, as 
described above, is seen in Figure 7.9B; here, the bilateral C6 roots are in different 
imaging planes. Decrease of the nrSI at C7 in the postcontrast injured rat, resulting from 
SPIO accumulation, is substantial (Figure 7.9D). 
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Figure 7.9 - Signal Ratio Through Roots. 
 
Raustral-to-caudal NR signal (relative to paraspinal muscle) for a representative sham; 
precontrast (A) and postcontrast (B), and an injured animal; precontrast (C) and 
postcontrast (D). Values of relative signal intensity were normalized to C6 maxima. In an 
evaluation of the nerve root rSI, periodic increases of signal were found to correlate with 
the appearance of roots. The signal minima correspond to bone and intervertebral tissue. 
Sham and precontrast injured subjects did not demonstrate discrepancy in normalized 
signal ratio intensity between C6 and C7 nerve roots for the ipsilateral (dashed) and 
contralateral (solid) sides. When investigating postcontrast injured animals a large 
difference in the C7 nerve root signal intensity ratio was observed, (NR = nerve root) 
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To quantitatively compare the sham and injured groups, pre- and postcontrast, the 
percentage difference between the contralateral and ipsilateral nrSI was calculated 
(double ended arrow, Figure 7.9D). These values are plotted as percent change in Figure 
7.10. SPIO accumulation over 24 hours led to local hypointensity and a difference in nrSI 
between the roots in the injured case of 72.9±31%. No significant change in precontrast 
images of nrSI was detected between ipsilateral and contralateral nerve roots in the 
injured (5.35±12.9) or sham (-10.8±5.4) animals. This result essentially recapitulates the 
deficit in clinical MR imaging of radiculopathy; there is no visible difference between 
injured and healthy nerve roots (without contrast). Further, the sham group showed no 
significant nerve root enhancement (2.8±14.1%) 24 hours after the SPIO injection.   
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Figure 7.10 - SPIO Enhanced Detection of Nerve Root Compression. 
 
The quantification of normalized relative signal intensity (nrSI) differences between the 
ipsilateral and contralateral nerve roots is shown. Precontrast subjects (filled symbols) 
and postcontrast (open) normalized differences are plotted along with the mean of each 
group (bold line) and the standard error for each group. Significant enhancement (p < 
0.01) between the (**) pre- and postcontrast nerve roots in the injured group as well as 
between the (*) sham and injured post-contrast roots was found. 
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 Histological evaluation of the nerve roots and spinal cord was performed to 
identify the presence or absence of activated macrophages and iron oxide particles. 
Representative micrographs of dorsal roots and spinal cord are shown in Figure 7.11. The 
detection of SPIO and macrophage by immunostaining was observed in the injured C7 
root (Figure 7.11E-F).  Very few inflammatory cells and little accumulated iron oxide 
was observed at the ipsilateral C6 root above the nerve root injury (Figure 7.11G-H).  
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Figure 7.11 - Histology; SPIO and Activated Macrophage 
 
 
Staining of dorsal nerve roots was performed for both macrophage and iron following the 
final imaging time point. Representative ipsilateral (Ipsi) C7 roots of sham animals were 
stained for macrophage and iron oxide (A and B, respectively). Neither immune cells, nor 
SPIO were detected. This was also the case for the C7 nerve roots on the contralateral 
(Con) side of injured animal (C and D). Activated macrophage staining (E) and 
corresponding iron (F) was evident on the transiently injured nerve root (ipsilateral side 
of C7). Finally, limited inflammatory cell infiltration and corresponding iron oxide was 
found in the C6 ipsilateral root of the injured subjects (G and H). The scale bar in H 
(equivalent to 100 !m) applies for (A through H). (I) Lower magnification section 
showing dorsal root ganglion (DRG), dorsal and ventral nerve roots (DNR and VNR, 
respectively), the dura matter (DM) and one half of the spinal cord (SC). Box denotes 
approximate area of magnification for (A-H). Scale bar in (I) is also 100 !m. 
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 Generally, the iron oxide was co-localized with macrophages at the injury site; 
however, the density of macrophage and extensive Prussian blue staining of iron oxide 
made 1:1 co-localization difficult. A 1:1 localization of iron to macrophage was observed 
further along the NR, at less dense sites of macrophage infiltration (Figure 7.12A-B). 
Inflammatory cells and accumulated SPIO were absent in the C7 roots of the sham and 
the contralateral root of the injured animals. Furthermore, no Prussian blue staining was 
observed in the injured roots in the absence of SPIO, Figure 7.12C-D. 
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Figure 7.12 – Macrophage and Iron Oxide Specificity. 
 
(A) Macrophage found at the site of a nerve root compression at day 7 after insult by 
anti-CD68 immunohistochemistry. (B) These macrophage co-localize with the presence 
of iron oxide as revealed by Prussian blue stain development in the less macrophage 
dense regions further distal from the injury site along the nerve root (towards the dorsal 
root ganglion). Histological investigation of the nerve root reveals that for (C) 
macrophage, again at 7 days after the injury, there is (D) no non-specific iron oxide 
accumulation in the absence of a SPIO administration.  
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7.6 - Conclusion  
MR imaging of the cervical spine provides high-resolution visualization of the 
spinal cord, nerve root and skeletal architecture. However, the difficulty in using this 
information to identify the anatomic origin responsible for cervical radiculopathy or to 
correlate pathology with pain symptoms is a significant challenge in clinical patient 
management (12). Noninvasive markers for the detection of neuroinflammation have 
significant potential to impact clinical practice through detection and monitoring of 
therapy for cervical pain. 
In animal pain model studies which involve the ligation (44), compression (86) or 
chemical irritation (46) of neural tissue, hypersensitivity of the affected enervated area is 
assessed through behavioral responses to mechanical and/or temperature stimuli. In the 
painful injury model investigated here, compression of the C7 nerve root induces 
sustained behavioral sensitivity that radiates to the forepaw, mimicking the clinical 
presentation of radicular persistent pain (57). This same mechanical loading of the nerve 
root also leads to macrophage infiltration at the root and release of inflammatory 
cytokines, further contributing to persistent behavioral hypersensitivity (50). In our study, 
we used SPIO contrast for the in vivo cellular detection of neuroinflammation (53).  
It was found that one day following the administration of SPIO, hypointense 
signal was observed at the injured site on a T2*-weighted image. Inflammation, signified 
by either hyper- or hypointensity was not detectable at injured roots prior to contrast 
enhancement (Figure 7.7A-B). Further, non-injured roots exhibited no significant change 
in signal ratio following contrast delivery. Confirmation that the decrease in signal at the 
injured site was due to the specific presence of SPIO was accomplished by co-localizing 
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the iron from the particles to the activated macrophage surface marker CD68 (Figures 
7.11-12). 
Comparison of nrSI between the ipsilateral and contralateral roots of the injured 
group revealed a significant change (72.9±31%) in the injured root after SPIO 
accumulation. No significant percentage difference of nrSI was determined outside of the 
injured postcontrast group. Small quantities of iron oxide and macrophage were detected 
by histology at the ipsilateral C6 root of the rats in which the C7 root was compressed; 
however, this extent of SPIO accumulation was below the MR detection limit. This 
provides motivation for use of this technique as being specific for detecting the site of 
injury, providing the potential for adoption as a means to guide surgical interventions for 
treatment of radiculopathy patients.  However, it should be noted that future use of the 
nrSI metric, which is dependent on C6 root signal intensity, requires that the injury be 
localized to a single level. This problem could potentially be alleviated through the 
imaging of additional nerve roots. 
In the present study, MR imaging was limited to only two vertebrae for each rat 
due to the flexibility and depth of the cervical spine, which is situated further from the 
back than the thoracic or lumbar spine. The surface coil was positioned with the C6 and 
C7 roots in the field of view, in order to evaluate both a non-injured and potentially-
injured level at the same time. 
Previous work using SPIO enhanced MR imaging of nerve injury reported 
hyperintensity at the injury site following compression, followed by darkening upon 
contrast administration (74). The hyperintense signal feature was not observed here and 
may have been masked by the bone surrounding the root or may only be present with of 
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the production of edema which occurs for more severe insults, such as used in that model. 
A further difference between the two studies was that contrast enhancement was only 
possible if SPIO were administered 1 day following injury, while the imaging studies 
here were not performed until 6 days after the initial injury. Earlier investigations of the 
model employed in this study have revealed macrophage accretion continues for at least 7 
days following transient injury (57). 
While the work presented here needs to be validated at clinically relevant 
scanning strengths, it should be noted that many of the anatomic challenges and 
limitations presented by the rat are not present to the same extent in humans. Cervical 
vertebrae are well visualized and aligned in the supine position (87). Furthermore, the 
much larger diameter of the roots in the human (approximately 0.5 cm) would enable 
greater distinction of bony versus neural tissues and identification of SPIO accumulation.  
The setting for which the neuroinflammation detected using SPIO was pre-
clinical. However this protocol may provide a basis for the clinical radiologist to correlate 
cervical nerve root injury to pain. These data indicate that the source of painful 
neuropathy can be identified 1 day following administration of SPIO and can enable 
diagnosis of the source of radiculopathy in patients that do not have obvious pathologies. 
This has been accomplished here using an analogue of commercially available and 
clinically approved agents (for example the 20-40 nm diameter Ferumoxtran (88)).  MR 
cellular imaging of the site of injury might also allow for personalized, quantitative and 
real-time monitoring of anti-inflammatory treatment strategies aimed at alleviating 
radicular pain. 
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CHAPTER 8. Summary and Future Directions  
8.1 - Introduction 
 Use of magnetic resonance (MR) for the tracking of immune relevant cells and 
delineation of their activity is a challenging engineering task. The potential impact that 
such techniques possess for enhancing the clinical diagnostic ability of MR and for the 
understanding of biological phenomena is a powerful impetus for continued 
advancements in the field. In this dissertation, an adaptable, derivitizable iron oxide 
nanoparticle platform was developed and applied in several cellular and animal systems.  
 Under a variety of physical, chemical and electromagnetic examinations the 
manufactured superparamagnetic iron oxide (SPIO) were well characterized. Several 
nanoparticle formulations were applied in the determination of key SPIO parameters that 
affect non-phagocytic cell uptake. Labeling of B cells was accomplished ex vivo. SPIO 
were used, in conjunction with a near infrared dye to track implanted B cells in vivo with 
and without the application of B cell depleting antibody. Particles were also utilized to 
visualize neurinflammation in a rodent cervical persistent pain model. Finally the SPIO 
were derivatized to accomplish highly efficient, functional, antibody labeling to facilitate 
in vivo targeting of B cells. The major findings of the work are catalogued in this chapter. 
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This is followed by a discussion of the likely implications of this work, suggestions for 
future work and a concise conclusion of results. 
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8.2  - Significance of Findings 
 Control over the starting synthesis parameters used in the co-precipitation of the 
iron salts in the presence of complexing agent was required to produce SPIO of desirable 
characteristics. Parameters of essential importance were found to include; inert 
atmospheric conditions, the relative ratio of iron-to-dextran, the rate of addition of 
reductant and rigid purification practices. The multi-component core (and resultant 
magnetic properties) and overall diameter of the particles could be modified by altering 
components of the reaction listed above. 
 Transmission electron microscopy, dynamic light scattering, viscometry, 
magnetic relaxation tests and a variety of surface charge probing methods were 
performed. The manufactured particles possess a non-ideal crystal lattice core of iron 
oxide likely in a mixed form of maghemite and magnetite, coated in a shell of dextran. 
SPIO ranging from approximately 20 nm through to 150 nm were synthesized. The 
surface layer of dextran was altered post-synthesis first through cross-linking the 
individually FeOH-complexed dextran macromolecules and functionalized with charged 
residues. Finally, these surface expressed groups were exploited to 1) directly conjugate 
fluorophores and proteins and 2) as points of conjugation for advanced ligation 
chemistries, such as the copper catalyzed azide alkyne cycloaddition.  
 Demonstrated in this work was the ability to functionalize particles with a range 
of surface properties (with respect to surface charge and expressed groups), physical 
characteristics (overall diameter, inner core components and magnetic properties) and 
conjugated moeities. These include but are not limited to fluorophores such as fluorescein 
isothyiocyanate, Cy5.5 and Alexa 680; amine reactive and characterizing molecules such 
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as N -Succinimidyl 3-(2-pyridyldithio)-propionate; click reactive molecules such as 
amine-reactive propargyl and azide conjugated PEG cross-linkers; and proteins and 
peptides such as the polyamine protamine and human B cell targeting anti-CD20.  
 We examined the T2-weighted contrast that resulted from by loading non-
phagocytic cells with SPIO. The SPIO properties were varied, according to surface 
charge, hydrodynamic diameter, concentration and time of incubation in order to 
determine the relevant factors for SPIO labeling of immortalized human T cells. The 
procedure was verified for primary murine B cells. These cells were then labeled by both 
SPIO and near infrared (NIR) dye for the purpose of monitoring B cell distribution in 
vivo in a mouse. The homing of cells to the spleen was verified by both MR and optical 
methods. The distribution following administration of a B cell depleting antibody was 
also monitored. These results indicated that SPIO may interfere with the biological 
process of antibody mediated B-lymphocyte cytotoxicity.  
 Finally, SPIO were utilized for the identification of the site of neurological insult 
in a transient compression model. It has previously been observed that transient 
compression of the rat C7 dorsal nerve root resulted in hypersensitivity of the affected 
dermatome (1-3). This has been correlated to the infiltration of activated macrophage into 
the neural tissue (4-6). The presence of these macrophage, was detected through the 
active uptake of long circulating (non-aminated) SPIO. The degree of contrast 
enhancement resulting from SPIO administration was determined semi-quantitatively. 
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8.3 - Future Directions 
 From both a materials engineering and biomedical study design standpoint, 
several avenues are available for extending the work completed in this dissertation. Areas 
of advancement include the refinement of the nanoparticle architecture itself, in vivo 
targeting of immune system relevant cells and further study of SPIO application to 
neuropathy. 
 
8.3.1 - Refinement of SPIO 
 Much of the work in this thesis demonstrated control over the production and 
physicochemical properties of SPIO for biomedical applications. Advances in materials 
engineering, however, mean that SPIO with augmented beneficial properties can be 
constructed. Extending out of the tight control of heterogeneous layered nanoparticles 
such as type II quantum dots (7), investigation and manipulation of the core-shell 
relationship has become a major area of research in its own right for magnetic 
nanoparticles. Two materials in particular would be relevant to coating of iron oxide 
nanoparticles, gold (8) and silica (9). While no longer a novel prescription, coating the 
iron with a thin layer of either silica or gold is hypothesized to allow for more robust, and 
eased, functionalization as the gold-sulfhydryl and silica-binding conjugation chemistries 
have considerable literature (10, 11). 
 Advantages of such an approach include better core crystallinity resulting in 
greater magnetic moment for the particles. This, coupled with the greater functionality, 
are significant assets when tracking particles or attempting to bind targets in the body. 
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The disadvantage of such strategies is that synthesis routes are undoubtedly more 
complex than the iron salt co-precipitation method. If significant work can be completed 
towards good manufacturing processes of core-shell magnetic nanoparticles, better 
signal-to-noise, lower dosage and more effective targeting vehicles may be developed. 
 
8.3.2 - In vivo targeting of B cells 
 The ex vivo loading of SPIO resulted in an apparent inability to detect antibody 
mediated depletion of B cells in the spleen. This reveals the possibility that an in vivo 
targeting approach may be better suited for MR detection of B-lymphocyte population 
migration or demise. The preliminary work towards this strategy has been accomplished. 
Probes consisting of B cell targeting antibody-SPIO conjugates have been manufactured. 
This process was determined to make highly efficient use of starting protein. Further, the 
functionality of the antibody was not degraded. Antibody-SPIO conjugates labeled B 
cells in vitro with greater avidity than particles developed using the conventional covalent 
amide linking approach.  
 The determination of B cell distribution in vivo using antibody-SPIO targeting 
conjugates is theoretically possible. No study to date has utilized SPIO to specifically 
label a cell population as populous as B-lymphocytes. However, selection of a targeting 
ligand (antibody or otherwise) that demonstrates high specificity for B cells with likewise 
low non-specific adherence to other tissues should allow for identification of sites of B 
cell concentration. The ability to repeatedly administer a targeted imaging agent should 
provide a means to identify the change in B cell distribution over the course of a 
depletion therapy. Furthermore, if the probe is itself benign and well tolerated, it is 
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conceivable that this SPIO contrast agent could be applied for the study of B cell 
distribution and response in other autoimmune disease and therapy models. 
 In a different direction, an interesting observation regarding spleen signal 
intensity in T2*-weighted imaging was made. It was noted that the spleens of mice 
subjected to the immunotherapy protocol, but devoid of nanoparticle MR contrast agent, 
darkened. This hypointensity was slight and developed over time, however it provides an 
noteworthy, hitherto unremarked-upon, example of MR imaging of B cell depletion 
therapy. Any clinically relevant conclusions are certainly premature at this juncture. 
However if it can be correlated to other therapeutic response markers this phenomenon 
may provide a non-invasive, agent free, means to determine treatment efficacy.  
 
8.3.3 - Advanced Imaging of Painful Neuropathy 
 There are several interesting areas in which our work on the in vivo imaging of 
transient nerve root injury in the rat could be continued. The goal of this work was to 
address a current deficit in the ability to identify nerve root injury causing radiculopathy 
in the absence of permanent and gross anatomical changes, such as nucleus pulposa or 
vertebral degeneration. This preclinical study could be a basis from which to conduct 
either larger animal (dog or non-human primate) or even human trials. While certainly a 
leap, human trials may not be beyond the scope of this work in the intermediate future. 
This assertion is based on the fact that the administered SPIO agents have clinically 
analogues with similar physical, chemical and magnetic properties that likely would 
experience comparable accumulation at the site of a pain producing neuropathy (12). 
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 From a cell migration standpoint, it may be possible to repeatedly image the 
injury in the rat, from insult through to full regeneration of the nerve. This would enable 
study of the entire process from initial injury to neuroinflammation to an amelioration of 
that condition. The study model employed for the detection of pain producing 
neuroinflammation was controlled with respect to the load applied (sufficient to provoke 
persistent hypersensitivity) and on the days that imaging was carried out. The dates that 
the imaging was conducted was limited by several factors; namely, the wound closing 
materials were metallic and it was required that they be removed prior to MR imaging. 
However, if an alternative could be found and approved, it would be of interest to non-
invasively determine, perhaps through repeated SPIO administration, the temporal 
infiltration of macrophage at early time points following insult. 
 Imaging approaches also provide a means to perhaps image the severity of injury, 
which is dependent on several factors such as magnitude of insult and pharmacological 
management. In the current study, the load and duration of compression were fixed at 10 
gmf and 15 minutes respectively. However, it has been previously shown that behavioral 
outcomes and spinal cellular responses depend on the magnitude of nerve root 
deformation (13-15). The application of SPIO as an in vivo diagnostic for the gradation 
of neuropathy could be of significant clinical relevance. In a related capacity, the 
application of non-invasive imaging techniques could be of tremendous pre- and clinical 
application to the monitoring of therapeutic efficacy. It has been shown that 
pharmacological treatment parameters have a significant behavioral and cellular impact 
in rat pain models. SPIO administration may allow for both imaging of the dynamics of 
reduction in inflammation following treatment, comparison of therapies and possibly 
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from a clinical standpoint evaluation of best practices for management of cervical 
radiculopathy. 
 Finally, it may be possible to administer magnetopharmaceuticals beyond the 
unmodified SPIO used in the CNS injury detection studies performed here. Positive 
contrast agents, such as Very-small SPIO (VSPIO) and Gadofluorine M (an amphiphilic 
macrocyclic gadolinium complex of relatively low molecular weight) have recently been 
used to visualize and grade severity of CNS injury in rat encephylitis models (16). 
Likewise, we have recently developed a nanoparticle formulation that provided excellent 
tumor signal increase in T1-weighted imaging. This gadolinium-conjugated dendritic 
nanocluster system has the potential to undergo inflammatory site accumulation through 
macrophage uptake similar to that observed for SPIO administered in the transient nerve 
root injury study (17). 
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8.4 - Conclusion 
 The foremost goal of this thesis was to observe the presence and distribution of 
immune relevant cells in vivo. We have demonstrated development of a functional 
nanoparticle contrast agent for use in magnetic resonance imaging. It was determined that 
agent properties could be controlled either during the synthesis or subsequently through 
modification of the surface properties and functionalities of the coating material.  
 Investigations of the interaction between cellular systems and the produced SPIO 
revealed that size, concentration and surface charge were critical towards labeling of non-
phagocytic cells. An optimal labeling configuration of particle was determined from these 
studies. In a surprising result, given the widespread use of 20 - 50 nm SPIO, and recent 
focus on larger micron-sized SPIO, our results indicated that a highly cationic particle of 
approximately 100 nm standard-SPIO (SSPIO) enabled maximum contrast. The T2-
weighted contrast enhancement as measured by a benchtop relaxometer operating near 
clinical field strength for the optimal particle labeling configuration was approximately 
an order of magnitude greater than the 33.4 nm ultrasmall-SPIO. Contrast was nearly two 
orders of magnitude greater than conventional micron-sized SPIO.  
 To enable lymphocyte tracking in vivo we progressed from an in vitro 
immortalized cell line to labeling of primary B cells for in vivo administration. In order to 
avoid detrimental biological effects the less charged smaller particles of 53.5 nm 
diameter were used. These SPIO and a cell surface membrane labeling near infrared dye 
enabled MR and optical monitoring of administered B cells in vivo. The primary goal of 
using these agents to determine B cell distribution in vivo was successfully 
accomplished. The presence of MR contrast agent in the spleen was confirmed by T2*-
Chapter 8  316 
weighted imaging using a dual surface and volume coil imaging configuration. The 
detection of hypointensity of the spleen was specific for SPIO loaded B cells. A ratio of 
splenic signal intensity over background (paraspinal muscle) signal was used to quantify 
the contrast enhancement. No significant change in signal was determined for controls. 
The homing of B cells was corroborated by fluorescent signal detection in the spleen 
from the near infrared dye. Contrast decreased from both modalities over time, as the 
particles and dye were apparently cleared. 
 The determination of a change in B cell distribution following administration of 
anti-CD79 B cell depleting antibody was evident only using the optical approach. 
Evidently, while the presence of SPIO accumulated in the B cells using the ex vivo 
loading approach enabled in vivo detection, it also prevented B cell depletion. No 
significant signal ratio change was detected between the SPIO B cell groups with or 
without depleting antibody.  
 We have applied SPIO in a rat pain model and demonstrated cellular visualization 
of an otherwise occult painful neural injury. The injured nerve roots were readily 
identified 24 hours following the injection of the contrast. Ratiometric assessment of 
nerve-to-background tissue specified a significant difference in the normalized signal 
intensity ratio (nrSI) following administration of SPIO. Imaging at the site of nerve root 
injury using SPIO resulted in an average postcontrast enhancement of 72.9 ± 31%, 
measured as the difference in nrSI between ipsilateral and contralateral roots. This was 
significantly greater than the 5.3 ± 12.9% difference in nrSI of injured animals prior to 
SPIO administration. 
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 Future studies will seek to utilize SPIO enhanced MR imaging in order to monitor 
treatment efficacy and study the 'root' causes of radicular pain. The research reported 
herein is preclinical, however the protocols established may provide a basis for the 
clinical radiologist to correlate cervical nerve root injury to pain. These data indicate that 
the source of painful neuropathy can be identified and may provide the means to diagnose 
the source of radiculopathy in patients that do not have obvious pathologies. MR cellular 
imaging of the site of injury might also allow for personalized, quantitative and real-time 
monitoring of anti-inflammatory treatment strategies aimed at alleviating radicular pain. 
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APPENDIX A. T1 Contrast Agents 
A.1 - Gadolinium(III)  
 The most widely used magnetic resonance (MR) contrast agent (CA) is the 
paramagnetic lanthanide ion gadolinium (III), referred to herein as Gd. Other 
paramagnetic ions that perform less well as CA, but are still of interest primarily at the 
bench-top, are magnanese(II), copper(II) and iron(III) for the same reasons described 
below. Paramagnetic relaxation of surrounding water protons occurs as the dipole-dipole 
interaction between the spins of the ion's unpaired electrons and the dipole moments of 
the surrounding 1H. In its unfilled d and f shells; the Gd has 7 unpaired electrons, the 
greatest of any stable ion (1). The resulting effect is a shorter T1; the nuclei regain their 
longitudinal magnetization faster and are thus brighter, or hyperintense, on all 
conventional T1-w images.  
 Contrast agents’ ability to relax surrounding protons affects both T1 and T2 
processes. Gadolinium(III) is a T1-w contrast agent as the R2/R1 ratio of approximately 1-
2 means the signal change for T1-w imaging is much greater than it would be for T2-w 
imaging. For comparison, common iron oxide T2-w contrast agents, discussed in detail 
throughout this dissertation, often effect an R2/R1 of 10 (2). 
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 The enhanced spin-lattice relaxation mechanism of paramagnetic ions has been 
described in the Solomon-Bloembergen theory (3). Here, observed T1 is due to a 
combination of the intrinsic T1 of the diamagnetic sample (the protons) and the T1 caused 
by the presence of the Gd. This latter T1 is composed of two terms, the inner and outer 
sphere effects. The inner sphere describes the relaxation of the 1H directly bound to 
(hydrating) the paramagnetic ion, and the outer sphere describes the interactions between 
the 1H diffusing as water closely by the Gd (4). The outer sphere effects are difficult to 
control given that they depend on tissue properties. 
 Numerous parameters affect the relaxivity of Gd-based MR CA, as demonstrated 
in Equation A.1, the description of the inner sphere term. For a fixed radiofrequency 
(RF), f, the R1 is a function of the inner sphere water coordination number, q (the number 
of bound water molecules per Gd), the effective magnetic moment, !eff, the internuclear 
distance of the water proton, r, and the correlation time, Tc.  
Equation A.1    
The correlation time can be represented through the rotational correlation time (Tr), 
electron spin relaxation time (T1e) and the inner sphere exchange correlation time (Tm), as 
shown in Equation 1.9.  
Equation A.2    
A schematic illustration of these parameters, in an physical sense, is given in Figure A.2.  
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Figure A.1 - Schematic of water molecule interaction with gadolinium(III). 
Critical parameters affecting Gd relaxivity. One inner sphere molecule of water (within 
the radius depicted by the dashed line) is depicted interacting with the Gd ion. The proton 
exchange rate is depicted by the bold double arrows. The rotational correlation time of 
the molecule is shown by the arrow. Adapted by Thorek from (5) and (4). 
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A.2 - Gd-Chelates and Toxicity 
 A major issue for use of Gd is that of safety; lanthanide ions are extremely toxic. 
They must be chelated for biological use to prevent uptake (as well as to provide 
solubility). Retention of Gd has been shown to cause nephrogenic systemic fibrosis 
(NSF) in patients with renal conditions (6). NSF is found to cause renal failure, organ 
complications, skin induration and ultimately death. Confirmation of the diagnosis is 
primarily made through skin biopsy revealing presence of gadolinium long after 
administration (7).  
 Gd-chelating compounds must have very high stability (logKGd ~ 20) so that the 
entire agent may be cleared prior to release or replacement of the ion by a metal found in 
the body (8). Chelation does not abrogate all health risk issues, as transmetallation may 
still occur to free the ion (9). Clinically relevant chelators can be classed into three 
primary groups that describe their structural chelation of the Gd as well as their stability, 
as shown in Figure A.2. In order of most stable (least likely to release Gd) to least stable 
(weakest chelator), there are: cyclical, ionic linear and non-ionic linear.  
 While required to prevent cellular uptake of the ion, chelates' osmolality 
following injection is an issue. Magnevist, for example, is highly hypertonic (Bayer 
HealthCare Pharmaceuticals, Inc. product information). The agent  has an osmolality 6.9 
times that of plasma (1973 mOsmol/kg versus 285 mOsmol/kg). Table A.1 contains a list 
of pharmacological parameters for four of the six U.S. Food and Drug Administration 
(FDA) approved gadolinium(III) agents. 
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Figure A.2 - Clinical Gadolinium(III)-Chelate Contrast Agents. 
 
Structure, formula description and trade name of commonly used gadolinium(III) 
chelators. Dotarem, Gadovist and ProHance are classified as cyclical-chelators, 
providing the greatest stability and therefore the safest for use. This is derived from the 
number of complexing ligands and ionic character of the agent. Magnevist, and 
MultiHance are ionic linear chelators, while Omniscan and OptiMARK are linear non-
ionic chelators. Figure modified from (2). 
 
these complexes is discussed, with particular empha-
sis on in vivo stability.
A. Solid State Structures
Owing to their large size, lanthanides tend to favor
high coordination numbers in aqueous media. Cur-
rently, all gadolinium(III)-based chelates approved
for use in MRI are nine-coordinate complexes in
which a ligand occupies eight binding sites at the
metal center and the ninth coordination site is
occupied by a solvent water molecule (Chart 1). For
nine-coordinate complexes the idealized coordination
geometries are tricapped trigonal prism (TTP) and
capped square antiprism (CSAP) (Figure 1). In the
absence of chelate ring steric effects, Guggenberger
and Muetterties identified the tricapped trigonal
prism as the most favorable polytopal form for an
ML9 coordination complex.19When the square basal
plane of a CSAP is bent along the (4,7) diagonal, the
CSAP is changed to a TTP geometry (Figure 1). Three
useful distinguishing features of the two geometries
are the dihedral angle between the trigonal faces
(4,5,6) and (7,8,9), which in idealized polyhedra is
180° fo TTP (coplanar to each other and to the (1,2,3)
plane) and 163.5° for CSAP, the dihedral angle
between the trigonal faces (1,4,7) and (3,4,7) which
should be 26.4° for TTP and 0° for CSAP, and the
mean deviation in the basal (1,4,3,7) plane, which
should be small in the CSAP case. Nine-coordinate
Ln(III) complexes are often described as distorted
TTP or distorted CSAP. Because the two geometries
are closely related, it is possible that a particular
structure is described equally well by both geom-
etries.
X-ray structures for Ln(III) complexes of DTPA
(Chart 2) were reported by Gries et al. (Gd(III)
complex, Na+ salt),20 Stezowski et al. (Nd(III) com-
plex, Ba salt),21 Jin et al. (Gd(III) complex, Mn salt),22
Inoue et al. (Gd(III) complex, NH4+ salt),23 Sakagami
et al. (Dy(III) complex, Cs salt),24 and Ruloff et al.
(Gd(III) complexes, guanidinium salts).25 All of these
structures contained a nine-coordinate metal ion
bonded to three nitrogens and five monodentate
carboxylate oxygen atoms of the DTPA ligand. In
some cases the observed geometries were distorted
from ideal prisms to such a degree that either the
TTP or CSAP description is justified. For example,
the dihedral angles in the Nd(III) complex (Table 3)
were intermediate to those of idealized TTP and
CSAP arrangements (Figure 2). In most cases, the
geometry is best described as a distorted TTP. The
complexes Na2[Gd(DTPA)(H2O)], Mn[Gd(DTPA)(H2O)],
Ba[Nd(DTPA)(H2O)], and CN3H6[Gd(HDTPA)(H2O)]
all have similar structures in which the remaining
coordination site (position 2 in Figure 1)was occupied
by a water molecule. Three examples of dimeric
structures, (NH4)4[Gd2(DTPA)2], (CN3H6)4[Gd2-
(DTPA)2], and Cs4[Dy2(DTPA)2], were also reported.
Chart 1
Figure 1. Tricapped trigonal prism (TTP) and mono-
capped square antiprism (CSAP) geometries.
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 The agents deemed safe for human use, and thereby approved for use by the FDA, 
are based on either diethylene triamine pentaacetic acid (DTPA) or 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA). Both of these materials occupy 
8 of the gadolinium(III) binding sites, leaving a single site for water interaction. The 
limitation of binding sites required to stabilize the ion for in vivo use is to the detriment 
of the ions use as a paramagnetic T1-w contrast agent. For example the longitudinal 
relaxivity of the commonly used Dotarem, is R1=3.1 (mM!sec)-1 at 1.41 T (10).  
 
Table A.1 - Gd-CA Properties; 37˚ C 
Generic name Trade name logKeq 
M-1 
T1/2 Osmolality 
(Osmol/kg) 
Viscosity 
(cP) 
R1 
(mM!sec)-1 
Gadoteridol ProHance 23.8 1.3 d 1.91 3.9 3.7 
Gadodiamide Omniscan 16.9 < 2 s 1.90 3.9 3.8 
Gadopentetate Magnevist 25.8 < 2 s 5.85 > 30 3.8 
Gadoterate Dotarem 25.8 95 d 4.02 11.3 3.5 
General features of Gd-chelates are listed above. The T1/2 dissociation times are for 
solutions at acidic pH, where d is days and s is seconds; where macrocycles demonstrate 
reduced dissociation proclivity. In vivo the situation is more complex, as pH is generally 
higher and the presence of competing endogenous ions  are heterogeneous. Osmolality 
measurements were conducted at 1.0 M of agent. 
Consolidated and adapted from (11).  
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A.3 - Gd-CA Applications and Cellular Imaging 
 Gadolinium(III) based contrast agents have found use in a wide variety of clinical 
applications; particularly for the detection, diagnosis and staging of heart disease, cancers 
and neurological diseases.  
 Neurological imaging applications have found great use for gadolinium(III) 
contrast. Initial diagnosis sensitivity is enhanced when using conventional Gd-CA (12, 
13). The agents benefit diagnosis through their accumulation in extracellular spaces 
allowing for visualization of disruptions of the blood brain barrier (BBB). Further, the 
CA can be used to monitor the course of !-interferon treatment (14, 15).  
 
A.4 - Gd-CA Limitations 
 There exist several significant difficulties when using conventional Gd-chelates to 
enhance tissue contrast. The agents require much higher concentration than radioisotope 
or optical probes used for (primarily tumor) detection, often in the micromolar range 
(16). This is a problem resulting from the generally low sensitivity of MR. Attempts to 
overcome this problem have largely centered on nanoparticle and polymer platforms that 
seek to deliver higher local concentrationos of Gd.  
 Conjugation of Gd to larger molecular weight structures, such as proteins (17-19) 
or dendrimers (20), or as particles (21), is an approach that seeks to effectively increase 
the rotational correlation time of the Gd-complexes. Another strategy is for the 
encapsulation of Gd within a nanocarrier to amplify local concentration (and therefore 
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signal), using liposomes (22), polymersomes (23) or micelles (24). There is often a 
tradeoff with both approaches that result in either long retention times (and fears of 
toxicity) or decreased access to tissues or pathological sites (due to pharmocological 
factors). 
 A more recent approach, generally seen as suitable only for research applications, 
is to modify chelates such that they are able to access and accumulate intracellularly. The 
main focus of this strategy has been to use individual Gd-chelates synthesized with 
highly cationic polypeptides (such as the HIV-Tat or polyarginine sequences). These 
chelates are able to gain access to the cellular compartment. The accumulation of chelates 
was not found to have appreciable toxicity on cultured cells, however application in vivo 
has not occurred (25, 26). 
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